US8652535B2 - Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments - Google Patents
Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments Download PDFInfo
- Publication number
- US8652535B2 US8652535B2 US13/218,164 US201113218164A US8652535B2 US 8652535 B2 US8652535 B2 US 8652535B2 US 201113218164 A US201113218164 A US 201113218164A US 8652535 B2 US8652535 B2 US 8652535B2
- Authority
- US
- United States
- Prior art keywords
- acacia
- free
- flavans
- cox
- lasoperin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime, expires
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 125
- 229930003935 flavonoid Natural products 0.000 title abstract description 165
- 235000017173 flavonoids Nutrition 0.000 title abstract description 165
- 150000002215 flavonoids Chemical class 0.000 title abstract description 164
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical class C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 title abstract description 100
- 208000010877 cognitive disease Diseases 0.000 title abstract description 25
- 206010027175 memory impairment Diseases 0.000 title abstract description 7
- 238000011282 treatment Methods 0.000 title description 49
- 238000009472 formulation Methods 0.000 title description 29
- 230000002265 prevention Effects 0.000 title description 18
- 230000006999 cognitive decline Effects 0.000 title description 17
- 238000000034 method Methods 0.000 claims abstract description 77
- 241000196324 Embryophyta Species 0.000 claims description 88
- 241000220479 Acacia Species 0.000 claims description 39
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 34
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 27
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 27
- 235000005487 catechin Nutrition 0.000 claims description 27
- 229950001002 cianidanol Drugs 0.000 claims description 23
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 21
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 21
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 21
- 229960003321 baicalin Drugs 0.000 claims description 21
- 241000207929 Scutellaria Species 0.000 claims description 19
- 244000235603 Acacia catechu Species 0.000 claims description 17
- 235000012734 epicatechin Nutrition 0.000 claims description 16
- 230000002314 neuroinflammatory effect Effects 0.000 claims description 14
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims description 13
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 13
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims description 13
- 235000006020 Acacia catechu Nutrition 0.000 claims description 11
- 239000001560 acacia catechu Substances 0.000 claims description 11
- 244000215068 Acacia senegal Species 0.000 claims description 9
- 235000006491 Acacia senegal Nutrition 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 235000006509 Acacia nilotica Nutrition 0.000 claims description 4
- 244000155717 Acacia sinuata Species 0.000 claims description 4
- 241000157352 Uncaria Species 0.000 claims description 4
- 244000044108 Acacia caesia Species 0.000 claims description 3
- 244000044167 Acacia concinna Species 0.000 claims description 3
- 235000015841 Acacia concinna Nutrition 0.000 claims description 3
- 241001199697 Acacia dealbata Species 0.000 claims description 3
- 244000020998 Acacia farnesiana Species 0.000 claims description 3
- 241000278701 Acacia mangium Species 0.000 claims description 3
- 241000993444 Acacia mearnsii Species 0.000 claims description 3
- 244000146446 Acacia pennata Species 0.000 claims description 3
- 240000006409 Acacia auriculiformis Species 0.000 claims description 2
- 235000003074 Acacia farnesiana Nutrition 0.000 claims description 2
- 241000683231 Uncaria africana Species 0.000 claims description 2
- 244000081822 Uncaria gambir Species 0.000 claims description 2
- 241000607122 Uncaria tomentosa Species 0.000 claims description 2
- 235000011472 cat’s claw Nutrition 0.000 claims description 2
- 239000003125 aqueous solvent Substances 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 235000017631 Acacia mangium Nutrition 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 68
- 230000000694 effects Effects 0.000 abstract description 51
- 230000002401 inhibitory effect Effects 0.000 abstract description 22
- 206010061218 Inflammation Diseases 0.000 abstract description 20
- 230000004054 inflammatory process Effects 0.000 abstract description 19
- 230000032683 aging Effects 0.000 abstract description 18
- 230000003920 cognitive function Effects 0.000 abstract description 17
- 102000004127 Cytokines Human genes 0.000 abstract description 16
- 108090000695 Cytokines Proteins 0.000 abstract description 16
- 230000000770 proinflammatory effect Effects 0.000 abstract description 12
- 230000036542 oxidative stress Effects 0.000 abstract description 9
- 230000015654 memory Effects 0.000 abstract description 8
- 230000006851 antioxidant defense Effects 0.000 abstract description 5
- 230000000626 neurodegenerative effect Effects 0.000 abstract description 4
- 230000003190 augmentative effect Effects 0.000 abstract description 2
- 230000004112 neuroprotection Effects 0.000 abstract description 2
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 45
- 230000005764 inhibitory process Effects 0.000 description 37
- 108020004999 messenger RNA Proteins 0.000 description 37
- 101150071146 COX2 gene Proteins 0.000 description 34
- 241000700159 Rattus Species 0.000 description 33
- -1 lipid peroxide Chemical class 0.000 description 33
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 32
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 32
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 31
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 31
- 239000000284 extract Substances 0.000 description 30
- 239000002158 endotoxin Substances 0.000 description 29
- 229920006008 lipopolysaccharide Polymers 0.000 description 29
- 238000004519 manufacturing process Methods 0.000 description 29
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 239000003963 antioxidant agent Substances 0.000 description 25
- 235000006708 antioxidants Nutrition 0.000 description 25
- 201000010099 disease Diseases 0.000 description 25
- 239000003642 reactive oxygen metabolite Substances 0.000 description 25
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 23
- 101150000187 PTGS2 gene Proteins 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 23
- 102000003820 Lipoxygenases Human genes 0.000 description 22
- 108090000128 Lipoxygenases Proteins 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 230000003078 antioxidant effect Effects 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 19
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 19
- 238000003556 assay Methods 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 230000007423 decrease Effects 0.000 description 17
- 230000009977 dual effect Effects 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 16
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 16
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 15
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 15
- 229940114079 arachidonic acid Drugs 0.000 description 15
- 235000021342 arachidonic acid Nutrition 0.000 description 15
- 230000008014 freezing Effects 0.000 description 15
- 238000007710 freezing Methods 0.000 description 15
- 238000012545 processing Methods 0.000 description 15
- 230000035939 shock Effects 0.000 description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 101100221647 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-1 gene Proteins 0.000 description 13
- 240000004534 Scutellaria baicalensis Species 0.000 description 13
- 235000005911 diet Nutrition 0.000 description 13
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 239000001301 oxygen Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 12
- 230000001149 cognitive effect Effects 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000003110 anti-inflammatory effect Effects 0.000 description 11
- 230000037213 diet Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 230000002757 inflammatory effect Effects 0.000 description 11
- 230000035484 reaction time Effects 0.000 description 11
- 238000012549 training Methods 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- PSFDQSOCUJVVGF-UHFFFAOYSA-N harman Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C PSFDQSOCUJVVGF-UHFFFAOYSA-N 0.000 description 10
- 210000001616 monocyte Anatomy 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 102000040945 Transcription factor Human genes 0.000 description 9
- 108091023040 Transcription factor Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 229960001680 ibuprofen Drugs 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 150000003180 prostaglandins Chemical class 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 7
- 101100496968 Caenorhabditis elegans ctc-1 gene Proteins 0.000 description 7
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 101150062589 PTGS1 gene Proteins 0.000 description 7
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 7
- 229940015301 baicalein Drugs 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 229940111134 coxibs Drugs 0.000 description 7
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000003828 downregulation Effects 0.000 description 7
- 229940100601 interleukin-6 Drugs 0.000 description 7
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 150000008163 sugars Chemical class 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 0 *.B.C.[1*]C1=C2C(=O)C([5*])=C(C3=CC=CC=C3)OC2=C([4*])C([3*])=C1[2*] Chemical compound *.B.C.[1*]C1=C2C(=O)C([5*])=C(C3=CC=CC=C3)OC2=C([4*])C([3*])=C1[2*] 0.000 description 6
- 108020004463 18S ribosomal RNA Proteins 0.000 description 6
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N 3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108010016731 PPAR gamma Proteins 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 6
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 150000001312 aldohexoses Chemical class 0.000 description 6
- 150000001320 aldopentoses Chemical class 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 150000001450 anions Chemical class 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 6
- 230000003750 conditioning effect Effects 0.000 description 6
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 229930182470 glycoside Natural products 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000000971 hippocampal effect Effects 0.000 description 6
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 150000002617 leukotrienes Chemical class 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 235000021590 normal diet Nutrition 0.000 description 6
- LKOJGSWUMISDOF-UHFFFAOYSA-N oroxylin A Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=CC=C1 LKOJGSWUMISDOF-UHFFFAOYSA-N 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 5
- 244000269722 Thea sinensis Species 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 235000020934 caloric restriction Nutrition 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000027928 long-term synaptic potentiation Effects 0.000 description 5
- 230000003955 neuronal function Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000003936 working memory Effects 0.000 description 5
- 229930013915 (+)-catechin Natural products 0.000 description 4
- 235000007219 (+)-catechin Nutrition 0.000 description 4
- 241000208838 Asteraceae Species 0.000 description 4
- 229940124638 COX inhibitor Drugs 0.000 description 4
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 4
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 4
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 4
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000001668 ameliorated effect Effects 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 150000001765 catechin Chemical class 0.000 description 4
- 229960000590 celecoxib Drugs 0.000 description 4
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000036992 cognitive tasks Effects 0.000 description 4
- 150000002066 eicosanoids Chemical class 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- VCCRNZQBSJXYJD-UHFFFAOYSA-N galangin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=CC=C1 VCCRNZQBSJXYJD-UHFFFAOYSA-N 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- IYSYLWYGCWTJSG-XFXZXTDPSA-N n-tert-butyl-1-phenylmethanimine oxide Chemical compound CC(C)(C)[N+](\[O-])=C\C1=CC=CC=C1 IYSYLWYGCWTJSG-XFXZXTDPSA-N 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 230000000324 neuroprotective effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 229940127293 prostanoid Drugs 0.000 description 4
- 150000003814 prostanoids Chemical class 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 4
- 235000018553 tannin Nutrition 0.000 description 4
- 229920001864 tannin Polymers 0.000 description 4
- 239000001648 tannin Substances 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 description 3
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000220485 Fabaceae Species 0.000 description 3
- 206010019799 Hepatitis viral Diseases 0.000 description 3
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- 244000061456 Solanum tuberosum Species 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 235000015838 chrysin Nutrition 0.000 description 3
- 229940043370 chrysin Drugs 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 3
- 150000002213 flavones Chemical class 0.000 description 3
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 235000009569 green tea Nutrition 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000005865 ionizing radiation Effects 0.000 description 3
- 230000013016 learning Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 230000003959 neuroinflammation Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 230000004783 oxidative metabolism Effects 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- 201000001862 viral hepatitis Diseases 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- RSYUFYQTACJFML-UKRRQHHQSA-N (-)-epiafzelechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C=C1 RSYUFYQTACJFML-UKRRQHHQSA-N 0.000 description 2
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- STRVVRPNBAHXRJ-UHFFFAOYSA-N 2-hydroxynon-2-enal Chemical compound CCCCCCC=C(O)C=O STRVVRPNBAHXRJ-UHFFFAOYSA-N 0.000 description 2
- JNUUNUQHXIOFDA-XTDASVJISA-N 5-HPETE Chemical compound CCCCC\C=C/C\C=C/C\C=C/C=C/C(OO)CCCC(O)=O JNUUNUQHXIOFDA-XTDASVJISA-N 0.000 description 2
- 241001238072 Achyrocline Species 0.000 description 2
- 241000605605 Actinodaphne Species 0.000 description 2
- 241000013298 Alpinia <beetle> Species 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 241000226665 Anaphalis Species 0.000 description 2
- 241001081440 Annonaceae Species 0.000 description 2
- 244000018217 Artocarpus elasticus Species 0.000 description 2
- 241000132016 Baccharis Species 0.000 description 2
- 241001090347 Bignoniaceae Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241001482485 Buchenavia Species 0.000 description 2
- 241000132570 Centaurea Species 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 241000531318 Colebrookea Species 0.000 description 2
- 241000221032 Combretaceae Species 0.000 description 2
- 241000404068 Cotula Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 244000147058 Derris elliptica Species 0.000 description 2
- 241000447394 Desmos Species 0.000 description 2
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 2
- 241000735527 Eupatorium Species 0.000 description 2
- 241000221017 Euphorbiaceae Species 0.000 description 2
- 241000218218 Ficus <angiosperm> Species 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 241000699694 Gerbillinae Species 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 241000608847 Gnaphalium Species 0.000 description 2
- 244000308760 Helichrysum petiolatum Species 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 241000546273 Lindera <angiosperm> Species 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 241000521581 Millettia Species 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 241000218231 Moraceae Species 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 241001504105 Notholaena Species 0.000 description 2
- 241001529744 Origanum Species 0.000 description 2
- 235000011203 Origanum Nutrition 0.000 description 2
- 235000012920 Oroxylum indicum Nutrition 0.000 description 2
- 240000005790 Oroxylum indicum Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
- 241000218641 Pinaceae Species 0.000 description 2
- 235000005205 Pinus Nutrition 0.000 description 2
- 241000218602 Pinus <genus> Species 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000370105 Pityrogramma Species 0.000 description 2
- 241000565347 Pongamia Species 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 241000736301 Pteridaceae Species 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241000994241 Sapium Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000519999 Stachys Species 0.000 description 2
- 241000213914 Tephrosia <angiosperm> Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 2
- 241000218220 Ulmaceae Species 0.000 description 2
- 241001106462 Ulmus Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 241001062995 Ziziphora Species 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 230000003931 cognitive performance Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000020805 dietary restrictions Nutrition 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 150000002206 flavan-3-ols Chemical class 0.000 description 2
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 2
- 150000002216 flavonol derivatives Chemical class 0.000 description 2
- 235000011957 flavonols Nutrition 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 150000002432 hydroperoxides Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- ZFKKRRMUPBBYRS-UHFFFAOYSA-N norwogonin Chemical compound OC=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 ZFKKRRMUPBBYRS-UHFFFAOYSA-N 0.000 description 2
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 2
- 238000009160 phytotherapy Methods 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
- JUVIOZPCNVVQFO-HBGVWJBISA-N rotenone Chemical compound O([C@H](CC1=C2O3)C(C)=C)C1=CC=C2C(=O)[C@@H]1[C@H]3COC2=C1C=C(OC)C(OC)=C2 JUVIOZPCNVVQFO-HBGVWJBISA-N 0.000 description 2
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 230000006403 short-term memory Effects 0.000 description 2
- 230000006886 spatial memory Effects 0.000 description 2
- 238000013319 spin trapping Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical group [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- DRKSTAFYCRUMEE-HZJYTTRNSA-N (9z,12z)-octadeca-9,12-dieneperoxoic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OO DRKSTAFYCRUMEE-HZJYTTRNSA-N 0.000 description 1
- HDPBUCGAWFIVEZ-UHFFFAOYSA-N *.B.C.O=C1C=C(C2=CC=CC=C2)OC2=CC=CC=C12 Chemical compound *.B.C.O=C1C=C(C2=CC=CC=C2)OC2=CC=CC=C12 HDPBUCGAWFIVEZ-UHFFFAOYSA-N 0.000 description 1
- ZIOZYRSDNLNNNJ-LQWMCKPYSA-N 12(S)-HPETE Chemical compound CCCCC\C=C/C[C@H](OO)\C=C\C=C/C\C=C/CCCC(O)=O ZIOZYRSDNLNNNJ-LQWMCKPYSA-N 0.000 description 1
- BFWYTORDSFIVKP-USWFWKISSA-N 15-HPETE Chemical compound CCCCCC(OO)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O BFWYTORDSFIVKP-USWFWKISSA-N 0.000 description 1
- NLLNKPDICRZXIY-UHFFFAOYSA-N 2,2-diphenyl-3h-chromen-4-one Chemical class O1C2=CC=CC=C2C(=O)CC1(C=1C=CC=CC=1)C1=CC=CC=C1 NLLNKPDICRZXIY-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 1
- BGZWDGSTBPMGPA-UHFFFAOYSA-N 5-methyl-wogonin-7-glucuronide Natural products COc1c(OC2OC(C(O)C(O)C2O)C(=O)O)cc(C)c3C(=O)C=C(Oc13)c4ccccc4 BGZWDGSTBPMGPA-UHFFFAOYSA-N 0.000 description 1
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 1
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 244000215036 Acacia tortilis Species 0.000 description 1
- 235000006489 Acacia tortilis Nutrition 0.000 description 1
- 241000990235 Acacia victoriae Species 0.000 description 1
- 108010031132 Alcohol Oxidoreductases Proteins 0.000 description 1
- 102000005751 Alcohol Oxidoreductases Human genes 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102000011730 Arachidonate 12-Lipoxygenase Human genes 0.000 description 1
- 108010076676 Arachidonate 12-lipoxygenase Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 240000006288 Asclepias speciosa Species 0.000 description 1
- 241001633048 Atuna racemosa Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010004016 Bacterial diarrhoea Diseases 0.000 description 1
- 235000004480 Bombax malabaricum Nutrition 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- ZIFMTQBHOSETDO-UHFFFAOYSA-N CC1=CC=C(C2OC3=CC(O)=CC(O)=C3CC2O)C=C1O Chemical compound CC1=CC=C(C2OC3=CC(O)=CC(O)=C3CC2O)C=C1O ZIFMTQBHOSETDO-UHFFFAOYSA-N 0.000 description 1
- HIYAVKIYRIFSCZ-CVXKHCKVSA-N Calcimycin Chemical compound CC([C@H]1OC2([C@@H](C[C@H]1C)C)O[C@H]([C@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-CVXKHCKVSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 244000146553 Ceiba pentandra Species 0.000 description 1
- 235000003301 Ceiba pentandra Nutrition 0.000 description 1
- 241000296615 Celastrus strigillosus Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- IDRSJGHHZXBATQ-ZAJNMQHRSA-N Chrysin 7-glucuronide Chemical compound O1C(C(O)=O)[C@@H](O)[C@H](O)C(O)[C@@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=CC=CC=3)OC2=C1 IDRSJGHHZXBATQ-ZAJNMQHRSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 235000016643 Eugenia malaccensis Nutrition 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- 241001251094 Formica Species 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940122959 Glucosyltransferase inhibitor Drugs 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 229940122393 Hyaluronidase inhibitor Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 229940122142 Lipoxygenase inhibitor Drugs 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- 229940123134 Nitric oxide inhibitor Drugs 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000015815 Rectal disease Diseases 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- 108010038912 Retinoid X Receptors Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 101710188106 SEC14-like protein 2 Proteins 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 244000045719 Syzygium Species 0.000 description 1
- 240000004120 Syzygium malaccense Species 0.000 description 1
- 235000012096 Syzygium samarangense Nutrition 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- BJBKXYIIWYIZCX-UHFFFAOYSA-N Trigraecum Natural products C1=C(O)C(OC)=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 BJBKXYIIWYIZCX-UHFFFAOYSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 244000291414 Vaccinium oxycoccus Species 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 244000077233 Vaccinium uliginosum Species 0.000 description 1
- 241000596606 Vantanea Species 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 201000004427 acute laryngopharyngitis Diseases 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000007000 age related cognitive decline Effects 0.000 description 1
- 150000007824 aliphatic compounds Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000001407 anti-thrombic effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 102000055104 bcl-X Human genes 0.000 description 1
- 108700000711 bcl-X Proteins 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 150000001766 catechin derivatives Chemical class 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001659 chemokinetic effect Effects 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 239000002820 chemotaxin Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- QYWBSMVYQYXQER-UHFFFAOYSA-N chrysin 7-O-beta-glucuronide Natural products OC1OC(C(O)C(O)C1O)C(=O)Oc2cc(O)c3C(=O)C=C(Oc3c2)c4ccccc4 QYWBSMVYQYXQER-UHFFFAOYSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 230000004734 cutaneous carcinogenesis Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000000550 effect on aging Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930182497 flavan-3-ol Natural products 0.000 description 1
- 150000002205 flavan-3-ol derivatives Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- CIPSYTVGZURWPT-UHFFFAOYSA-N galangin Natural products OC1=C(Oc2cc(O)c(O)cc2C1=O)c3ccccc3 CIPSYTVGZURWPT-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940109738 hematin Drugs 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 150000002535 isoprostanes Chemical class 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
- OTZRAYGBFWZKMX-JUDRUQEKSA-N leukotriene E4 Chemical compound CCCCCC=CCC=C\C=C\C=C\[C@@H](SC[C@H](N)C(O)=O)[C@@H](O)CCCC(O)=O OTZRAYGBFWZKMX-JUDRUQEKSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005056 memory consolidation Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 230000006724 microglial activation Effects 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 241000220478 mimosoid clade Species 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108010058393 monophenolase Proteins 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- QXIPXNZUEQYPLZ-QSUZLTIMSA-N oroxylin A 7-O-beta-D-glucuronide Chemical compound C1=C2OC(C=3C=CC=CC=3)=CC(=O)C2=C(O)C(OC)=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O QXIPXNZUEQYPLZ-QSUZLTIMSA-N 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940097156 peroxyl Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- SUYJZKRQHBQNCA-UHFFFAOYSA-N pinobanksin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=CC=C1 SUYJZKRQHBQNCA-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 description 1
- 229930190376 scutellarin Natural products 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003033 spasmogenic effect Effects 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000002325 super-antigenic effect Effects 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 101150065190 term gene Proteins 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 235000014620 theaflavin Nutrition 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- OXHYRVSBKWIFES-WWSDOYNLSA-N trap-14 peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 OXHYRVSBKWIFES-WWSDOYNLSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940087652 vioxx Drugs 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- This invention relates generally to a composition of matter formulated for use in the prevention and treatment of neurodegradation, neuroinflammation and cumulative cognitive declines, disorders, diseases and conditions resulting from exposure to reactive oxygen species (ROS), inflammatory proteins and eicosanoids.
- the present invention relates to a novel composition of matter comprised of a mixture of a blend of two specific classes of compounds—Free-B-Ring flavonoids and flavans—for use in the prevention and treatment of age, cognitive, neuroinflammatory and neurodegenerative related diseases and conditions mediated by oxidative insult, inflammation and the cycloxygenase (COX) and lipoxygenase (LOX) pathways.
- the diseases and conditions include, but are not limited to, neurodegenerative disorders, stroke, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis (ALS) and cognitive declines resulting from advancing age.
- AA arachidonic acid
- 5-LO 5-lipoxygenase
- COX cycloxygenase
- COX-1 is a constitutive form of the enzyme that has been linked to the production of physiologically important prostaglandins involved in the regulation of normal physiological functions such as platelet aggregation, protection of cell function in the stomach and maintenance of normal kidney function (Dannhardt and Kiefer (2001) Eur. J. Med. Chem. 36:109-126).
- the second isoform, COX-2 is a form of the enzyme that is inducible by pro-inflammatory cytokines such as interleukin-1 ⁇ (IL-1 ⁇ ) and other growth factors (Herschmann (1994) Cancer Metastasis Rev. 134:241-256; Xie et al. (1992) Drugs Dev. Res. 25:249-265).
- This isoform catalyzes the production of prostaglandin E2 (PGE 2 ) from AA.
- PGE 2 prostaglandin E2
- Inhibition of COX-2 is responsible for the anti-inflammatory activities of conventional NSAIDs.
- COX inhibitors are used to treat many of the same symptoms, such as the pain and swelling associated with inflammation in transient conditions and chronic diseases in which inflammation plays a critical role.
- Transient conditions include the treatment of inflammation associated with minor abrasions, sunburn or contact dermatitis, as well as, the relief of pain associated with tension and migraine headaches and menstrual cramps.
- Chronic conditions include arthritic diseases such as rheumatoid arthritis and osteoarthritis.
- COX inhibitors are also used for the relief of inflammatory skin conditions that are not of rheumatic origin, such as psoriasis, in which reducing the inflammation resulting from the over production of prostaglandins could provide a direct benefit (Fogh et al. (1993) Acta Derm. Venereol (Oslo) 73:191-193).
- NSAIDs also inhibit ⁇ -secretase activity thereby preventing amyloid precursor protein (APP) processing, elevation of amyloid-beta (A ⁇ ) peptide levels and development of neurofibrillary tangles (NFT) and neuritic plaque (Weggen et al. (2001) Nature 414:212-216; Takahashi et al. (2003) J. Biol. Chem. 278:18664-18670).
- APP amyloid precursor protein
- a ⁇ amyloid-beta
- NFT neurofibrillary tangles
- neuritic plaque Weggen et al. (2001) Nature 414:212-216; Takahashi et al. (2003) J. Biol. Chem. 278:18664-18670.
- NSAIDs which have cognitive preserving and neuroprotective properties resulting from their multifactoral activity on ROS, cytokines and pro-inflammatory eicosanoids. They act to inhibit amyloid deposition, diminish thromboxane and prostanoid production, attenuate cytokine production, prevent microglial activation, lower ROS generation, and, in some instances, possess a high antioxidant capacity. All of these activities can prevent cognitive decline and slow the cumulative effect upon neurodegeneration resulting from oxidative stress and aging.
- NSAID's The neuroprotective activity of NSAID's forms the basis of current theories regarding somatic and neurodegenerative decline seen with varying degenerative disease states, aging, inflammation and oxidative stress.
- Administration of antioxidants prior to exposure provided the organism with some protection against the damaging effects of radiation.
- N-tert-butyl- ⁇ -phenylnitrone demonstrates the ability to pharmacologically attenuate neurodegeneration induced by aging and ROS.
- PBN is a free radical scavenger, which has been shown to decrease ROS (Floyd (1999) Proc Soc Exp Biol Med. 222(3):236-245), lower protein carbonyl generation in the senescence accelerated mouse model (Butterfield et al. (1997) Proc. Natl. Acad. Sci. USA 94:674-678), protect the brains of gerbils in ischemia re-perfusion injuries (Floyd and Hensley (2000) Ann NY Acad. Sci.
- inflammatory prostanoids compromise LTP by up-regulating the inflammatory cytokine IL-1 ⁇ .
- This cytokine which has been shown to increase with age and oxidative stress, inhibits LTP in the CA1 region of the hippocampus and the DG.
- IL-1 ⁇ Associated with the up-regulation in IL-1 ⁇ expression is an increase in lipid peroxidation in the hippocampus.
- Flavonoids or bioflavonoids are a widely distributed group of natural products, which have been reported to have antibacterial, anti-inflammatory, antiallergic, antimutagenic, antiviral, antineoplastic, anti-thrombic and vasodilatory activity.
- the structural unit common to this group of compounds includes two benzene rings on either side of a 3-carbon ring as illustrated by the following general structural formula:
- flavonoids include flavanols, flavones, flavan-3-ols (catechins), anthocyanins and isoflavones.
- RT-qPCR and DNA microarray analysis rely on mRNA levels for analysis and can be used to evaluate levels of gene expression under different conditions, i.e. in the presence or absence of a pharmaceutical agent.
- Applicant is unaware of any reported methods that specifically measure the amount of mRNA, directly or indirectly, when a composition comprised of a combination of Free-B-ring flavonoids and flavans are used as the therapeutic agents.
- Free-B-Ring flavones and flavonols are a specific class of flavonoids, which have no substituent groups on the aromatic B ring (referred to herein as Free-B-Ring flavonoids), as illustrated by the following general structure:
- R 1 , R 2 , R 3 , R 4 , and R 5 are independently selected from the group consisting of —H, —OH, —SH, OR, —SR, —NH 2 , —NHR, —NR 2 , —NR 3 + X ⁇ , a carbon, oxygen, nitrogen or sulfur, glycoside of a single or a combination of multiple sugars including, but not limited to aldopentoses, methyl-aldopentose, aldohexoses, ketohexose and their chemical derivatives thereof;
- R is an alkyl group having between 1-10 carbon atoms
- X is selected from the group of pharmaceutically acceptable counter anions including, but not limited to hydroxyl, chloride, iodide, fluoride, sulfate, phosphate, acetate, carbonate, etc.
- Free-B-ring flavonoids are relatively rare. Out of 9,396 flavonoids synthesized or isolated from natural sources, only 231 Free-B-ring flavonoids are known ( The Combined Chemical Dictionary , Chapman & Hall/CRC, Version 5:1 Jun. 2001). Free-B-ring flavonoids have been reported to have diverse biological activity. For example, galangin (3,5,7-trihydroxyflavone) acts as an anti-oxidant and free radical scavenger and is believed to be a promising candidate for anti-genotoxicity and cancer chemoprevention. (Heo et al. (2001) Mutat. Res. 488:135-150).
- flavonoids have been tested for biological activity randomly based upon their availability. Occasionally, the requirement of substitution on the B-ring has been emphasized for specific biological activity, such as the B-ring substitution required for high affinity binding to p-glycoprotein (Boumendjel et al. (2001) Bioorg. Med. Chem. Lett. 11 (1):75-77); cardiotonic effect (Itoigawa et al. (1999) J. Ethnopharmacol. 65(3): 267-272), protective effect on endothelial cells against linoleic acid hydroperoxide-induced toxicity (Kaneko and Baba (1999) Biosci Biotechnol.
- Baicalin from Scutellaria baicalensis reportedly inhibits superantigenic staphylococcal exotoxins stimulated T-cell proliferation and production of IL-1 ⁇ , IL-6, TNF- ⁇ , and interferon- ⁇ (IFN- ⁇ ).
- IFN- ⁇ interferon- ⁇
- baicalin has been associated with inhibiting the pro-inflammatory cytokines mediated signaling pathways activated by superantigens.
- the anti-inflammatory activity of baicalin is due to the binding of a variety of chemokines, which limits their biological activity. (Li et al. (2000) Immunopharmacology 49:295-306).
- the Chinese medicinal plant, Scutellaria baicalensis contains significant amounts of Free-B-Ring flavonoids, including baicalein, baicalin, wogonin and baicalenoside.
- this plant has been used to treat a number of conditions including clearing away heat, purging fire, dampness-warm and summer fever syndromes; polydipsia resulting from high fever; carbuncle, sores and other pyogenic skin infections; upper respiratory infections, such as acute tonsillitis, laryngopharyngitis and scarlet fever; viral hepatitis; nephritis; pelvitis; dysentery; hematemesis and epistaxis.
- This plant has also traditionally been used to prevent miscarriage.
- Scutellaria baicalensis root extract has been formulated as a supplemental sun screen agent with additive effects of the cumulative SPFs of each individual component in a topical formulation (WO98/19651).
- Chrysin has been used for its anxiety reducing properties (U.S. Pat. No. 5,756,538).
- Anti-inflammatory flavonoids are used for the control and treatment of anorectal and colonic diseases (U.S. Pat. No. 5,858,371), and inhibition of lipoxygenase (U.S. Pat. No. 6,217,875). These compounds are also formulated with glucosamine collagen and other ingredients for repair and maintenance of connective tissue (U.S. Pat. No. 6,333,304).
- Flavonoid esters constitute active ingredients for cosmetic compositions (U.S. Pat. No. 6,235,294).
- Japanese Pat. No. 63027435 describes the extraction, and enrichment of baicalein and Japanese Pat. No. 61050921 describes the purification of baicalin.
- Flavans include compounds illustrated by the following general structure:
- R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of —H, —OH, —SH, —OCH 3 , —SCH 3 , —OR, —SR, —NH 2 , —NRH, —NR 2 , —NR 3 + X ⁇ , esters of the mentioned substitution groups, including, but not limited to, gallate, acetate, cinnamoyl and hydroxyl-cinnamoyl esters, trihydroxybenzoyl esters and caffeoyl esters, and their chemical derivatives thereof; a carbon, oxygen, nitrogen or sulfur glycoside of a single or a combination of multiple sugars including, but not limited to, aldopentoses, methyl aldopentose, aldohexoses, ketohexose and their chemical derivatives thereof; dimer, trimer and other polymerized flavans;
- R is an alkyl group having between 1-10 carbon atoms
- X is selected from the group of pharmaceutically acceptable counter anions including, but not limited to hydroxyl, chloride, iodide, sulfate, phosphate, acetate, fluoride, and carbonate, etc.
- Catechin is a flavan, found primarily in green tea, having the following structure:
- Catechin works both alone and in conjunction with other flavonoids found in tea, and has both antiviral and antioxidant activity. Catechin has been shown to be effective in the treatment of viral hepatitis. It also appears to prevent oxidative damage to the heart, kidney, lungs and spleen and has been shown to inhibit the growth of stomach cancer cells.
- (+)-Catechin isolated from the bark of Ceiba pentandra , inhibits COX-1 with an IC 50 value of 80 ⁇ M.
- Commercially available pure (+)-catechin inhibits COX-1 with an IC 50 value of around 183 to 279 ⁇ M depending upon the experimental conditions, with no selectivity for COX-2. (Noreen et al. (1998) J. Nat. Prod. 61:1-7).
- Green tea catechin when supplemented into the diets of Sprague Dawley male rats, lowered the activity level of platelet PLA 2 and significantly reduced platelet cycloxygenase levels.
- (+)-catechin from red wine results from the antioxidant properties of catechin, rather than inhibitory effects on intracellular enzymes, such as cycloxygenase, lipoxygenase, or nitric oxide synthase (Bastianetto et al. (2000) Br. J. Pharmacol. 131:711-720).
- Catechin derivatives purified from green and black tea such as epigallocatechin-3-gallate (EGCG), epigallocatechin (EGC), epicatechin-3-gallate (ECG), and theaflavins showed inhibition of cycloxygenase and lipoxygenase dependent metabolism of AA in human colon mucosa and colon tumor tissues (Hong et al. (2001) Biochem.
- Acacia is a genus of leguminous trees and shrubs.
- the genus Acacia includes more than 1000 species belonging to the family of Leguminosae and the subfamily of Mimosoideae.
- Acacias are distributed worldwide in tropical and subtropical areas of Central and South America, Africa, parts of Asia, as well as, Australia, which has the largest number of endemic species.
- Acacias are very important economically, providing a source of tannins, gums, timber, fuel and fodder. Tannins, which are isolated primarily from bark, are used extensively for tanning hides and skins. Some Acacia barks are also used for flavoring local spirits. Some indigenous species like A.
- saponins are any of various plant glucosides that form soapy lathers when mixed and agitated with water. Saponins are used in detergents, foaming agents and emulsifiers. The flowers of some Acacia species are fragrant and used to make perfume. The heartwood of many Acacias is used for making agricultural implements and also provides a source of firewood. Acacia gums find extensive use in medicine and confectionery and as sizing and finishing materials in the textile industry.
- Flavonoids are the major class of compounds isolated from Acacias . Approximately 180 different flavonoids have been identified, 111 of which are flavans. Terpenoids are second largest class of compounds isolated from species of the Acacia genus, with 48 compounds having been identified. Other classes of compounds isolated from Acacia include, alkaloids (28), amino acids/peptides (20), tannins (16), carbohydrates (15), oxygen heterocycles (15) and aliphatic compounds (10). (Buckingham, The Combined Chemical Dictionary , Chapman & Hall CRC, version 5:2, December 2001).
- Phenolic compounds, particularly flavans are found in moderate to high concentrations in all Acacia species. (Abdulrazak et al. (2000) Journal of Animal Sciences. 13:935-940). Historically, most of the plants and extracts of the Acacia genus have been utilized as astringents to treat gastrointestinal disorders, diarrhea, indigestion and to stop bleeding. (Vautrin (1996) Universite Bourgogne (France) European abstract 58-01C:177; Saleem et al. (1998) Hamdard Midicus. 41:63-67). The bark and pods of Acacia arabica Willd . contain large quantities of tannins and have been utilized as astringents and expectorants.
- the extract from the bark of Acacia has been patented in Japan for external use as a whitening agent (Abe, JP10025238), as a glucosyl transferase inhibitor for dental applications (Abe, JP07242555), as a protein synthesis inhibitor (Fukai, JP 07165598), as an active oxygen scavenging agent for external skin preparations (Honda, JP 07017847, Bindra U.S. Pat. No. 6,1266,950) and as a hyaluronidase inhibitor for oral consumption to prevent inflammation, pollinosis and cough (Ogura, JP 07010768).
- the present invention includes methods that are effective in simultaneously inhibiting both the cycloxygenase (COX) and lipoxygenase (LOX) enzymes.
- the method for the simultaneous dual inhibition of the COX and LOX enzymes is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants to a host in need thereof.
- This composition of matter is referred to herein as LasoperinTM.
- the ratio of Free-B-Ring flavonoids to flavans in the composition of matter can be adjusted based on the indications and the specific requirements with respect to prevention and treatment of a specific disease or condition.
- the ratio of the Free-B-Ring flavonoids to flavans in the composition can be in the range of 99.9:0.1 of Free-B-Ring flavonoids:flavans to 0.1:99.9 Free-B-Ring flavonoids:flavans.
- the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90.
- the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is 80:20.
- the Free-B-Ring flavonoids are isolated from a plant or plants in the Scutellaria genus of plants and the flavans are isolated from a plant or plants in the Acacia genus of plants.
- the efficacy of this method was demonstrated with purified enzymes, in different cell lines, in multiple animal models and eventually in a human clinical study.
- the present includes methods for the prevention and treatment of COX and LOX mediated diseases and conditions related to neuronal and cognitive function, said method comprising administering to a host in need thereof an effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants and a pharmaceutically acceptable carrier.
- the ratio of Free-B-Ring flavonoids to flavans in the composition can be in the range of 99.9:0.1 of Free-B-Ring flavonoids:flavans to 0.1:99.9 Free-B-Ring flavonoids:flavans.
- the ratio of Free-B-Ring flavonoids to flavans can be selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In one embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20. In a preferred embodiment, the Free-B-Ring flavonoids are isolated from a plant or plants in the Scutellaria genus of plants and flavans are isolated from a plant or plants in the Acacia genus of plants.
- the present includes a method for the prevention and treatment of general cognitive decline, age-related memory loss, neuroinflammatory and neurodegenerative disorders, said method comprising administering to a host in need thereof an effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants together with a pharmaceutically acceptable carrier.
- the ratio of Free-B-Ring flavonoids to flavans can be in the range of 99.9:0.1 to 0.1:99.9 Free-B-Ring flavonoids:flavans.
- the ratio of Free-B-Ring flavonoids to flavans is from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In one embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20. In a preferred embodiment, the Free-B-ring flavonoids are isolated from a plant or plants in the Scutellaria genus of plants and flavans are isolated from a plant or plants in the Acacia genus of plants.
- the present invention includes a method for modulating the production of mRNA implicated in cognitive decline and other age-, neurodegenerative-, and neuroinflammatory-related conditions, said method comprising administering to a host in need thereof an effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants and a pharmaceutically acceptable carrier.
- the ratio of Free-B-Ring flavonoids to flavans can be in the range of 99.9:0.1 to 0.1:99.9 Free-B-Ring flavonoids:flavans.
- the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In one embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20. In one embodiment the Free-B-Ring flavonoids are isolated from a plant or plants in the Scutellaria genus of plants and flavans are isolated from a plant or plants in the Acacia genus of plants.
- the present invention also includes a method for modulating the production of mRNA of transcription factors that control production of cytokine mRNA implicated in cognitive decline and other age-, neurodegenerative-, and neuroinflammatory-related conditions, said method comprising administering to a host in need thereof an effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants and a pharmaceutically acceptable carrier.
- the ratio of Free-B-Ring flavonoids to flavans can be in the range of 99.9:0.1 to 0.1:99.9 Free-B-Ring flavonoids:flavans.
- the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In one embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20. In a preferred embodiment the Free-B-Ring flavonoids are isolated from a plant or plants in the Scutellaria genus of plants and flavans are isolated from a plant or plants in the Acacia genus of plants.
- the present invention includes a method for modulating the production of mRNA transcription factors that controls production of cox-2, but not cox-1 mRNA implicated in cognitive decline and other age-, neurodegenerative-, and neuroinflammatory-related conditions, said method comprising administering to a host in need thereof an effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants and a pharmaceutically acceptable carrier.
- the ratio of Free-B-Ring flavonoids to flavans can be in the range of 99.9:0.1 to 0.1:99.9 Free-B-ring flavonoids:flavans.
- the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In one embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20. In a preferred embodiment the Free-B-Ring flavonoids are isolated from a plant or plants in the Scutellaria genus of plants and flavans are isolated from a plant or plants in the Acacia genus of plants.
- composition of the instant invention acts by inhibiting pro-inflammatory cytokines via down-regulation of the nuclear factor kappa B (NF ⁇ B) transcription factor, which controls gene expression of interleukin-1 beta (IL-1 ⁇ ), tumor necrosis factor-alpha (TNF ⁇ ), and interleukin-6 (IL-6). It is also believed that the composition inhibits the gene expression of another transcription factor, peroxisome proliferator activated receptor gamma (PPAR ⁇ ), which helps control the gene expression of cyclooxygenase-2 (COX-2).
- NF ⁇ B nuclear factor kappa B
- PPAR ⁇ peroxisome proliferator activated receptor gamma
- composition of the instant invention inhibits the activity of COX-2 and 5-lipoxygenase (5-LO) thereby suppressing the conversion of AA to prostaglandins, thromboxanes, and leukotrienes, each of which exacerbate inflammation.
- the composition also possesses a strong antioxidant capacity which neutralizes reactive oxygen species (ROS), molecules that can lead to greater NF ⁇ B expression, and thus, greater pro-inflammatory gene expression of cytokines.
- ROS reactive oxygen species
- Free-B-Ring flavonoids also referred to herein as Free-B-Ring flavones and flavonols, that can be used in accordance with the following invention include compounds illustrated by the following general structure:
- R 1 , R 2 , R 3 , R 4 , and R 5 are independently selected from the group consisting of —H, —OH, —SH, OR, —SR, —NH 2 , —NHR, —NR 2 , —NR 3 + X ⁇ , a carbon, oxygen, nitrogen or sulfur, glycoside of a single or a combination of multiple sugars including, but not limited to aldopentoses, methyl-aldopentose, aldohexoses, ketohexose and their chemical derivatives thereof;
- R is an alkyl group having between 1-10 carbon atoms
- X is selected from the group of pharmaceutically acceptable counter anions including, but not limited to hydroxyl, chloride, iodide, sulfate, phosphate, acetate, fluoride, carbonate, etc.
- the Free-B-Ring flavonoids of this invention may be obtained by synthetic methods or extracted from the family of plants including, but not limited to Annonaceae, Asteraceae, Bignoniaceae, Combretaceae, Compositae, Euphorbiaceae, Labiatae, Lauranceae, Leguminosae, Moraceae, Pinaceae, Pteridaceae, Sinopteridaceae, Ulmaceae and Zingiberacea.
- the Free-B-Ring flavonoids can be extracted, concentrated, and purified from the following genus of high plants, including but not limited to Desmos, Achyrocline, Oroxylum, Buchenavia, Anaphalis, Cotula, Gnaphalium, Helichrysum, Centaurea, Eupatorium, Baccharis, Sapium, Scutellaria, Molsa, Colebrookea, Stachys, Origanum, Ziziphora, Lindera, Actinodaphne, Acacia, Derris, Glycyrrhiza, Millettia, Pongamia, Tephrosia, Artocarpus, Ficus, Pityrogramma, Notholaena, Pinus, Ulmus and Alpinia.
- the flavans that can be used in accordance with the following invention include compounds illustrated by the following general structure: generally represented by the following general structure:
- R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of H, —OH, —SH, —OCH 3 , —SCH 3 , —OR, —SR, —NH 2 , —NRH, —NR 2 , —NR 3 + X ⁇ , esters of substitution groups, including, but not limited to, gallate, acetate, cinnamoyl and hydroxyl-cinnamoyl esters, trihydroxybenzoyl esters and caffeoyl esters and their chemical derivatives thereof; carbon, oxygen, nitrogen or sulfur glycoside of a single or a combination of multiple sugars including, but not limited to, aldopentoses, methyl aldopentose, aldohexoses, ketohexose and their chemical derivatives thereof; dimer, trimer and other polymerized flavans;
- R is an alkyl group having between 1-10 carbon atoms
- X is selected from the group of pharmaceutically acceptable counter anions including, but not limited to hydroxyl, chloride, iodide, sulfate, phosphate, acetate, fluoride, carbonate, etc.
- the flavans of this invention may be obtained from a plant or plants selected from the genus of Acacia .
- the plant is selected from the group consisting of Acacia catechu, Acacia concinna, Acacia farnesiana, Acacia Senegal, Acacia speciosa, Acacia arabica, A. caesia, A. pennata, A. sinuata. A. mearnsii, A. picnantha, A. dealbata, A. auriculiformis, A. holoserecia and A. mangium.
- the present invention includes a method for preventing and treating a number of COX and LOX mediated diseases and conditions related to neuronal and cognitive function, including, but not limited to general cognitive decline, age-related memory loss, neuroinflammatory and neurodegenerative disorders and other conditions relating to neuronal and cognitive function.
- the present invention includes a method for modulating the production of mRNA implicated in cognitive decline and other age-, neurodegenerative-, and neuroinflammatory-related conditions.
- the method of prevention and treatment according to this invention comprises administering to a host in need thereof a therapeutically effective amount of the formulated Free-B-Ring flavonoids and flavans isolated from a single source or multiple sources.
- the purity of the individual and/or a mixture of multiple Free-B-Ring flavonoids and flavans includes, but is not limited to 0.01% to 100%, depending on the methodology used to obtain the compound(s).
- doses of the mixture of Free-B-Ring flavonoids and flavans containing the same are an efficacious, nontoxic quantity generally selected from the range of 0.001% to 100% based on total weight of the formulation. Persons skilled in the art using routine clinical testing are able to determine optimum doses for the particular ailment being treated.
- the present invention includes an evaluation of different compositions of Free-B-Ring flavonoids and flavans using enzymatic and in vivo models to optimize the formulation and obtain the desired physiological activity. The efficacy and safety of these formulations is demonstrated in human clinical studies.
- the present invention also includes therapeutic compositions comprising the therapeutic agents of the present invention.
- the compositions of this invention can be administered by any method known to one of ordinary skill in the art.
- the modes of administration include, but are not limited to, enteral (oral) administration, parenteral (intravenous, subcutaneous, and intramuscular) administration and topical application.
- FIGS. 1A-1C depict graphically the effect of LasoperinTM administered daily in a 13-week radial arm water maze (RAWM) test to Fisher 344 aged male rats fed a normal diet and a diet supplemented with 3, 7 or 34 mg/kg of LasoperinTM, respectively, as described in Example 2.
- the LasoperinTM formulation (80:20) was prepared as described in Example 1 using two standardized extracts isolated from the bark of Acacia catechu and the roots of Scutellaria baicalensis .
- FIG. 1A illustrates the results following pre-testing during weeks 1 and 2 (Baseline).
- FIG. 1B illustrates the results following week 5 (Session II)
- FIG. 1C illustrates the results following week 11 (Session III).
- FIG. 2 illustrates the effect of LasoperinTM administered daily for 12 weeks prior to contextual fear conditioning (CFC) testing in Fisher 344 aged male rats fed a normal diet or a diet supplemented with 3, 7 or 34 mg/kg LasoperinTM, as described in Example 3.
- the LasoperinTM formulation (80:20) was prepared as described in Example 1 using two standardized extracts isolated from the bark of Acacia catechu and the roots of Scutellaria baicalensis .
- FIG. 3 depicts graphically the effect of LasoperinTM on complex choice reaction time as described in Example 4.
- the LasoperinTM was administered daily to 40 individuals in a 4 week clinical trial. The results are compared to a group of 46 individuals that were given a placebo over the same time period.
- the LasoperinTM formulation (80:20) was prepared as described in Example 1 using two standardized extracts isolated from the bark of Acacia catechu and the roots of Scutellaria baicalensis . The data is presented as percent change from baseline. This figure demonstrates that LasoperinTM (300 mg/d) increased speed of processing for subjects presented with complex choices and information.
- FIG. 4 depicts graphically the effect of LasoperinTM on reaction time standard deviation (RTSD) as described in Example 5.
- the LasoperinTM was administered daily to 40 individuals in a 4 week clinical trial. The results are compared to a group of 46 individuals that were given a placebo over the same time period.
- the LasoperinTM formulation (80:20) was prepared as described in Example 1 using two standardized extracts isolated from the bark of Acacia catechu and the roots of Scutellaria baicalensis . The data is presented as percent change from baseline. This figure demonstrates that LasoperinTM (300 mg/d) increased the intra-trial reaction time standard deviation, that is the ability to stay focused and attentive improved during demanding cognitive tasks.
- FIG. 5 depicts graphically the inhibition of COX-1 and COX-2 by LasoperinTM
- the LasoperinTM formulation (50:50) was prepared as described in Example 1 using two standardized extracts isolated from the bark of Acacia catechu and the roots of Scutellaria baicalensis . LasoperinTM was examined for its inhibition of the peroxidase activity of recombinant ovine COX-1 ( ⁇ ) and ovine COX-2 ( ⁇ ). The data is presented as percent inhibition vs. inhibitor concentration ( ⁇ g/mL) The IC 50 for COX-1 was 0.38 ⁇ g/mL/unit of enzyme, while the IC 50 for COX-2 was 0.84 ⁇ g/mL/unit.
- FIG. 6 depicts graphically a profile of the inhibition of 5-LO by the purified flavan catechin isolated from A. catechu .
- the compound was examined for its inhibition of recombinant potato 5-lipoxygenase activity ( ⁇ ).
- the data is presented as percent inhibition of assays without inhibitor vs. inhibitor concentration ( ⁇ g/mL)
- the IC 50 for 5-LO was 1.38 ⁇ g/mL/unit of enzyme.
- FIG. 7 compares the LTB 4 levels as determined by ELISA that remain in HT-29 cells after treatment with 3 ⁇ g/mL LasoperinTM in non-induced cells to treatment with 3 ⁇ g/mL ibuprofen as described in Example 8.
- the LasoperinTM formulation (80:20) was prepared as described in Example 1 using two standardized extracts isolated from the bark of Acacia catechu and the roots of Scutellaria baicalensis.
- FIG. 8 illustrates graphically the effect of a mixture of Free-B-Ring flavonoids and flavans (80:20) on the lipopolysaccharide (LPS)-induced level of TNF ⁇ in peripheal blood monocytes (PBMC) following exposure to the lipopolysaccharide in conjunction with different concentrations of the Free-B-Ring flavonoid and flavan mixture for one hour.
- the level of TNF ⁇ is expressed in pg/mL.
- FIG. 9 depicts the effect of a mixture of Free-B-Ring flavonoids and flavans (80:20) on the lipopolysaccharide (LPS)-induced level of IL-1 ⁇ in peripheal blood monocytes (PBMC) following exposure to the lipopolysaccharide in conjunction with different concentrations of the Free-B-Ring flavonoid and flavan mixture for four hours.
- the level of IL-1 ⁇ is expressed in pg/mL
- FIG. 10 illustrates graphically the effect of a mixture of Free-B-Ring flavonoids and flavans (80:20) on the lipopolysaccharide (LPS)-induced level of IL-6 in peripheal blood monocytes (PBMC) following exposure to the lipopolysaccharide in conjunction with different concentrations of the Free-B-Ring flavonoid and flavan mixture for four hours.
- the level of IL-6 is expressed in pg/mL The standard deviation is shown for each data point.
- FIG. 11 compares the effect of various concentrations of LasoperinTM on cox-1 and cox-2 gene expression.
- the expression levels are standardized to 18S rRNA expression levels (internal control) and then normalized to the no-treatment, no-LPS condition.
- This Figure demonstrates a decrease in cox-2, but not cox-1 gene expression following LPS-stimulation and exposure to LasoperinTM
- FIG. 12 compares the effect of 3 ⁇ g/mL LasoperinTM on cox-1 and cox-2 gene expression with the equivalent concentration of other NSAIDs.
- the expression levels are standardized to 18S rRNA expression levels (internal control) and then normalized to the no-treatment, no-LPS condition.
- FIGS. 13A and 13B illustrate the effect of various concentrations of LasoperinTM on tnf ⁇ -1 ( FIG. 13A ) and il-1 ⁇ ( FIG. 13B ) gene expression.
- the expression levels are standardized to 18S rRNA expression levels (internal control) and then normalized to the no-treatment, no-LPS condition.
- These figures demonstrate a decrease in tnf ⁇ -1 and il-1 ⁇ gene expression following LPS-stimulation and exposure to LasoperinTM.
- FIG. 14 illustrates the effect of LasoperinTM on the lipopolysaccharide (LPS)-induced level of cox-1, cox-2, il-1 ⁇ , tnf ⁇ , il-6, nf ⁇ b and ppar ⁇ in peripheral blood monocytes (PBMC) from three subjects following exposure for four hours as described in Example 11.
- LPS lipopolysaccharide
- FIG. 15 illustrates the promoters for tnf ⁇ , il-1 ⁇ , il-6 and cox-2 affected by down-regulation of nf ⁇ b and ppar ⁇ gene expression reduction.
- FIG. 16 illustrates the High Pressure Liquid Chromatography (HPLC) chromatogram of the mixture of Free-B-Ring flavonoids and flavans carried out under the conditions as described in Example 14. Using the described conditions the Free B-ring flavonoids eluted between 11 to 14 minutes and the flavans eluted between 3 to 5 minutes.
- HPLC High Pressure Liquid Chromatography
- FIG. 17 depicts an HPLC chromatogram of the mixture of Free-B-Ring flavonoids and flavans carried out under the conditions as described in Example 14.
- the two flavans catechins and epicatechins
- the Free-B-Ring flavonoids bacalein and bacalin
- the separation is based upon differences in molar absorptivity of the Free-B-Ring flavonoids and flavans.
- the present invention includes methods that are effective in simultaneously inhibiting both the cycloxygenase (COX) and lipoxygenase (LOX) enzymes, for use in the prevention and treatment of diseases and conditions related to neuronal and cognitive function.
- the method for the simultaneous dual inhibition of the COX and LOX enzymes is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants to a host in need thereof.
- This composition of matter is referred to herein as LasoperinTM.
- the ratio of Free-B-Ring flavonoids to flavans in the composition of matter can be adjusted based on the indications and the specific requirements with respect to prevention and treatment of a specific disease or condition.
- a or “an” entity refers to one or more of that entity; for example, a flavonoid refers to one or more flavonoids.
- a flavonoid refers to one or more flavonoids.
- the terms “a” or “an”, “one or more” and “at least one” are used interchangeably herein.
- Free-B-ring Flavonoids as used herein are a specific class of flavonoids, which have no substitute groups on the aromatic B-ring, as illustrated by the following general structure:
- R 1 , R 2 , R 3 , R 4 , and R 5 are independently selected from the group consisting of —H, —OH, —SH, OR, —SR, —NH 2 , —NHR, —NR 2 , —NR 3 + X ⁇ , a carbon, oxygen, nitrogen or sulfur, glycoside of a single or a combination of multiple sugars including, but not limited to aldopentoses, methyl-aldopentose, aldohexoses, ketohexose and their chemical derivatives thereof;
- R is an alkyl group having between 1-10 carbon atoms
- X is selected from the group of pharmaceutically acceptable counter anions including, but not limited to hydroxyl, chloride, iodide, sulfate, phosphate, acetate, fluoride, carbonate, etc.
- Flavonoids as used herein refer to a specific class of flavonoids, which can be generally represented by the following general structure:
- R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of H, —OH, —SH, —OCH 3 , —OR, —SR, —NH 2 , —NRH, —NR 2 , —NR 3 + X ⁇ , esters of substitution groups, including, but not limited to, gallate, acetate, cinnamoyl and hydroxyl-cinnamoyl esters, trihydroxybenzoyl esters and caffeoyl esters and their chemical derivatives thereof; carbon, oxygen, nitrogen or sulfur glycoside of a single or a combination of multiple sugars including, but not limited to, aldopentoses, methyl aldopentose, aldohexoses, ketohexose and their chemical derivatives thereof; dimer, trimer and other polymerized flavans;
- R is an alkyl group having between 1-10 carbon atoms
- X is selected from the group of pharmaceutically acceptable counter anions including, but not limited to hydroxyl, chloride, iodide, sulfate, phosphate, acetate, fluoride, carbonate, etc.
- “Therapeutic” as used herein, includes treatment and/or prophylaxis. When used, therapeutic refers to humans as well as other animals
- “Pharmaceutically or therapeutically effective dose or amount” refers to a dosage level sufficient to induce a desired biological result. That result may be the alleviation of the signs, symptoms or causes of a disease or any other alteration of a biological system that is desired. The precise dosage will vary according to a variety of factors, including but not limited to the age and size of the subject, the disease and the treatment being effected.
- “Placebo” refers to the substitution of the pharmaceutically or therapeutically effective dose or amount dose sufficient to induce a desired biological that may alleviate the signs, symptoms or causes of a disease with a non-active substance.
- a “host” or “patient” or “subject” is a living mammal, human or animal, for whom therapy is desired.
- the “host,” “patient” or “subject” generally refers to the recipient of the therapy to be practiced according to the method of the invention.
- a “pharmaceutically acceptable carrier” refers to any carrier, which does not interfere with effectiveness of the biological activity of the active ingredient and which is not toxic to the host to which it is administered.
- pharmaceutically acceptable carriers include, but are not limited to, any of the standard pharmaceutical carriers such as a saline solution, i.e. Ringer's solution, a buffered saline solution, water, a dextrose solution, serum albumin. and other excipients and preservatives for tableting and capsulating formulations.
- Gene expression refers to the transcription of a gene to mRNA.
- Protein expression refers to the translation of mRNA to a protein.
- RT-qPCR refers to a method for reverse transcribing (RT) an mRNA molecule into a cDNA molecule and then quantitatively evaluating the level of gene expression using a polymerase chain reaction (PCR) coupled with a fluorescent reporter.
- PCR polymerase chain reaction
- the present invention includes methods that are effective in simultaneously inhibiting both the COX and LOX enzymes for use in the prevention and treatment of diseases and conditions related to neuronal and cognitive function.
- the method for the simultaneous dual inhibition of the COX and LOX enzymes is comprised of administering a composition comprised of a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants to a host in need thereof.
- This composition of matter which is referred to herein as LasoperinTM, is also distributed under the trade name of UnivestinTM, as described in U.S.
- the ratio of Free-B-Ring flavonoids to flavans can be in the range of 99.9:0.1 Free-B-Ring flavonoids:flavans to 0.1:99.9 Free-B-Ring flavonoids:flavans.
- the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90.
- the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20.
- the present invention includes methods that are effective in the prevention and treatment of age-, cognitive-, neurodegenerative- and neuroinflammatory-related diseases and conditions.
- the method for the prevention and treatment of these cognitive and neuronal diseases and conditions is comprised of administering to a host in need thereof a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants.
- the ratio of Free-B-Ring flavonoids to flavans in the composition can be in the range of 99.9:0.1 Free-B-Ring flavonoids:flavans to 0.1:99.9 of Free-B-Ring flavonoids:flavans.
- the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In one embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20.
- a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants together with a pharmaceutically acceptable carrier.
- the ratio of Free-B-Ring flavonoids to flavans in the composition can be in the range of 99.9:0.1 Free-B-Ring flavonoids:flavans to 0.1:99.9 of Free-B-Ring flavonoids:flavans.
- the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In one embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20.
- the method for the reduction of TNF ⁇ and IL-1 ⁇ is comprised of administering to a host in need thereof an effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants together with a pharmaceutically acceptable carrier.
- the ratio of Free-B-Ring flavonoids to flavans in the composition can be in the range of 99.9:0.1 Free-B-ring flavonoids:flavans to 0.1:99.9 of Free-B-Ring flavonoids:flavans.
- the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In a preferred embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20.
- the present further includes a method for the prevention and treatment of diseases and conditions mediated by ROS, via the reduction of ROS.
- ROS are a pivotal product of oxidative stress and lipid metabolism and can be significantly elevated in age-, cognitive-, neurodegenerative- and neuroinflammatory-related diseases and conditions.
- the method for treating ROS-mediated diseases and conditions is comprised of administering to a host in need thereof an effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants, together with a pharmaceutically acceptable carrier.
- the ratio of Free-B-Ring flavonoids to flavans in the composition can be in the range of 99.9:0.1 Free-B-Ring flavonoids:flavans to 0.1:99.9 of Free-B-Ring flavonoids:flavans.
- the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90.
- the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20.
- the present invention also includes a method for modulating the production of mRNA implicated in cognitive decline and other age-, neurodegenerative-, and neuroinflammatory-related conditions, including a method for modulating the production of mRNA of transcription factors that control the production of cytokine mRNA and a method for modulating the production of mRNA of the transcription factors that control the production of cox-2, but not cox-1 mRNA.
- the method for modulating the production of m-RNA implicated in cognitive decline and other age-, neurodegenerative-, and neuroinflammatory-related conditions is comprised of administering to a host in need thereof an effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants together with a pharmaceutically acceptable carrier.
- the ratio of Free-B-Ring flavonoids to flavans can be in the range of 99:1 to 1:99 Free-B-Ring flavonoids:flavans.
- the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In one embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20.
- the Free-B-ring flavonoids that can be used in accordance with the following include compounds illustrated by the general structure set forth above.
- the Free-B-Ring flavonoids of this invention may be obtained by synthetic methods or may be isolated from the family of plants including, but not limited to Annonaceae, Asteraceae, Bignoniaceae, Combretaceae, Compositae, Euphorbiaceae, Labiatae, Lauranceae, Leguminosae, Moraceae, Pinaceae, Pteridaceae, Sinopteridaceae, Ulmaceae, and Zingiberaceae.
- the Free-B-Ring flavonoids can also be isolated from the following genera of high plants, including but not limited to Desmos, Achyrocline, Oroxylum, Buchenavia, Anaphalis, Cotula, Gnaphalium, Helichrysum, Centaurea, Eupatorium, Baccharis, Sapium, Scutellaria, Molsa, Colebrookea, Stachys, Origanum, Ziziphora, Lindera, Actinodaphne, Acacia, Derris, Glycyrrhiza, Millettia, Pongamia, Tephrosia, Artocarpus, Ficus, Pityrogramma, Notholaena, Pinus, Ulmus , and Alpinia.
- the Free-B-Ring flavonoids can be found in different parts of plants, including but not limited to stems, stem barks, twigs, tubers, roots, root barks, young shoots, seeds, rhizomes, flowers and other reproductive organs, leaves and other aerial parts.
- Methods for the isolation and purification of Free-B-Ring flavonoids are described in U.S. application Ser. No. 10/091,362, filed Mar. 1, 2002, entitled “Identification of Free-B-ring Flavonoids as Potent COX-2 Inhibitors,” and U.S. application Ser. No. 10/427,746, filed Apr. 30, 2003, entitled “Formulation with Dual Cox-2 and 5-Lipoxygenase Inhibitory Activity”, each of which is incorporated herein by reference in its entirety.
- the flavans that can be used in accordance with the method of this invention include compounds illustrated by the general structure set forth above.
- the flavans of this invention may be obtained by synthetic methods or may be isolated from a plant selected from the group including, but not limited to Acacia catechu, A. concinna, A. farnesiana, A. Senegal, A. speciosa, A. arabica, A. caesia, A. pennata, A. sinuata. A. mearnsii, A. picnantha, A. dealbata, A. auricuhformis, A. holoserecia, A. mangium, Uncaria gambir, Uncaria tomentosa, Uncaria africana and Uncaria qabir.
- the flavans can be found in different parts of plants, including but not limited to stems, stem barks, trunks, trunk barks, twigs, tubers, roots, root barks, young shoots, seeds, rhizomes, flowers and other reproductive organs, leaves and other aerial parts.
- Methods for the isolation and purification of flavans are described in U.S. application Ser. No. 10/104,477, filed Mar. 22, 2002, entitled “Isolation of a Dual COX-2 and 5-Lipoxygenase Inhibitor from Acacia ,” which is incorporated herein by reference in its entirety.
- the Free-B-ring flavonoids are isolated from a plant or plants in the Scutellaria genus of plants and flavans are isolated from a plant or plants in the Acacia genus of plants.
- the present invention implements a strategy that combines several in vivo cognitive tasks as well as in vitro biochemical, cellular and gene expression screens to identify active plant extracts that specifically inhibit COX and LOX enzymatic activity, decrease pro-inflammatory cytokines via down-regulation of key transcription factors that promote the production of the mRNA of said cytokines, and ROS production, maintain antioxidant properties pertaining to the prevention and treatment of neurodegradation, neuroinflammation, and cumulative cognitive declines, disorders, diseases and conditions resulting from the exposure to reactive oxygen species (ROS), inflammatory proteins, and eicosanoids.
- ROS reactive oxygen species
- the extracts are further evaluated for their impact on mRNA gene expression. Free-B-Ring flavonoids and flavans were tested for their ability in prevent age-related cognitive decline when administered orally as an added component to food.
- Example 1 sets forth a general method for the preparation of LasoperinTM, using two standardized extracts isolated from Acacia and Scutellaria , respectively, together with one or more excipient(s).
- this specific batch of LasoperinTM contained 86% total active ingredients, including 75.7% Free-B-Ring flavonoids and 10.3% flavans.
- One or more excipient(s) can optionally be added to the composition of matter. The amount of excipient added can be adjusted based on the actual active content of each ingredient desired.
- Example 2 illustrates the effect of LasoperinTM on hippocampal-dependant cognitive function as measured by the radial arm water maze (RAWM) test.
- FIGS. 1A-1C depict graphically the effect of LasoperinTM administered daily in a 13-week radial arm water maze (RAWM) test to Fisher 344 aged male rats fed a diet supplemented with 3, 7 or 34 mg/kg LasoperinTM, respectively.
- FIG. 1A illustrates the results following pre-testing during weeks 1 and 2 (baseline).
- FIG. 1B illustrates the results following week 5 (Session II) and
- FIG. 1C illustrates the results following week 11 (Session III).
- the data depicted in FIGS. 1A-C demonstrate that LasoperinTM (7 and 34 mg/kg dose groups) prevents age-related memory impairment.
- Example 3 illustrates the effect of LasoperinTM on hippocampal-dependent cognitive function as measured by the contextual fear conditioning (CFC) test. Sixty Fisher 344 male rats were used in this study as described in Example 2. The results are set forth in FIG.
- FIG. 2 illustrates the effect of LasoperinTM administered daily for 12 weeks prior to contextual fear conditioning testing in 344 aged male rats fed a diet supplemented with 3, 7 or 34 mg/kg LasoperinTM.
- FIG. 2 demonstrates that LasoperinTM (7 and 34 mg/kg dose groups) ameliorated age-related impairments.
- Examples 4 and 5 illustrate the effect of LasoperinTM administered daily at 300 mg/day over a 4 week period to 40 individuals in a randomized, placebo-controlled, double-blind clinical trial on cognitive function. The results were compared to 46 individuals who were treated with a placebo. Measurement of cognitive performance was obtained using a series of web-based Cognitive Care tests which assess Psychomotor speed, Working Memory Speed (executive decision making, quickness & flexibility) and Immediate Memory (verbal & spatial memory processing). Before the study began, participants were required to practice the tests on two consecutive days to establish baseline performance. The data analysis compares baseline performance to performance post-treatment.
- Psychomotor speed or physical reflexes is a simple reaction time test that requires the person to respond by pressing a key as quickly as possible after a figure appears on the computer screen.
- Working Memory Speed presents a word and picture simultaneously and requires the person to decide if they are the same or different.
- a reversal cue is also presented randomly and requires the person to respond opposite of the correct response, so that a response to a correct pair would be no and visa versa.
- This task requires suppression or “inhibition of a learned response” and then a reversal (“task shifting”) of the response contingency.
- the speed of switching from one task or one response mode to another is often equated with mental flexibility and higher-order cognitive processing, as well as superior decision-making.
- Immediate Memory is similar to the classic Sternberg task in which a string of stimulus “target” items to be remembered are followed by a “probe” item. The subject must determine if the probe item was a member of the previous target list. List length can be varied to provide an estimate of the short-term memory capacity of the individual. Both letters and spatial position are examined in this task.
- FIG. 3 depicts graphically the effect of LasoperinTM on complex choice reaction time
- FIG. 4 depicts graphically the effect of LasoperinTM on reaction time standard deviation (RTSD).
- Reaction time standard deviation represents the intra-trial variance.
- FIGS. 3 and 4 demonstrate that LasoperinTM increases the speed of processing in subjects presented with complex choices and information.
- Example 6 describes a COX inhibition assay performed using LasoperinTM.
- the biochemical assay, used to measure inhibition of COX relies on the protein's peroxidase activity in the presence of heme and arachidonic acid.
- the dose response and IC 50 results for LasoperinTM are set forth in FIG. 5 .
- the IC 50 for COX-1 was 0.38 ⁇ g/mL/unit of enzyme, while the IC 50 for COX-2 was 0.84 ⁇ g/mL/unit.
- Example 7 describes a LOX inhibition assay using the flavan catechin isolated from A. catechu .
- the inhibition of LOX activity was assessed using a lipoxygenase screening assay in vitro. The results of this assay are set forth in FIG. 6 .
- the IC 50 for 5-LO inhibition by catechin was determined to be 1.38 ⁇ g/mL/unit of enzyme.
- Example 8 describes cell assays performed that targeted inhibition of compounds in the breakdown of arachidonic acid in the LOX pathway, namely LTB4. The results are set forth in FIG. 7 . With reference to FIG. 7 it can be seen that LasoperinTM inhibited the generation of 80% of the newly synthesized LTB 4 in HT-29 cells. Ibuprofen showed only a 20% reduction in the amount of LTB 4 over the same time period.
- Example 9 describes the measurement of the effect of LasoperinTM on LPS-induced levels of TNF ⁇ , IL-1 ⁇ , and IL-6 in Peripheral Blood Monocytes.
- the results are set forth in FIGS. 8-10 .
- the extract decreased TNF ⁇ secreted into the cell culture supernatant substantially over a wide range of concentrations from 2 to 100 ⁇ g/mL.
- a concentration of 10 ⁇ g/mL of LPS showed the greatest level of TNF ⁇ and IL-1 ⁇ induction following co-incubation with LasoperinTM for one and four hours respectively.
- the extract decreased TNF ⁇ and IL-1 ⁇ excreted in the cell culture supernatant substantially over a wide range of concentrations from 2 to 100 ⁇ g/mL (see FIGS. 8 and 9 ). Since TNF ⁇ , IL-1 ⁇ , and IL-6 are elevated during inflammation and aging-related disorders, by decreasing these pro-inflammatory cytokines and transcription factors in primed inflammatory cells LasoperinTM can have significant impact with respect to these disorders.
- Example 10 describes an experiment performed to determine the differential inhibition of the cox-2 gene by LasoperinTM versus other NSAIDS.
- Gene expression data was obtained for the inhibition of cox-1 and cox-2 mRNA production in a semi-quantitative RT-qPCR assay. The results are set forth in FIGS. 11-13 .
- FIG. 11 it can be seen that LasoperinTM inhibited cox-2 mRNA production without effecting cox-1 gene expression.
- LasoperinTM was able to decrease LPS-stimulated increases in cox-1 and cox-2 gene expression
- celecoxib and ibuprofen both increased cox-2 gene expression ( FIG. 12 ).
- FIGS. 13A and B it can be seen that treatment with LasoperinTM resulted in a decrease in the production of both tnf ⁇ -1 and il-1 ⁇ .
- Example 11 describes an experiment performed to determine the effect of LasoperinTM on the LPS-induced level of cox-1, cox-2, il-1 ⁇ , tnf ⁇ , il-6, nf ⁇ b and ppar ⁇ in peripheral blood monocytes (PBMC) from three subjects following exposure for four hours as described in Example 11.
- PBMC peripheral blood monocytes
- Example 12 describes the down-regulation of promoter elements of inflammatory genes by LasoperinTM. These promoter elements are shown in FIG. 15 .
- Example 13 describes a method used to determine the effectiveness of LasoperinTM as an antioxidant as measured by the Oxygen Radical Absorption Capacity (ORAC) test.
- the ORAC analysis which utilizes fluorescein as a fluorescent probe, provides a measure of the capacity of antioxidants to scavenge for peroxyl radicals, which are one of the most common reactive oxygen species found in the body.
- Table 2 illustrates that relative to concentrates of several well-known food-based antioxidants.
- LasoperinTM has a high ORAC score. In fact, the ORAC of LasoperinTM is comparable to the antioxidant Vitamin C and thus should effectively decrease ROS levels in the body.
- Examples 14 and 15 describe two methods used to determine the amount of Free-B-Ring flavonoids and flavans in the standardized extract. The results are set forth in FIGS. 16 and 17 .
- LasoperinTM was formulated using two standardized extracts isolated from Acacia and Scutellaria , respectively, together with one or more excipient(s).
- the Acacia extract used contained >60% total flavans, as catechin and epicatechin, and the Scutellaria extract contained >70% Free-B-Ring flavonoids, which was primarily baicalin.
- the Scutellaria extract contained other minor amounts of Free-B-Ring flavonoids as set forth in Table 1.
- One or more excipient(s) were added to the composition of matter.
- the ratio of flavans and Free-B-Ring flavonoids can be adjusted based on the indications and the specific requirements with respect to inhibition of COX-2 vs. 5-LO and potency requirements of the product.
- the amount of the excipient(s) can be adjusted based on the actual active content of each ingredient.
- a blending table for each individual batch of product must be generated based on the product specification and quality control (QC) results. Additional amounts of active ingredients in the range of 2-5% are recommended to meet the product specification.
- Table 1 illustrates a blending table generated for one batch of LasoperinTM (lot # G1702-COX-2). Briefly, Scutellaria baicalensis root extract (38.5 kg) (lot # RM052302-01) having a Free-B-Ring flavonoid content of 82.2% (baicalin); Acacia catechu bark extract (6.9 kg) (lot # RM052902-01) with a total flavan content of 80.4% and the excipient Candex (5.0 kg) were combined to provide a LasoperinTM formulation (50.4 kg) having a blending ratio of 85:15.
- Table 1 provides the quantification of the active Free-B-Ring flavonoids and flavans of this specific batch of LasoperinTM (lot # G1702-COX-2), determined using the methods described in U.S. application Ser. No. 10/427,746, filed Apr. 30, 2003, entitled “Formulation With Dual Cox-2 And 5-Lipoxygenase Inhibitory Activity,” which is incorporated herein by reference in its entirety.
- Flavonoids Trigger-B-Ring Flavonoid and Flavan content of a Lasoperin TM Formulation Active Components % Content
- Flavonoids Baicalin 62.5% Minor flavonoids wogonin-7-glucuronide 6.7% oroxylin A 7-glucuronide 2.0% baicalein 1.5% wogonin 1.1% Chrysin-7-glucuronide 0.8% 5-methyl-wogonin-7-glucuronide 0.5% scutellarin 0.3% norwogonin 0.3% Chrysin ⁇ 0.2% oroxylin A ⁇ 0.2% Total Free-B-ring Flavonoids 75.7% Flavans catechin 9.9% epicatechin 0.4% Total Flavans 10.3% Total Active Ingredients 86%
- this specific batch of LasoperinTM is comprised of 86% total active ingredients, including 75.7% Free-B-Ring flavonoids and 10.3% flavans.
- Two different dosage levels of final product in capsule form were produced from this batch of LasoperinTM (50.0 kg): 125 mg per dose (60 capsules) and 250 mg per dose (60 capsules).
- two additional batches of LasoperinTM were prepared having a blending ratio of 50:50 and 20:80, respectively.
- a LasoperinTM formulation (80:20) was prepared as described in Example 1. (See also Example 14 of U.S. patent application Ser. No. 10/427,746, filed Apr. 30, 2003, entitled “Formulation With Dual COX-2 And 5-Lipoxygenase Inhibitory Activity,” which is incorporated herein by reference in its entirety) by combining a standardized Free-B-Ring flavonoid extract isolated from Scutellaria baicalensis roots and a standardized flavan extract isolated from Acacia catechu bark with a blending ratio of 80:20.
- RAWM radial arm testing maze
- the No Delay condition demonstrates the animal's ability to perform the task and acts as a control for differences in the ability to perform the task (e.g., locomotion, vision, motivation, etc.).
- the Delay condition introduces a 4 hour delay between trials 3 and 4, making the task more difficult. It is under the Delay condition that the age-related memory impairments are demonstrated.
- the rats were microchipped to ensure proper identification during all aspects of the study. Due to the large number of animals, the experiment was split into two cohorts of 30 rats, which each group containing 6 animals To obtain a baseline the animals were assessed in the RAWM prior to being placed on the experimental diet. Upon completion of the initial RAWM test, the aged rats were assigned to one of four groups (Aged Control, 3, 7, and 34 mg/kg LasoperinTM) in a counter-balanced manner, such that each group was equivocal in RAWM performance. Animal weight and food intake were monitored weekly to determine general health and the ingestion of food. No differences in these indexes were observed between groups.
- RAWM Radial Arm Water Maze
- the RAWM consisted of 12 arms (15 cm wide ⁇ 43 cm long) emanating from a circular choice area (60 cm diameter) in a 1.5 m tank of water. An escape platform (10 cm ⁇ 13 cm) was situated at the end of one of the arms, 2 cm below the surface of the water. Rats were pre-trained in the maze for five days. Pre-training consisted of shaping the animals to find the goal arm by initially blocking entry into the non-goal arms and gradually increasing the number of available arms until all 12 were open. The rats were then trained for two blocks of five days each. The entire training process required three weeks. The start arm for each trial was determined in a pseudo-random manner from the 11 available arms. A given arm was used only once per day so that there were four different start arms each day.
- the start and goal arms were different for each animal within a group on a given day, but equivalent across groups.
- Four trials were administered per day (180 second (s) maximum) with a 30 s inter-trial interval. If a rat did not find the escape platform within 180 s, it was gently guided to the correct arm. The number of arms entered prior to entering the arm containing the escape platform (Errors) was recorded. A 3 hour delay was introduced between trials three and four for days six through ten. During the delay, the rats were placed back into their home cage. The results are set forth in FIGS. 1A-C . Data are presented as the mean for each trial versus trial number.
- CFC Contextual fear conditioning
- the CS and US co-terminated at the end of the training block. All rats reacted to the footshock by jumping. The rats remained in the training box for 30 s following the second training block. Retention was tested 2 days after training by first placing the animals in the same apparatus, using 3% acetic acid as an odorant, in which training was performed for 5 minutes (min), without the CS or US. Two to three hours later, the rats were placed in a the same chamber except that the grid floor was covered with a piece of black Formica and the cage was cleaned with 3% ammonium hydroxide (Novel Context) for 6 min, during which the CS was administered for the final 3 min Freezing was quantified manually every 10 s by an experimenter blind to the treatment groups of the rats. At 10 s intervals the experimenter assessed whether the rat was freezing or not. Percent freezing was calculated as: number of intervals during which the rat was assessed as freezing/by the total number of intervals ⁇ 100. The results are set forth in FIG. 2 .
- Freezing to the noise conditioned stimulus measures non-hippocampal dependent memory. With respect to this measurement, there were no statistically significant differences in freezing between any of the groups (data not shown).
- Freezing to the novel context is a control measure to determine baseline freezing. To obtain this measurement, the amount of freezing that occurs during the training context and the CS are compared to the baseline freezing to determine if learning occurred. There were no statistically significant differences in freezing between any of the groups (data not shown).
- Nociceptive Threshold The apparatus consisted of a test chamber 30.5 ⁇ 25.4 ⁇ 30.5 cm (Coulbourn Instruments, Allenstown, Pa.). The top and two sides of the chamber were made of aluminum. The two other sides were made of transparent plastic. The box was dimly illuminated (xx lux). The floor consisted of stainless steel rods (5 mm dia, 1.68 cm between rods). Shock was delivered with a Precision Regulated Shocker (Model H12-16, Coulbourn Instruments). Rats were placed in a cage with a metal grid floor (grid dimensions). A mirror was placed on the opposite side of the chamber from the experimenter to facilitate observation. All rats were given a 2 min habituation period prior to the start of an experiment.
- Each rat was placed in the chamber for 2 min before a shock series was begun and after the grid floor had been cleaned with steel wool and water.
- Each shock pulse was 0.5 s in duration and the shocks were delivered at approximately 10 s intervals.
- Shock intensities were available from 0.05 to 4.0 mA in 20 steps arranged logarithmically. The full range was not used in determining thresholds. The ranges of intensities within which thresholds were to be found were estimated from preliminary observations. The midpoints of these ranges served as the beginning intensities in the experiments.
- a flinch was defined as elevation of one paw and jump as rapid movement of three or more paws, both responses required withdrawal from the floor.
- An adaptation of the “up-and-down” method for small samples was used for determining the order of presentation of shock intensities during each shock series.
- d is the log interval between shock intensities.
- Two series of shocks were performed to assess the flinch threshold, which were followed by two series of shocks to assess the jump threshold. This test controls for shock intensities given in the contextual fear conditioning behavioral paradigm and does not have separate results associated with it.
- An analysis of the data compares baseline performance of treated individuals to those given a placebo over the same time period. Only subjects who completed the tests for the baseline and all dosing weeks were included in the analysis. Outliers who scored more than 2 standard deviations from the test mean, and who were not internally consistent with other test scores, were eliminated to exclude abnormal results that may be due to distractions or web/computer “glitches” that could invalidate the test session. Data was analyzed with a repeated measures analysis of variance (ANOVA) across days of testing, and comparisons between baseline and the final week of testing, with appropriate post hoc tests.
- ANOVA analysis of variance
- Psychomotor speed or physical reflex is a simple reaction time test that requires the subject to respond by pressing a key as quickly as possible after a figure appears on a computer screen. Overall performance for all ages on the psychomotor task was very stable and did not show any significant difference between groups for the mean, median or standard deviation measures (p>0.05). Thus, the Psychomotor speed test did not indicate any differences between treatment and control groups. There was however a generalized improvement in performance for all groups over the period of testing.
- Working Memory Speed a Complex Choice Reaction Time task
- a reversal cue is also presented randomly and requires the person to respond opposite to the correct response, so that a response to a correct pair would be no and visa versa.
- This task requires suppression or “inhibition of a learned response” and then a reversal (“task shifting”) of the response contingency.
- the speed of switching from one task or one response mode to another is often equated with mental flexibility and higher-order cognitive processing, as well as superior decision-making.
- the cognitive aspects of this test can assess the executive cognitive function, including processing speed, sustained attention, cognitive fluidity and ability to correctly make rapid decisions in a complex and demanding cognitive task.
- Immediate Memory is similar to the classic Sternberg task in which a string of stimulus “target” items to be remembered are followed by a “probe” item. The subject must determine if the probe item was a member of the previous target list. List length can be varied to provide an estimate of the short-term memory capacity of the individual. Both letters and spatial position are examined in this task.
- Measurement of the IC 50 of LasoperinTM was performed using the following method.
- a cleavable, peroxide chromophore was included in the assay to visualize the peroxidase activity of each enzyme in the presence of arachidonic acid as a cofactor.
- the assays were performed in a 96-well format.
- Each inhibitor taken from a 10 mg/mL stock in 100% DMSO, was tested in triplicate at room temperature using the following range of concentrations: 0, 0.1, 1, 5, 10, 20, 50, 100, and 500 ⁇ g/mL
- 150 ⁇ L of 100 mM Tris-HCl, pH 7.5 was added together with 10 ⁇ L of 22 ⁇ M Hematin diluted in tris buffer, 10 ⁇ L of inhibitor diluted in DMSO, and 25 units of either COX-1 or COX-2 enzyme.
- the components were mixed for 10 seconds on a rotating platform, after which 20 ⁇ L of 2 mM N,N,N′N′-tetramethyl-p-phenylenediamine dihydrochloride (TMPD) and 20 ⁇ L of 1.1 mM AA was added to initiate the reaction.
- TMPD N,N,N′N′-tetramethyl-p-phenylenediamine dihydrochloride
- the plate was shaken for 10 seconds and then incubated for 5 minutes before reading the absorbance at 570 nm
- the inhibitor concentration vs. percentage inhibition was plotted and the IC 50 determined by taking the half-maximal point along the isotherm and intersecting the concentration on the x-axis. The IC 50 was then normalized to the number of enzyme units in the assay.
- the dose response and IC 50 results for LasoperinTM are provided in FIG. 5 .
- the 15-LO from soybeans normally used in the kit was replaced with potato 5-LO after a buffer change from phosphate to a Tris-based buffer using microfiltration was performed.
- This assay detects the formation of hydroperoxides through an oxygen sensing chromagen. Briefly, the assay was performed in triplicate by adding 90 ⁇ L of 0.17 units/ ⁇ L potato 5-LO, 20 ⁇ L of 1.1 mM AA, 100 ⁇ L of oxygen-sensing chromagen, and 1 ⁇ L of purified flavan inhibitor to final concentrations ranging from 0 to 500 ⁇ g/mL. The results are set forth in FIG. 6 .
- the IC 50 for 5-LO inhibition from catechin was determined to be 1.38 ⁇ g/mL/unit of enzyme.
- a LasoperinTM formulation was prepared as outlined in Example 1, using a standardized Free-B-Ring flavonoid extract from S. baicalensis roots and a standardized flavan extract from A. catechu bark with a blending ratio of 80:20 LasoperinTM.
- the LasoperinTM and ibuprofen, another known 5-LO inhibitor were added to HT-29 cells, monocyte cell lines that express COX-1, COX-2 and 5-LO, at 3 ⁇ g/mL and incubated for 48 hours at 37° C. with 5% CO 2 in a humidified environment. Each treated cell line was then harvested by centrifugation and disrupted by gentle dounce homogenization in physiological lysis buffer.
- LTB 4 A competitive ELISA for LTB 4 (LTB 4 ; Neogen, Inc., Cat #406110) was used to assess the effect of LasoperinTM on newly synthesized levels of LTB 4 present in each cell line as a measure of Lasoperin'sTM inhibitory effect on the 5-LO pathway.
- the assay was performed in duplicate by adding 160,000 to 180,000 cells per well in 6-well plates. The results are set forth in FIG. 7 . As shown in FIG. 7 , LasoperinTM inhibited generation of 80% of the newly synthesized LTB 4 in HT-29 cells. Ibuprofen only showed a 20% reduction in the amount of LTB 4 over the same time period.
- PBMCs Peripheral blood monocytes
- LPS lipopolysaccharide
- PBMCs peripheral blood monocytes
- LPS lipopolysaccharide
- LasoperinTM LasoperinTM
- celecoxib celecoxib
- ibuprofen acetaminophen
- the total RNA produced was then harvested and evaluated by semi-quantitative RT-qPCR.
- the assay was constructed by adding 130,000 cells per well in 6-well plates. The cells were then stimulated with 10 ng/mL LPS and co-incubated with LasoperinTM at 1, 3, 10, 30 and 100 ⁇ g/mL and celecoxib, ibuprofen and acetaminophen at 3 ⁇ g/mL for 18 hours at 37° C.
- M-MLV RT Moloney Murine Leukemia Virus reverse transcriptase
- qPCR experiments were performed on an ABI Prism®7700 Sequence Detection System using pre-developed validated Assays-on-Demand products (AOD from Applied Biosystems, Inc., Cat #4331182) for 18S rRNA internal standard and gene specific assays.
- Gene specific expression values were standardized to their respective 18S rRNA gene expression values (internal control) and then the no-LPS no-drug treatment condition normalized to 100. Treatment conditions are relative to this null condition. LasoperinTM decreased normalized gene expression of cox-2 by over 100-fold while cox-1 normalized gene expression showed little variation. Under the same treatment conditions, normalized TNF ⁇ gene expression was decreased 6-fold and normalized IL-1 ⁇ gene expression was decreased by over 100-fold.
- PBMCs from human blood donors were isolated using a Histopaque gradient (Sigma). The cells were then cultured in RPMI 1640 supplemented with 1% bovine serum albumin for approximately 24 hours before being treated with LPS (10 ⁇ g/mL) and increasing concentrations LasoperinTM (80:20). Specifically, the assay was constructed by adding 130,000 cells per well in 6-well plates. The cells were then stimulated with 10 ⁇ g/mL LPS and co-incubated with LasoperinTM at 100 ⁇ g/mL for 18 hours at 37° C. with 5% CO 2 in a humidified environment.
- RNA produced was isolated using TRIzol® reagent (InvitrogenTM Life Technologies, Cat #15596-026) and the recommended TRIzol® reagent manufacturer protocol.
- Total RNA was reverse transcribed using Moloney Murine Leukemia Virus reverse transcriptase (M-MLV RT; Promega Corp., Cat # M1701) using random hexamers (Promega Corp., Cat#C1181).
- qPCR experiments were performed on an ABI Prism®7700 Sequence Detection System using pre-developed validated Assays-on-Demand products (AOD from Applied Biosystems, Inc., Cat #4331182) for 18S rRNA internal standard and gene specific assays.
- LasoperinTM decreased normalized gene expression of cox-2 by an average of 3-fold while cox-1 normalized gene expression showed little variation.
- normalized tnf ⁇ gene expression was decreased by an average of 3-fold
- normalized il-1 ⁇ gene expression was decreased by an average of 45-fold
- normalized il-6 gene expression was decreased by an average of 37-fold.
- Other studies cited in the literature have used protein specific methods to infer gene expression rather than show it directly as put forth in FIG. 14 .
- the promoter regions for the inflammatory genes tnf ⁇ , il-1 ⁇ , il-6 and cox-2 all contain NF ⁇ B binding sites which may account for down-regulation of gene expression when cells are treated with LasoperinTM.
- the cox-2 promoter region also contains a PPAR ⁇ responsive element (PPRE) which interacts with the retinoid X receptor transcription protein. LasoperinTM down-regulates ppar ⁇ gene expression which presumably decreases PPAR ⁇ protein such that it cannot interact to stimulate cox-2 gene expression. Additionally, LasoperinTM also down-regulates nf ⁇ b gene expression. Therefore, the compound hits two transcription factors that affect cox-2 gene expression and presumably COX-2 protein production. These promoter elements are shown in FIG. 15 .
- LasoperinTM was tested for its Oxygen Radical Absorption Capacity (ORAC) relative to several well known food based antioxidants using the experimental procedures described in Cao et al. (1994) Free Radic. Biol. Med. 16:135-137 and Prior and Cao (1999) Proc. Soc. Exp. Biol. Med. 220:255-261.
- the ORAC analysis which utilizes fluorescein as a fluorescent probe, provides a measure the capacity of antioxidants to scavenge for the peroxyl radical, which is one of the most common reactive oxygen species found in the body.
- ORAC hydro reflects the water-soluble antioxidant capacity and the ORAC lipo is the lipid soluble antioxidant capacity.
- Trolox a water-soluble Vitamin E analog
- TE micromole Trolox equivalent
- the Free-B-Ring flavonoids (bacalein and bacalin) eluted as the major peak between 11 to 14 minutes and the flavans (catechins and epicatechins) eluted as the minor peak at approximately 3 to 5 minutes.
- the amount of Free-B-Ring flavonoids and flavans were determined by measuring the area under each curve and comparison with known standards.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
Abstract
The present invention provides a novel method for preventing and treating memory and cognitive impairment resulting from oxidative stress, inflammation and the process of aging, as well as, neurodegenerative conditions. The method is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants to a host in need thereof. The present also includes a novel method for simultaneously inhibiting expression of pro-inflammatory cytokines, preventing ROS generation and augmenting anti-oxidant defenses. The activity of this composition is conducive to ultimately preserving cognitive function and providing a level of neuroprotection.
Description
This application is a continuation of U.S. application Ser. No. 10/932,571, filed Sep. 1, 2004, entitled “Formulation Of A Mixture Of Free-B-Ring Flavonoids And Flavans For Use In The Prevention And Treatment Of Cognitive Decline And Age-Related Memory Impairments”, which claims priority from U.S. Provisional Application Ser. No. 60/499,742, filed Sep. 2, 2003, entitled “Formulation with dual COX-2 and 5-lipoxygenase inhibitory activity for use in the prevention and treatment of cognitive decline and age-related memory impairments.” This application is also a continuation in part of U.S. application Ser. No. 10/427,746, filed Apr. 30, 2003, which claims priority from 60/377,168, filed Apr. 30, 2002, each of which is entitled “Formulation With Dual Cox-2 And 5-Lipoxygenase Inhibitory Activity”. Each of these applications is incorporated herein by reference in its entirety.
This invention relates generally to a composition of matter formulated for use in the prevention and treatment of neurodegradation, neuroinflammation and cumulative cognitive declines, disorders, diseases and conditions resulting from exposure to reactive oxygen species (ROS), inflammatory proteins and eicosanoids. Specifically, the present invention relates to a novel composition of matter comprised of a mixture of a blend of two specific classes of compounds—Free-B-Ring flavonoids and flavans—for use in the prevention and treatment of age, cognitive, neuroinflammatory and neurodegenerative related diseases and conditions mediated by oxidative insult, inflammation and the cycloxygenase (COX) and lipoxygenase (LOX) pathways. The diseases and conditions include, but are not limited to, neurodegenerative disorders, stroke, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis (ALS) and cognitive declines resulting from advancing age.
The liberation and metabolism of arachidonic acid (AA) from the cell membrane results in the generation of pro-inflammatory metabolites by several different pathways. Arguably, two of the most important pathways to inflammation are mediated by the enzymes 5-lipoxygenase (5-LO) and cycloxygenase (COX). These parallel pathways result in the generation of leukotrienes and prostaglandins, respectively, which play important roles in the initiation and progression of the inflammatory response. These vasoactive compounds are chemotaxins, which promote infiltration of inflammatory cells into tissues and serve to prolong the inflammatory response. Consequently, the enzymes responsible for generating these mediators of inflammation have become the targets for many new drugs aimed at the treatment of inflammation that contributes to the pathogenesis of diseases such as rheumatoid arthritis, osteoarthritis, Alzheimer's disease and certain types of cancer.
Inhibition of the COX enzyme is the mechanism of action attributed to most nonsteroidal anti-inflammatory drugs (NSAIDS). There are two distinct isoforms of the COX enzyme (COX-1 and COX-2) that share approximately 60% sequence homology, but differ in expression profiles and function. COX-1 is a constitutive form of the enzyme that has been linked to the production of physiologically important prostaglandins involved in the regulation of normal physiological functions such as platelet aggregation, protection of cell function in the stomach and maintenance of normal kidney function (Dannhardt and Kiefer (2001) Eur. J. Med. Chem. 36:109-126). The second isoform, COX-2, is a form of the enzyme that is inducible by pro-inflammatory cytokines such as interleukin-1β (IL-1β) and other growth factors (Herschmann (1994) Cancer Metastasis Rev. 134:241-256; Xie et al. (1992) Drugs Dev. Res. 25:249-265). This isoform catalyzes the production of prostaglandin E2 (PGE2) from AA. Inhibition of COX-2 is responsible for the anti-inflammatory activities of conventional NSAIDs.
Inhibitors that demonstrate dual specificity for COX-2 and 5-LO, while maintaining COX-2 selectivity relative to COX-1, would have the obvious benefit of inhibiting multiple pathways of AA metabolism. Such inhibitors would block the inflammatory effects of prostaglandins (PG), as well as, those of multiple leukotrienes (LT) by limiting their production. This includes the vasodilation, vasopermeability and chemotactic effects of PGE2, LTB4, LTD4 and LTE4, also known as the slow reacting substance of anaphylaxis. Of these, LTB4 has the most potent chemotactic and chemokinetic effects. (Moore (1985) in Prostanoids: Pharmacological, Physiological and Clinical Relevance, Cambridge University Press, N.Y., pp. 229-230.
In addition to the above-mentioned benefits of dual COX-2/5-LO inhibitors, many dual inhibitors do not cause some of the side effects that are typical of NSAIDs or COX-2 inhibitors, including both the gastrointestinal damage and discomfort caused by traditional NSAIDs. It has been suggested that NSAID-induced gastric inflammation is largely due to metabolites of 5-LO, particularly LTB4, which attracts cells to the site of a gastric lesion thus causing further damage. (Kircher et al. (1997) Prostaglandins Leukot. Essent. Fatty Acids 56:417-423). Leukotrienes represent the primary AA metabolites within the gastric mucosa following prostanoid inhibition. It appears that these compounds contribute to a significant amount of the gastric epithelial injury resulting from the use of NSAIDs. (Celotti and Laufer (2001) Pharmacological Research 43:429-436). Dual inhibitors of COX and 5-LO were also demonstrated to inhibit the coronary vasoconstriction in arthritic hearts in a rat model. (Gok et al. (2000) Pharmacology 60:41-46). Taken together, these characteristics suggest that there may be distinct advantages to dual inhibitors of COX-2 and 5-LO over specific COX-2 inhibitors and non-specific NSAIDs with regard to both increased efficacy and reduced side effects.
Because the mechanism of action of COX inhibitors overlaps that of most conventional NSAIDs, COX inhibitors are used to treat many of the same symptoms, such as the pain and swelling associated with inflammation in transient conditions and chronic diseases in which inflammation plays a critical role. Transient conditions include the treatment of inflammation associated with minor abrasions, sunburn or contact dermatitis, as well as, the relief of pain associated with tension and migraine headaches and menstrual cramps. Chronic conditions include arthritic diseases such as rheumatoid arthritis and osteoarthritis. Although rheumatoid arthritis is largely an autoimmune disease and osteoarthritis is caused by the degradation of cartilage in joints, reducing the inflammation associated with each provides a significant increase in the quality of life for those suffering from these diseases (Wienberg (2001) Immunol. Res. 22:319-341; Wollhiem (2000) Curr. Opin. Rheum. 13:193-201). As inflammation is a component of rheumatic diseases in general, the use of COX inhibitors has been expanded to include diseases such as systemic lupus erythromatosus (SLE) (Goebel et al. (1999) Chem. Res. Tox. 12:488-500; Patrono et al. (1985) J. Clin. Invest. 76:1011-1018) and rheumatic skin conditions such as scleroderma. COX inhibitors are also used for the relief of inflammatory skin conditions that are not of rheumatic origin, such as psoriasis, in which reducing the inflammation resulting from the over production of prostaglandins could provide a direct benefit (Fogh et al. (1993) Acta Derm. Venereol (Oslo) 73:191-193).
Recent scientific progress has identified correlations between COX-2 expression, general inflammation and the pathogenesis of Alzheimer's disease (AD). (Ho et al. (2001) Arch. Neurol. 58:487-92). In animal models, transgenic mice that over-express the COX-2 enzyme have neurons that are more susceptible to damage. The National Institute on Aging (NIA) is launching a clinical trial to determine whether NSAIDs can slow the progression of Alzheimer's disease. Naproxen (a non-selective NSAID) and rofecoxib (Vioxx, a COX-2 specific selective NSAID) will be evaluated. Previous evidence has indicated that inflammation contributes to Alzheimer's disease. According to the Alzheimer's Association and the NIA, about 4 million people suffer from AD in the United States and this is expected to increase to 14 million by mid-century.
The protective effect of NSAIDs in the pathogenesis of AD is attributed to COX-2 inhibition and the direct prevention of amyloidosis in the brain. (Xiang et al. (2002) Gene Expression 10:271-278). By suppressing COX-2 production of the pro-inflammatory prostaglandin PGE2, the surrounding neurons are also spared from the oxidative and inflammatory insult that would be generated by activated microglia. (Combs et al. (2001) Neurochem. Intl. 39:449-457). This action eliminates the subsequent microglial generation of cytokines and ROS that feed the cycle and propagate neurodegeneration. (Kalaria et al. (1996) Neurodegeneration 5:497-503; Combs et al. (1999) J. Neurosci. 19:928-939). NSAIDs also inhibit γ-secretase activity thereby preventing amyloid precursor protein (APP) processing, elevation of amyloid-beta (Aβ) peptide levels and development of neurofibrillary tangles (NFT) and neuritic plaque (Weggen et al. (2001) Nature 414:212-216; Takahashi et al. (2003) J. Biol. Chem. 278:18664-18670).
The progressive neural deterioration resulting from exposure to ROS, cytokines and pro-inflammatory eicosanoids manifests itself in a number of disease states all of which share common roots. These diseases are currently treated with NSAIDs which have cognitive preserving and neuroprotective properties resulting from their multifactoral activity on ROS, cytokines and pro-inflammatory eicosanoids. They act to inhibit amyloid deposition, diminish thromboxane and prostanoid production, attenuate cytokine production, prevent microglial activation, lower ROS generation, and, in some instances, possess a high antioxidant capacity. All of these activities can prevent cognitive decline and slow the cumulative effect upon neurodegeneration resulting from oxidative stress and aging.
The neuroprotective activity of NSAID's forms the basis of current theories regarding somatic and neurodegenerative decline seen with varying degenerative disease states, aging, inflammation and oxidative stress. Initial observations that exposure to ionizing radiation mimics some of these conditions by causing similar histopathological changes in irradiated organs and their antioxidant status implicated the generation of free radicals as a causal factor. (Gerschman et al. (1954) Science 119:623-626; Harman (1956) J. Gerontol. 11:289-300; Harman (1957) J. Gerontol. 2:298-300). Administration of antioxidants prior to exposure provided the organism with some protection against the damaging effects of radiation. The conclusion derived from these studies was that prolonged exposure to free radical oxidative stress generated by ionizing radiation or oxidative metabolism disturbs the REDOX balance of the intracellular environment and is damaging in and of itself, if not held in check through antioxidant defenses. From this observation arose the leading studies on increasing longevity and neuroprotection, involving the lowering of free radical levels through manipulating basal metabolism via caloric restriction. (Berg and Simms (1960) J. Nutr. 71: 255-261; Weindruch and Walford (1988) The retardation of aging and disease by dietary restriction. C. C. Thomas, Springfield, Ill.).
Berg and Simms proposed that maintenance of somatic function was correlated with restricted caloric intake and the subsequent reduced production of free radicals via oxidative metabolism, essentially, caloric restriction (CR). (Berg and Simms (1960) J. Nutr. 71: 255-261). Harman suggested that this protection, through the use of antioxidants, would extend to the nervous system by preventing lipid peroxidation. (Harman (1969) J. Gerontol. 23:476-482). Other investigators observed that cellular and DNA damage appeared to be roughly correlated to the organism's basal metabolic rate (BMR) and demonstrated that the higher the BMR, the shorter the lifespan and the greater the cellular and DNA damage. (Barja (2002) Free Rad. Biol. Med. 33:1167-1172). The explanation being that the generation of destructive ROS from mitochondrial and cytoplasmic oxidative metabolism produces an accumulation of free radical-induced damage at both the cellular and molecular level and is responsible, in part, for numerous degenerative and age-related disorders. The damage caused by ROS, however, can be reduced by suppressing BMR via CR or by augmenting antioxidant defenses to compete with ROS production. CR has repeatedly been shown to be an effective method to increase the longevity of a number of species. (Weindruch and Walford (1988) The retardation of aging and disease by dietary restriction, C. C. Thomas, Springfield, Ill.; Weindruch (1989) Prog. Clin. Biol. Res. 287:97-103). This research has lead to an invigorated examination of the antioxidant status of the organism with respect to progressive somatic and neurodeterioration seen with aging and the subsequent development of a free radical theory of aging. (Harman (1994) Ann. NY Acad. Sci. 717:1-15).
Additional studies, which demonstrate neuroprotective activity associated with augmentation or supplementation of an organism's antioxidant defenses, support this theory. Dietary supplementation in rodents with micronutrients (Liu et al. (2002) Ann. NY Acad. Sci. 959:133-166), antioxidants (Floyd and Hensley (2000) Ann NY Acad. Sci. 899:222-237; Joseph et al. (2000) Mech. Ageing Dev. 116:141-153; Galli et al. (2002) Ann. NY Acad. Sci. 959:128-132) and plant extracts (Bickford et al. (2000) Brain. Res. 866:211-217; Cartford et al. (2002) J. Neurosci. 22:5813-5816) were shown to protect the aging nervous system against ionizing radiation (Lenton and Greenstock (1999) Mech. Ageing Dev. 107:15-20) or oxidative insult (Butterfield et al. (1998) Ann NY Acad. Sci. 854:448-462; Cao et al. (1999) J. Applied Physiol. 86:1817-1822), in addition to improving behavior in cognitive tasks (Bickford et al. (1999) Mech. Ageing Dev. 11:141-154) and restoring CNS electrophysiological responses (Gould et al. (1998) Neurosci. Lett. 250:165-168; Bickford et al. (1999) Free Rad. Biol. Med. 26:817-824). All of these intervention therapies are presumed to alter the antioxidant status of the intracellular milieu and protect key cytoplasmic and mitochondrial contents from degradation by ROS, thereby restoring and/or preserving homeostasis. Indices of antioxidant status have shown corresponding changes with these dietary manipulations. For example, lipid peroxide markers, malondialdehyde (MDA) (Gemma et al. (2002) J. Neurosci. 22:6114-6120) and hydroxynonenal (HNE) are lowered (Yoshimura et al. (2002) Free Rad. Res. 36:107-112), isoprostanes are decreased (Montine et al. (2003) Biochem. Pharmacol. 65:611-617), 8-hydroxy-2-deoxyguanosine levels are reduced (Lee et al. (1998) Cancer Lett. 132:219-227), protein carbonyls (Carney et al. (1991) Proc. Natl. Acad. Sci. USA 88:3633-3636; Stadtman and Berlett (1998) Drug Metab. Rev. 30:225-243) and nitrotyrosine residues drop (Whiteman and Halliwell (1996) Free Rad. Res. 25:275-283), and spin trapping antioxidants show lowered reactivity (Carney et al. (1991) Proc. Natl. Acad. Sci. USA 88:3633-3636).
Treatment with the spin-trapping antioxidant N-tert-butyl-α-phenylnitrone (PBN) demonstrates the ability to pharmacologically attenuate neurodegeneration induced by aging and ROS. PBN is a free radical scavenger, which has been shown to decrease ROS (Floyd (1999) Proc Soc Exp Biol Med. 222(3):236-245), lower protein carbonyl generation in the senescence accelerated mouse model (Butterfield et al. (1997) Proc. Natl. Acad. Sci. USA 94:674-678), protect the brains of gerbils in ischemia re-perfusion injuries (Floyd and Hensley (2000) Ann NY Acad. Sci. 899:222-237), preserve cerebellar responsiveness in aged rats (Gould and Bickford (1994) Brain Res. 660:333-336), and decrease the rate of telomere shortening in human fibroblasts (von Zglinicki et al. (2000) Free Rad. Biol. Med. 28:64-74). PBN has also proven effective in lowering protein carbonyl content in aged gerbils and improving their performance in the radial arm maze behavioral task. (Carney et al. (1991) Proc. Natl. Acad. Sci. USA 88:3633-3636). It remains, therefore, a compelling proposition to augment an organism's antioxidant defenses by various nutritional interventions.
Aging and oxidative stress are associated with declines in hippocampal processing of information (Barnes (1990) Prog. Brain Res. 86:89-104; McGahon et al. (1997) Neuroscience 81:9-16; Murray and Lynch (1998a) J. Neurosci. 273:12161-12168), as demonstrated by the deficits seen in spatial learning, memory formation and the decline in Long Term Potentiation (LTP), which is necessary for memory consolidation. The composition of matter disclosed herein, which is a COX and LOX inhibitor, as well as, a strong antioxidant can reduce declines in hippocampal processing resulting from oxidative stress, inflammation or aging.
Lastly, inflammatory prostanoids compromise LTP by up-regulating the inflammatory cytokine IL-1β. This cytokine, which has been shown to increase with age and oxidative stress, inhibits LTP in the CA1 region of the hippocampus and the DG. (Murray and Lynch (1998a) J. Neurosci. 273:12161-12168). Associated with the up-regulation in IL-1β expression is an increase in lipid peroxidation in the hippocampus. (Murray et al. (1999) Gerontology 45:136-142). Further evaluation of this process revealed that animals treated with an antioxidant rich diet experienced a reversal of age-related changes in IL-1β, lipid peroxidation and the associated deficit in LTP. (Lynch (1998) Prog. Neurobiol. 56:571-589). Additionally, the age-related decrease in membrane AA concentration was also ameliorated by dietary supplementation with an antioxidant. (Murray and Lynch (1998b) J. Biol. Chem. 273:12161-12168). All of these factors clearly indicate that cognitive declines resulting from exposure to oxidative stress, inflammation and aging can be slowed or ameliorated by dietary and pharmacological interventions.
Flavonoids or bioflavonoids are a widely distributed group of natural products, which have been reported to have antibacterial, anti-inflammatory, antiallergic, antimutagenic, antiviral, antineoplastic, anti-thrombic and vasodilatory activity. The structural unit common to this group of compounds includes two benzene rings on either side of a 3-carbon ring as illustrated by the following general structural formula:
Various combinations of hydroxyl groups, sugars, oxygen and methyl groups attached to this general three ring structure create the various classes of flavonoids, which include flavanols, flavones, flavan-3-ols (catechins), anthocyanins and isoflavones.
The intake of flavonoids has been demonstrated to be inversely related to the risk of incident dementia. The mechanism of action, while not known, has been speculated as being due to the anti-oxidative effects of flavonoids. (Commenges et al. (2000) Eur. J. Epidemiol. 16:357-363). Polyphenol flavones induce programmed cell death, differentiation and growth inhibition in transformed colonocytes by acting at the mRNA level on genes including cox-2, Nuclear Factor kappa B (NFκB) and bcl-X(L). (Wenzel et al. (2000) Cancer Res. 60:3823-3831). It has been reported that the number of hydroxyl groups on the B ring is important in the suppression of cox-2 transcriptional activity. (Mutoh et al. (2000) Jnp. J. Cancer Res. 91:686-691).
Recent reports have addressed the possible involvement of flavonoids, isolated from the medicinal herb Scutellaria baicalensis, in alterations in cox-2 gene expression. (Wakabayashi and Yasui (2000) Eur. J. Pharmacol. 406(3):477-481; Chen et al. (2001) Biochem. Pharmacol. 61:1417-1427; Chi et al. (2001) Biochem. Pharmacol. 61:1195-1203; Raso et al. (2001) Life Sci. 68(8):921-931). The term gene expression is often used to describe both mRNA production and protein synthesis. In fact, changes in actual gene expression may never result in observable changes in protein levels. The corollary, that changes in protein levels do not always result from changes in gene expression, can also be true. There are six possible points of regulation in the pathway leading from genomic DNA to a functional protein: (1) transcriptional regulation by nuclear factors and other signals leading to production of pre-mRNA; (2) pre-mRNA processing regulation involving exon splicing, the additions of a 5′ cap structure and 3′ poly-adenylation sequence and transport of the mature mRNA from the nucleus into the cytoplasm; (3) mRNA transport regulation controlling localization of the mRNA to a specific cytoplasmic site for translation into protein; (4) mRNA degradation regulation controlling the size of the mRNA pool either prior to any protein translation or as a means of ending translation from that specific mRNA; (5) translational regulation of the specific rate of protein translation initiation and (6) post-translation processing regulation involving modifications such as glycosylation and proteolytic cleavage. In the context of genomics research it is important to use techniques that measure gene expression levels closer to the initial steps (e.g. mRNA levels), rather than the later steps (e.g. protein levels) in this pathway.
Each of above cited studies related to cox-2 gene expression use a Western Blot technique, for protein analysis, to evaluate putative alterations in gene expression without validation on the DNA or mRNA levels. Since the Western Blot technique measures only protein levels and not the specific transcription product, mRNA, it is possible that other mechanisms are involved leading to the observed increase in protein expression. For example, LPS has been reported to modulate mRNA half-lives via instability sequences found in the 3′ untranslated region (3′UTR) of mRNAs (Watkins et al. (1999) Life Sci. 65:449-481), which could account for increased protein expression without alternations in the rate of gene transcription. Consequently, this leaves open the question of whether or not these treatment conditions resulted in a meaningful change in gene expression.
Techniques such as RT-qPCR and DNA microarray analysis rely on mRNA levels for analysis and can be used to evaluate levels of gene expression under different conditions, i.e. in the presence or absence of a pharmaceutical agent. To date Applicant is unaware of any reported methods that specifically measure the amount of mRNA, directly or indirectly, when a composition comprised of a combination of Free-B-ring flavonoids and flavans are used as the therapeutic agents.
Free-B-Ring flavones and flavonols are a specific class of flavonoids, which have no substituent groups on the aromatic B ring (referred to herein as Free-B-Ring flavonoids), as illustrated by the following general structure:
wherein
R1, R2, R3, R4, and R5 are independently selected from the group consisting of —H, —OH, —SH, OR, —SR, —NH2, —NHR, —NR2, —NR3 +X−, a carbon, oxygen, nitrogen or sulfur, glycoside of a single or a combination of multiple sugars including, but not limited to aldopentoses, methyl-aldopentose, aldohexoses, ketohexose and their chemical derivatives thereof;
wherein
R is an alkyl group having between 1-10 carbon atoms; and
X is selected from the group of pharmaceutically acceptable counter anions including, but not limited to hydroxyl, chloride, iodide, fluoride, sulfate, phosphate, acetate, carbonate, etc.
Free-B-ring flavonoids are relatively rare. Out of 9,396 flavonoids synthesized or isolated from natural sources, only 231 Free-B-ring flavonoids are known (The Combined Chemical Dictionary, Chapman & Hall/CRC, Version 5:1 Jun. 2001). Free-B-ring flavonoids have been reported to have diverse biological activity. For example, galangin (3,5,7-trihydroxyflavone) acts as an anti-oxidant and free radical scavenger and is believed to be a promising candidate for anti-genotoxicity and cancer chemoprevention. (Heo et al. (2001) Mutat. Res. 488:135-150). It is an inhibitor of tyrosinase monophenolase (Kubo et al. (2000) Bioorg. Med. Chem. 8:1749-1755), an inhibitor of rabbit heart carbonyl reductase (Imamura et al. (2000) J. Biochem. 127:653-658), has antimicrobial activity (Afolayan and Meyer (1997) Ethnopharmacol. 57:177-181) and antiviral activity (Meyer et al. (1997) J. Ethnopharmacol. 56:165-169). Baicalein and two other Free-B-ring flavonoids, have antiproliferative activity against human breast cancer cells. (So et al. (1997) Cancer Lett. 112:127-133).
Typically, flavonoids have been tested for biological activity randomly based upon their availability. Occasionally, the requirement of substitution on the B-ring has been emphasized for specific biological activity, such as the B-ring substitution required for high affinity binding to p-glycoprotein (Boumendjel et al. (2001) Bioorg. Med. Chem. Lett. 11 (1):75-77); cardiotonic effect (Itoigawa et al. (1999) J. Ethnopharmacol. 65(3): 267-272), protective effect on endothelial cells against linoleic acid hydroperoxide-induced toxicity (Kaneko and Baba (1999) Biosci Biotechnol. Biochem 63(2):323-328), COX-1 inhibitory activity (Wang (2000) Phytomedicine 7:15-19) and prostaglandin endoperoxide synthase (Kalkbrenner et al. (1992) Pharmacology 44(1):1-12). Only a few publications have mentioned the significance of the unsubstituted B ring of the Free-B-Ring flavonoids. One example is the use of 2-phenyl flavones, which inhibit NADPH quinone acceptor oxidoreductase, as potential anticoagulants. (Chen et al. (2001) Biochem. Pharmacol. 61(11):1417-1427).
The mechanism of action relative to the anti-inflammatory activity of various Free-B-Ring flavonoids has been controversial. The anti-inflammatory activity of the Free-B-Ring flavonoids, chrysin (Liang et al. (2001) FEBS Lett. 496(1):12-18), wogonin (Chi et al. (2001) Biochem. Pharmacol. 61:1195-1203) and halangin (Raso et al. (2001) Life Sci. 68(8):921-931), has been associated with the suppression of inducible cycloxygenase and nitric oxide synthase via activation of peroxisome proliferator activated receptor gamma (PPARγ) and influence on degranulation and AA release. (Tordera et al. (1994) Z. Naturforsch [C] 49:235-240). It has been reported that oroxylin, baicalein and wogonin inhibit 12-lipoxygenase activity without affecting cycloxygenase. (You et al. (1999) Arch. Pharm. Res. 22(1):18-24). More recently, the anti-inflammatory activity of wogonin, baicalin and baicalein has been reported as occurring through inhibition of inducible nitric oxide synthase and cox-2 gene expression induced by nitric oxide inhibitors and lipopolysaccharide. (Chen et al. (2001) Biochem. Pharmacol. 61(11):1417-1427). It has also been reported that oroxylin acts via suppression of NFκB activation. (Chen et al. (2001) Biochem. Pharmacol. 61(11):1417-1427). Finally, wogonin reportedly inhibits inducible PGE2 production in macrophages. (Wakabayashi and Yasui (2000) Eur. J. Pharmacol. 406(3):477-481).
Inhibition of the phosphorylation of mitrogen-activated protein kinase and inhibition of Ca2+ ionophore A23187 induced PGE2 release by baicalein has been reported as the mechanism of anti-inflammatory activity of Scutellariae radix. (Nakahata et al. (1999) Nippon Yakurigaku Zasshi, 114, Supp. 11:215 P-219P; Nakahata et al. (1998) Am. J. Chin Med. 26:311-323). Baicalin from Scutellaria baicalensis, reportedly inhibits superantigenic staphylococcal exotoxins stimulated T-cell proliferation and production of IL-1β, IL-6, TNF-α, and interferon-γ (IFN-γ). (Krakauer et al. (2001) FEBS Lett. 500:52-55). Thus, the anti-inflammatory activity of baicalin has been associated with inhibiting the pro-inflammatory cytokines mediated signaling pathways activated by superantigens. However, it has also been postulated that the anti-inflammatory activity of baicalin is due to the binding of a variety of chemokines, which limits their biological activity. (Li et al. (2000) Immunopharmacology 49:295-306). Recently, the effects of baicalin on adhesion molecule expression induced by thrombin and thrombin receptor agonist peptide (Kimura et al. (2001) Planta Med. 67:331-334), as well as, the inhibition of mitogen-activated protein kinase cascade (MAPK) (Nakahata et al. (1999) Nippon Yakurigaku Zasshi, 114, Supp 11:215 P-219P; Nakahata et al. (1998) Am. J. Chin Med. 26:311-323) have been reported.
The Chinese medicinal plant, Scutellaria baicalensis contains significant amounts of Free-B-Ring flavonoids, including baicalein, baicalin, wogonin and baicalenoside. Traditionally, this plant has been used to treat a number of conditions including clearing away heat, purging fire, dampness-warm and summer fever syndromes; polydipsia resulting from high fever; carbuncle, sores and other pyogenic skin infections; upper respiratory infections, such as acute tonsillitis, laryngopharyngitis and scarlet fever; viral hepatitis; nephritis; pelvitis; dysentery; hematemesis and epistaxis. This plant has also traditionally been used to prevent miscarriage. (Encyclopedia of Chinese Traditional Medicine, ShangHai Science and Technology Press, ShangHai, China, 1998). Clinically Scutellaria is now used to treat conditions such as pediatric pneumonia, pediatric bacterial diarrhea, viral hepatitis, acute gallbladder inflammation, hypertension, topical acute inflammation, resulting from cuts and surgery, bronchial asthma and upper respiratory infections. (Encyclopedia of Chinese Traditional Medicine, ShangHai Science and Technology Press, ShangHai, China, 1998). The pharmacological efficacy of Scutellaria roots for treating bronchial asthma is reportedly related to the presence of Free-B-Ring flavonoids and their suppression of eotaxin associated recruitment of eosinophils. (Nakajima et al. (2001) Planta Med. 67(2):132-135).
To date, a number of naturally occurring Free-B-Ring flavonoids have been commercialized for various uses. For example, liposome formulations of Scutellaria extracts have been utilized for skin care. (U.S. Pat. Nos. 5,643,598; 5,443,983). Baicalin has been used for preventing cancer, due to its inhibitory effects on oncogenes. (U.S. Pat. No. 6,290,995). Baicalin and other compounds have been used as antiviral, antibacterial and immunomodulating agents (U.S. Pat. No. 6,083,921 and WO98/42363) and as natural anti-oxidants (WO98/49256 and Poland Pub. No. 9,849,256). Scutellaria baicalensis root extract has been formulated as a supplemental sun screen agent with additive effects of the cumulative SPFs of each individual component in a topical formulation (WO98/19651). Chrysin has been used for its anxiety reducing properties (U.S. Pat. No. 5,756,538). Anti-inflammatory flavonoids are used for the control and treatment of anorectal and colonic diseases (U.S. Pat. No. 5,858,371), and inhibition of lipoxygenase (U.S. Pat. No. 6,217,875). These compounds are also formulated with glucosamine collagen and other ingredients for repair and maintenance of connective tissue (U.S. Pat. No. 6,333,304). Flavonoid esters constitute active ingredients for cosmetic compositions (U.S. Pat. No. 6,235,294). U.S. application Ser. No. 10/091,362, filed Mar. 1, 2002, entitled “Identification of Free-B-Ring Flavonoids as Potent COX-2 Inhibitors,” and U.S. application Ser. No. 10/427,746, filed Apr. 30, 2003, entitled “Formulation With Dual Cox-2 And 5-Lipoxygenase Inhibitory Activity,” both disclose a method for inhibiting the cycloxygenase enzyme COX-2 by administering a composition comprising a Free-B-Ring flavonoid or a composition containing a mixture of Free-B-Ring flavonoids to a host in need thereof. This is the first report of a link between Free-B-Ring flavonoids and COX-2 inhibitory activity. These applications are specifically incorporated herein by reference in their entirety.
Japanese Pat. No. 63027435, describes the extraction, and enrichment of baicalein and Japanese Pat. No. 61050921 describes the purification of baicalin.
Flavans include compounds illustrated by the following general structure:
wherein
R1, R2, R3, R4 and R5 are independently selected from the group consisting of —H, —OH, —SH, —OCH3, —SCH3, —OR, —SR, —NH2, —NRH, —NR2, —NR3 +X−, esters of the mentioned substitution groups, including, but not limited to, gallate, acetate, cinnamoyl and hydroxyl-cinnamoyl esters, trihydroxybenzoyl esters and caffeoyl esters, and their chemical derivatives thereof; a carbon, oxygen, nitrogen or sulfur glycoside of a single or a combination of multiple sugars including, but not limited to, aldopentoses, methyl aldopentose, aldohexoses, ketohexose and their chemical derivatives thereof; dimer, trimer and other polymerized flavans;
wherein
R is an alkyl group having between 1-10 carbon atoms; and
X is selected from the group of pharmaceutically acceptable counter anions including, but not limited to hydroxyl, chloride, iodide, sulfate, phosphate, acetate, fluoride, and carbonate, etc.
Catechin is a flavan, found primarily in green tea, having the following structure:
Catechin works both alone and in conjunction with other flavonoids found in tea, and has both antiviral and antioxidant activity. Catechin has been shown to be effective in the treatment of viral hepatitis. It also appears to prevent oxidative damage to the heart, kidney, lungs and spleen and has been shown to inhibit the growth of stomach cancer cells.
Catechin and its isomer epicatechin inhibit prostaglandin endoperoxide synthase with an IC50 value of 40 μM. (Kalkbrenner et al. (1992) Pharmacol. 44:1-12). Five flavan-3-ol derivatives, including (+)-catechin and gallocatechin, isolated from four plant species: Atuna racemosa, Syzygium carynocarpum, Syzygium malaccense and Vantanea peruviana, exhibit equal to weaker inhibitory activity against COX-2, relative to COX-1, with IC50 values ranging from 3.3 μM to 138 μM. (Noreen et al. (1998) Planta Med. 64:520-524). (+)-Catechin, isolated from the bark of Ceiba pentandra, inhibits COX-1 with an IC50 value of 80 μM. (Noreen et al. (1998) J. Nat. Prod. 61:8-12). Commercially available pure (+)-catechin inhibits COX-1 with an IC50 value of around 183 to 279 μM depending upon the experimental conditions, with no selectivity for COX-2. (Noreen et al. (1998) J. Nat. Prod. 61:1-7).
Green tea catechin, when supplemented into the diets of Sprague Dawley male rats, lowered the activity level of platelet PLA2 and significantly reduced platelet cycloxygenase levels. (Yang et al. (1999) J. Nutr. Sci. Vitaminol. 45:337-346). Catechin and epicatechin reportedly weakly suppress cox-2 gene transcription in human colon cancer DLD-1 cells (IC50=415.3 μM). (Mutoh et al. (2000) Jpn. J. Cancer Res. 91:686-691). The neuroprotective ability of (+)-catechin from red wine results from the antioxidant properties of catechin, rather than inhibitory effects on intracellular enzymes, such as cycloxygenase, lipoxygenase, or nitric oxide synthase (Bastianetto et al. (2000) Br. J. Pharmacol. 131:711-720). Catechin derivatives purified from green and black tea, such as epigallocatechin-3-gallate (EGCG), epigallocatechin (EGC), epicatechin-3-gallate (ECG), and theaflavins showed inhibition of cycloxygenase and lipoxygenase dependent metabolism of AA in human colon mucosa and colon tumor tissues (Hong et al. (2001) Biochem. Pharmacol. 62:1175-1183) and induce cox-2 expression and PGE2 production (Park et al. (2001) Biochem. Biophys. Res. Commun. 286:721-725). Epiafzelechin isolated from the aerial parts of Celastrus orbiculatus exhibited dose-dependent inhibition of COX-1 activity with an IC50 value of 15 μM and also demonstrated anti-inflammatory activity against carrageenin-induced mouse paw edema following oral administration at a dosage of 100 mg/kg. (Min et al. (1999) Planta Med. 65:460-462).
Acacia is a genus of leguminous trees and shrubs. The genus Acacia includes more than 1000 species belonging to the family of Leguminosae and the subfamily of Mimosoideae. Acacias are distributed worldwide in tropical and subtropical areas of Central and South America, Africa, parts of Asia, as well as, Australia, which has the largest number of endemic species. Acacias are very important economically, providing a source of tannins, gums, timber, fuel and fodder. Tannins, which are isolated primarily from bark, are used extensively for tanning hides and skins. Some Acacia barks are also used for flavoring local spirits. Some indigenous species like A. sinuata also yield saponins, which are any of various plant glucosides that form soapy lathers when mixed and agitated with water. Saponins are used in detergents, foaming agents and emulsifiers. The flowers of some Acacia species are fragrant and used to make perfume. The heartwood of many Acacias is used for making agricultural implements and also provides a source of firewood. Acacia gums find extensive use in medicine and confectionery and as sizing and finishing materials in the textile industry.
To date, approximately 330 compounds have been isolated from various Acacia species. Flavonoids are the major class of compounds isolated from Acacias. Approximately 180 different flavonoids have been identified, 111 of which are flavans. Terpenoids are second largest class of compounds isolated from species of the Acacia genus, with 48 compounds having been identified. Other classes of compounds isolated from Acacia include, alkaloids (28), amino acids/peptides (20), tannins (16), carbohydrates (15), oxygen heterocycles (15) and aliphatic compounds (10). (Buckingham, The Combined Chemical Dictionary, Chapman & Hall CRC, version 5:2, December 2001).
Phenolic compounds, particularly flavans are found in moderate to high concentrations in all Acacia species. (Abdulrazak et al. (2000) Journal of Animal Sciences. 13:935-940). Historically, most of the plants and extracts of the Acacia genus have been utilized as astringents to treat gastrointestinal disorders, diarrhea, indigestion and to stop bleeding. (Vautrin (1996) Universite Bourgogne (France) European abstract 58-01C:177; Saleem et al. (1998) Hamdard Midicus. 41:63-67). The bark and pods of Acacia arabica Willd. contain large quantities of tannins and have been utilized as astringents and expectorants. (Nadkarni (1996) India Materia Medica, Bombay Popular Prakashan, pp. 9-17). Diarylpropanol derivatives, isolated from stem bark of Acacia tortilis from Somalia, have been reported to have smooth muscle relaxing effects. (Hagos et al. (1987) Planta Medica. 53:27-31, 1987). It has also been reported that terpenoid saponins isolated from Acacia victoriae have an inhibitory effect on dimethylbenz(a)anthracene-induced murine skin carcinogenesis (Hanausek et al. (2000) Proceedings American Association for Cancer Research Annual Meeting 41:663) and induce apotosis (Haridas et al. (2000) Proceedings American Association for Cancer Research Annual Meeting. 41:600). Plant extracts from Acacia nilotica have been reported to have spasmogenic, vasoconstrictor and anti-hypertensive activity (Amos et al. (1999) Phytotherapy Research 13:683-685; Gilani et al. (1999) Phytotherapy Research. 13:665-669), and antiplatelet aggregatory activity (Shah et al. (1997) General Pharmacology. 29:251-255). Anti-inflammatory activity has been reported for A. nilotica. It was speculated that flavonoids, polysaccharides and organic acids were potential active components. (Dafallah and Al-Mustafa (1996) American Journal of Chinese Medicine. 24:263-269). To date, the only reported 5-lipoxygenase inhibitor isolated from Acacia is a monoterpenoidal carboxamide. (Seikine et al. (1997) Chemical and Pharmaceutical Bulletin. 45:148-11).
The extract from the bark of Acacia has been patented in Japan for external use as a whitening agent (Abe, JP10025238), as a glucosyl transferase inhibitor for dental applications (Abe, JP07242555), as a protein synthesis inhibitor (Fukai, JP 07165598), as an active oxygen scavenging agent for external skin preparations (Honda, JP 07017847, Bindra U.S. Pat. No. 6,1266,950) and as a hyaluronidase inhibitor for oral consumption to prevent inflammation, pollinosis and cough (Ogura, JP 07010768).
To date, Applicant is unaware of any reports of a formulation combining Free-B-ring flavonoids and flavans for use in the prevention and treatment of neurodegradation, neuroinflammation and cumulative cognitive declines, disorders and diseases.
The present invention includes methods that are effective in simultaneously inhibiting both the cycloxygenase (COX) and lipoxygenase (LOX) enzymes. The method for the simultaneous dual inhibition of the COX and LOX enzymes is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants to a host in need thereof. This composition of matter is referred to herein as Lasoperin™. The ratio of Free-B-Ring flavonoids to flavans in the composition of matter can be adjusted based on the indications and the specific requirements with respect to prevention and treatment of a specific disease or condition. Generally, the ratio of the Free-B-Ring flavonoids to flavans in the composition can be in the range of 99.9:0.1 of Free-B-Ring flavonoids:flavans to 0.1:99.9 Free-B-Ring flavonoids:flavans. In specific embodiments of the present invention, the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In one embodiment of this invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is 80:20. In a preferred embodiment, the Free-B-Ring flavonoids are isolated from a plant or plants in the Scutellaria genus of plants and the flavans are isolated from a plant or plants in the Acacia genus of plants. The efficacy of this method was demonstrated with purified enzymes, in different cell lines, in multiple animal models and eventually in a human clinical study.
Specifically, the present includes methods for the prevention and treatment of COX and LOX mediated diseases and conditions related to neuronal and cognitive function, said method comprising administering to a host in need thereof an effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants and a pharmaceutically acceptable carrier. The ratio of Free-B-Ring flavonoids to flavans in the composition can be in the range of 99.9:0.1 of Free-B-Ring flavonoids:flavans to 0.1:99.9 Free-B-Ring flavonoids:flavans. In specific embodiments of the present invention, the ratio of Free-B-Ring flavonoids to flavans can be selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In one embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20. In a preferred embodiment, the Free-B-Ring flavonoids are isolated from a plant or plants in the Scutellaria genus of plants and flavans are isolated from a plant or plants in the Acacia genus of plants.
In another embodiment, the present includes a method for the prevention and treatment of general cognitive decline, age-related memory loss, neuroinflammatory and neurodegenerative disorders, said method comprising administering to a host in need thereof an effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants together with a pharmaceutically acceptable carrier. The ratio of Free-B-Ring flavonoids to flavans can be in the range of 99.9:0.1 to 0.1:99.9 Free-B-Ring flavonoids:flavans. In specific embodiments of the present invention, the ratio of Free-B-Ring flavonoids to flavans is from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In one embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20. In a preferred embodiment, the Free-B-ring flavonoids are isolated from a plant or plants in the Scutellaria genus of plants and flavans are isolated from a plant or plants in the Acacia genus of plants.
In another embodiment, the present invention includes a method for modulating the production of mRNA implicated in cognitive decline and other age-, neurodegenerative-, and neuroinflammatory-related conditions, said method comprising administering to a host in need thereof an effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants and a pharmaceutically acceptable carrier. The ratio of Free-B-Ring flavonoids to flavans can be in the range of 99.9:0.1 to 0.1:99.9 Free-B-Ring flavonoids:flavans. In specific embodiments of the present invention, the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In one embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20. In one embodiment the Free-B-Ring flavonoids are isolated from a plant or plants in the Scutellaria genus of plants and flavans are isolated from a plant or plants in the Acacia genus of plants.
The present invention also includes a method for modulating the production of mRNA of transcription factors that control production of cytokine mRNA implicated in cognitive decline and other age-, neurodegenerative-, and neuroinflammatory-related conditions, said method comprising administering to a host in need thereof an effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants and a pharmaceutically acceptable carrier. The ratio of Free-B-Ring flavonoids to flavans can be in the range of 99.9:0.1 to 0.1:99.9 Free-B-Ring flavonoids:flavans. In specific embodiments of the present invention, the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In one embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20. In a preferred embodiment the Free-B-Ring flavonoids are isolated from a plant or plants in the Scutellaria genus of plants and flavans are isolated from a plant or plants in the Acacia genus of plants.
In yet another embodiment, the present invention includes a method for modulating the production of mRNA transcription factors that controls production of cox-2, but not cox-1 mRNA implicated in cognitive decline and other age-, neurodegenerative-, and neuroinflammatory-related conditions, said method comprising administering to a host in need thereof an effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants and a pharmaceutically acceptable carrier. The ratio of Free-B-Ring flavonoids to flavans can be in the range of 99.9:0.1 to 0.1:99.9 Free-B-ring flavonoids:flavans. In specific embodiments of the present invention, the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In one embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20. In a preferred embodiment the Free-B-Ring flavonoids are isolated from a plant or plants in the Scutellaria genus of plants and flavans are isolated from a plant or plants in the Acacia genus of plants.
While not limited by theory, it is believed that the composition of the instant invention acts by inhibiting pro-inflammatory cytokines via down-regulation of the nuclear factor kappa B (NFκB) transcription factor, which controls gene expression of interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNFα), and interleukin-6 (IL-6). It is also believed that the composition inhibits the gene expression of another transcription factor, peroxisome proliferator activated receptor gamma (PPARγ), which helps control the gene expression of cyclooxygenase-2 (COX-2). Additionally, the composition of the instant invention inhibits the activity of COX-2 and 5-lipoxygenase (5-LO) thereby suppressing the conversion of AA to prostaglandins, thromboxanes, and leukotrienes, each of which exacerbate inflammation. The composition also possesses a strong antioxidant capacity which neutralizes reactive oxygen species (ROS), molecules that can lead to greater NFκB expression, and thus, greater pro-inflammatory gene expression of cytokines.
The Free-B-Ring flavonoids, also referred to herein as Free-B-Ring flavones and flavonols, that can be used in accordance with the following invention include compounds illustrated by the following general structure:
wherein
R1, R2, R3, R4, and R5 are independently selected from the group consisting of —H, —OH, —SH, OR, —SR, —NH2, —NHR, —NR2, —NR3 +X−, a carbon, oxygen, nitrogen or sulfur, glycoside of a single or a combination of multiple sugars including, but not limited to aldopentoses, methyl-aldopentose, aldohexoses, ketohexose and their chemical derivatives thereof;
wherein
R is an alkyl group having between 1-10 carbon atoms; and
X is selected from the group of pharmaceutically acceptable counter anions including, but not limited to hydroxyl, chloride, iodide, sulfate, phosphate, acetate, fluoride, carbonate, etc.
The Free-B-Ring flavonoids of this invention may be obtained by synthetic methods or extracted from the family of plants including, but not limited to Annonaceae, Asteraceae, Bignoniaceae, Combretaceae, Compositae, Euphorbiaceae, Labiatae, Lauranceae, Leguminosae, Moraceae, Pinaceae, Pteridaceae, Sinopteridaceae, Ulmaceae and Zingiberacea. The Free-B-Ring flavonoids can be extracted, concentrated, and purified from the following genus of high plants, including but not limited to Desmos, Achyrocline, Oroxylum, Buchenavia, Anaphalis, Cotula, Gnaphalium, Helichrysum, Centaurea, Eupatorium, Baccharis, Sapium, Scutellaria, Molsa, Colebrookea, Stachys, Origanum, Ziziphora, Lindera, Actinodaphne, Acacia, Derris, Glycyrrhiza, Millettia, Pongamia, Tephrosia, Artocarpus, Ficus, Pityrogramma, Notholaena, Pinus, Ulmus and Alpinia.
The flavans that can be used in accordance with the following invention include compounds illustrated by the following general structure: generally represented by the following general structure:
wherein
R1, R2, R3, R4 and R5 are independently selected from the group consisting of H, —OH, —SH, —OCH3, —SCH3, —OR, —SR, —NH2, —NRH, —NR2, —NR3 +X−, esters of substitution groups, including, but not limited to, gallate, acetate, cinnamoyl and hydroxyl-cinnamoyl esters, trihydroxybenzoyl esters and caffeoyl esters and their chemical derivatives thereof; carbon, oxygen, nitrogen or sulfur glycoside of a single or a combination of multiple sugars including, but not limited to, aldopentoses, methyl aldopentose, aldohexoses, ketohexose and their chemical derivatives thereof; dimer, trimer and other polymerized flavans;
wherein
R is an alkyl group having between 1-10 carbon atoms; and
X is selected from the group of pharmaceutically acceptable counter anions including, but not limited to hydroxyl, chloride, iodide, sulfate, phosphate, acetate, fluoride, carbonate, etc.
The flavans of this invention may be obtained from a plant or plants selected from the genus of Acacia. In a preferred embodiment, the plant is selected from the group consisting of Acacia catechu, Acacia concinna, Acacia farnesiana, Acacia Senegal, Acacia speciosa, Acacia arabica, A. caesia, A. pennata, A. sinuata. A. mearnsii, A. picnantha, A. dealbata, A. auriculiformis, A. holoserecia and A. mangium.
In one embodiment, the present invention includes a method for preventing and treating a number of COX and LOX mediated diseases and conditions related to neuronal and cognitive function, including, but not limited to general cognitive decline, age-related memory loss, neuroinflammatory and neurodegenerative disorders and other conditions relating to neuronal and cognitive function. In another embodiment, the present invention includes a method for modulating the production of mRNA implicated in cognitive decline and other age-, neurodegenerative-, and neuroinflammatory-related conditions.
The method of prevention and treatment according to this invention comprises administering to a host in need thereof a therapeutically effective amount of the formulated Free-B-Ring flavonoids and flavans isolated from a single source or multiple sources. The purity of the individual and/or a mixture of multiple Free-B-Ring flavonoids and flavans includes, but is not limited to 0.01% to 100%, depending on the methodology used to obtain the compound(s). In a preferred embodiment, doses of the mixture of Free-B-Ring flavonoids and flavans containing the same are an efficacious, nontoxic quantity generally selected from the range of 0.001% to 100% based on total weight of the formulation. Persons skilled in the art using routine clinical testing are able to determine optimum doses for the particular ailment being treated.
The present invention includes an evaluation of different compositions of Free-B-Ring flavonoids and flavans using enzymatic and in vivo models to optimize the formulation and obtain the desired physiological activity. The efficacy and safety of these formulations is demonstrated in human clinical studies. Thus, the present invention also includes therapeutic compositions comprising the therapeutic agents of the present invention. The compositions of this invention can be administered by any method known to one of ordinary skill in the art. The modes of administration include, but are not limited to, enteral (oral) administration, parenteral (intravenous, subcutaneous, and intramuscular) administration and topical application.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention as claimed.
The present invention includes methods that are effective in simultaneously inhibiting both the cycloxygenase (COX) and lipoxygenase (LOX) enzymes, for use in the prevention and treatment of diseases and conditions related to neuronal and cognitive function. The method for the simultaneous dual inhibition of the COX and LOX enzymes is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants to a host in need thereof. This composition of matter is referred to herein as Lasoperin™. The ratio of Free-B-Ring flavonoids to flavans in the composition of matter can be adjusted based on the indications and the specific requirements with respect to prevention and treatment of a specific disease or condition.
Various terms are used herein to refer to aspects of the present invention. To aid in the clarification of the description of the components of this invention, the following definitions are provided.
Unless defined otherwise all technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs.
It is to be noted that as used herein the term “a” or “an” entity refers to one or more of that entity; for example, a flavonoid refers to one or more flavonoids. As such, the terms “a” or “an”, “one or more” and “at least one” are used interchangeably herein.
“Free-B-ring Flavonoids” as used herein are a specific class of flavonoids, which have no substitute groups on the aromatic B-ring, as illustrated by the following general structure:
wherein
R1, R2, R3, R4, and R5 are independently selected from the group consisting of —H, —OH, —SH, OR, —SR, —NH2, —NHR, —NR2, —NR3 +X−, a carbon, oxygen, nitrogen or sulfur, glycoside of a single or a combination of multiple sugars including, but not limited to aldopentoses, methyl-aldopentose, aldohexoses, ketohexose and their chemical derivatives thereof;
wherein
R is an alkyl group having between 1-10 carbon atoms; and
X is selected from the group of pharmaceutically acceptable counter anions including, but not limited to hydroxyl, chloride, iodide, sulfate, phosphate, acetate, fluoride, carbonate, etc.
“Flavans” as used herein refer to a specific class of flavonoids, which can be generally represented by the following general structure:
wherein
R1, R2, R3, R4 and R5 are independently selected from the group consisting of H, —OH, —SH, —OCH3, —OR, —SR, —NH2, —NRH, —NR2, —NR3 +X−, esters of substitution groups, including, but not limited to, gallate, acetate, cinnamoyl and hydroxyl-cinnamoyl esters, trihydroxybenzoyl esters and caffeoyl esters and their chemical derivatives thereof; carbon, oxygen, nitrogen or sulfur glycoside of a single or a combination of multiple sugars including, but not limited to, aldopentoses, methyl aldopentose, aldohexoses, ketohexose and their chemical derivatives thereof; dimer, trimer and other polymerized flavans;
wherein
R is an alkyl group having between 1-10 carbon atoms; and
X is selected from the group of pharmaceutically acceptable counter anions including, but not limited to hydroxyl, chloride, iodide, sulfate, phosphate, acetate, fluoride, carbonate, etc.
“Therapeutic” as used herein, includes treatment and/or prophylaxis. When used, therapeutic refers to humans as well as other animals
“Pharmaceutically or therapeutically effective dose or amount” refers to a dosage level sufficient to induce a desired biological result. That result may be the alleviation of the signs, symptoms or causes of a disease or any other alteration of a biological system that is desired. The precise dosage will vary according to a variety of factors, including but not limited to the age and size of the subject, the disease and the treatment being effected.
“Placebo” refers to the substitution of the pharmaceutically or therapeutically effective dose or amount dose sufficient to induce a desired biological that may alleviate the signs, symptoms or causes of a disease with a non-active substance.
A “host” or “patient” or “subject” is a living mammal, human or animal, for whom therapy is desired. The “host,” “patient” or “subject” generally refers to the recipient of the therapy to be practiced according to the method of the invention.
As used herein a “pharmaceutically acceptable carrier” refers to any carrier, which does not interfere with effectiveness of the biological activity of the active ingredient and which is not toxic to the host to which it is administered. Examples of “pharmaceutically acceptable carriers” include, but are not limited to, any of the standard pharmaceutical carriers such as a saline solution, i.e. Ringer's solution, a buffered saline solution, water, a dextrose solution, serum albumin. and other excipients and preservatives for tableting and capsulating formulations.
“Gene expression” refers to the transcription of a gene to mRNA.
“Protein expression” refers to the translation of mRNA to a protein.
“RT-qPCR” as used herein refers to a method for reverse transcribing (RT) an mRNA molecule into a cDNA molecule and then quantitatively evaluating the level of gene expression using a polymerase chain reaction (PCR) coupled with a fluorescent reporter.
Note that throughout this application various citations are provided. Each of these citations is specifically incorporated herein by reference in its entirety.
The present invention includes methods that are effective in simultaneously inhibiting both the COX and LOX enzymes for use in the prevention and treatment of diseases and conditions related to neuronal and cognitive function. The method for the simultaneous dual inhibition of the COX and LOX enzymes is comprised of administering a composition comprised of a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants to a host in need thereof. This composition of matter which is referred to herein as Lasoperin™, is also distributed under the trade name of Univestin™, as described in U.S. patent application Ser. No. 10/427,746, filed Apr. 30, 2003, entitled “Formulation with Dual Cox-2 and 5-Lipoxygenase Inhibitory Activity,” which is incorporated herein by reference in its entirety. The ratio of Free-B-Ring flavonoids to flavans can be in the range of 99.9:0.1 Free-B-Ring flavonoids:flavans to 0.1:99.9 Free-B-Ring flavonoids:flavans. In specific embodiments of the present invention, the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In one embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20.
The isolation and identification of Free-B-Ring flavonoids from the Scutellaria genus of plants is described in U.S. patent application Ser. No. 10/091,362, filed Mar. 1, 2002, entitled “Identification of Free-B-Ring Flavonoids as Potent Cox-2 Inhibitors,” which is incorporated herein by reference in its entirety. The isolation identification of flavans from the Acacia genus of plants is described in U.S. patent application Ser. No. 10/104,477, filed Mar. 22, 2002, entitled “Isolation of a Dual Cox-2 and 5-Lipoxygenase Inhibitor from Acacia,” which is incorporated herein by reference in its entirety.
The present invention includes methods that are effective in the prevention and treatment of age-, cognitive-, neurodegenerative- and neuroinflammatory-related diseases and conditions. The method for the prevention and treatment of these cognitive and neuronal diseases and conditions is comprised of administering to a host in need thereof a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants. The ratio of Free-B-Ring flavonoids to flavans in the composition can be in the range of 99.9:0.1 Free-B-Ring flavonoids:flavans to 0.1:99.9 of Free-B-Ring flavonoids:flavans. In specific embodiments of the present invention, the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In one embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20.
Further included in the present invention are methods for preventing and treating pro-inflammatory cytokine-mediated neuronal and cognitive diseases and conditions said method comprised of administering to a host in need thereof an effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants together with a pharmaceutically acceptable carrier. The ratio of Free-B-Ring flavonoids to flavans in the composition can be in the range of 99.9:0.1 Free-B-Ring flavonoids:flavans to 0.1:99.9 of Free-B-Ring flavonoids:flavans. In specific embodiments of the present invention, the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In one embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20.
Also included in the present invention is a method for the reduction of TNFα, and IL-1β, two key components in age-, cognitive-, neurodegenerative and neuroinflammatory-related diseases and conditions. The method for the reduction of TNFα and IL-1β is comprised of administering to a host in need thereof an effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants together with a pharmaceutically acceptable carrier. The ratio of Free-B-Ring flavonoids to flavans in the composition can be in the range of 99.9:0.1 Free-B-ring flavonoids:flavans to 0.1:99.9 of Free-B-Ring flavonoids:flavans. In specific embodiments of the present invention, the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In a preferred embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20.
The present further includes a method for the prevention and treatment of diseases and conditions mediated by ROS, via the reduction of ROS. ROS are a pivotal product of oxidative stress and lipid metabolism and can be significantly elevated in age-, cognitive-, neurodegenerative- and neuroinflammatory-related diseases and conditions. The method for treating ROS-mediated diseases and conditions is comprised of administering to a host in need thereof an effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants, together with a pharmaceutically acceptable carrier. The ratio of Free-B-Ring flavonoids to flavans in the composition can be in the range of 99.9:0.1 Free-B-Ring flavonoids:flavans to 0.1:99.9 of Free-B-Ring flavonoids:flavans. In specific embodiments of the present invention, the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In one embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20.
Finally, the present invention also includes a method for modulating the production of mRNA implicated in cognitive decline and other age-, neurodegenerative-, and neuroinflammatory-related conditions, including a method for modulating the production of mRNA of transcription factors that control the production of cytokine mRNA and a method for modulating the production of mRNA of the transcription factors that control the production of cox-2, but not cox-1 mRNA. The method for modulating the production of m-RNA implicated in cognitive decline and other age-, neurodegenerative-, and neuroinflammatory-related conditions is comprised of administering to a host in need thereof an effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants together with a pharmaceutically acceptable carrier. The ratio of Free-B-Ring flavonoids to flavans can be in the range of 99:1 to 1:99 Free-B-Ring flavonoids:flavans. In specific embodiments of the present invention, the ratio of Free-B-Ring flavonoids to flavans is selected from the group consisting of approximately 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70, 20:80 and 10:90. In one embodiment of the invention, the ratio of Free-B-Ring flavonoids:flavans in the composition of matter is approximately 80:20.
The Free-B-ring flavonoids that can be used in accordance with the following include compounds illustrated by the general structure set forth above. The Free-B-Ring flavonoids of this invention may be obtained by synthetic methods or may be isolated from the family of plants including, but not limited to Annonaceae, Asteraceae, Bignoniaceae, Combretaceae, Compositae, Euphorbiaceae, Labiatae, Lauranceae, Leguminosae, Moraceae, Pinaceae, Pteridaceae, Sinopteridaceae, Ulmaceae, and Zingiberaceae. The Free-B-Ring flavonoids can also be isolated from the following genera of high plants, including but not limited to Desmos, Achyrocline, Oroxylum, Buchenavia, Anaphalis, Cotula, Gnaphalium, Helichrysum, Centaurea, Eupatorium, Baccharis, Sapium, Scutellaria, Molsa, Colebrookea, Stachys, Origanum, Ziziphora, Lindera, Actinodaphne, Acacia, Derris, Glycyrrhiza, Millettia, Pongamia, Tephrosia, Artocarpus, Ficus, Pityrogramma, Notholaena, Pinus, Ulmus, and Alpinia.
The Free-B-Ring flavonoids can be found in different parts of plants, including but not limited to stems, stem barks, twigs, tubers, roots, root barks, young shoots, seeds, rhizomes, flowers and other reproductive organs, leaves and other aerial parts. Methods for the isolation and purification of Free-B-Ring flavonoids are described in U.S. application Ser. No. 10/091,362, filed Mar. 1, 2002, entitled “Identification of Free-B-ring Flavonoids as Potent COX-2 Inhibitors,” and U.S. application Ser. No. 10/427,746, filed Apr. 30, 2003, entitled “Formulation with Dual Cox-2 and 5-Lipoxygenase Inhibitory Activity”, each of which is incorporated herein by reference in its entirety.
The flavans that can be used in accordance with the method of this invention include compounds illustrated by the general structure set forth above. The flavans of this invention may be obtained by synthetic methods or may be isolated from a plant selected from the group including, but not limited to Acacia catechu, A. concinna, A. farnesiana, A. Senegal, A. speciosa, A. arabica, A. caesia, A. pennata, A. sinuata. A. mearnsii, A. picnantha, A. dealbata, A. auricuhformis, A. holoserecia, A. mangium, Uncaria gambir, Uncaria tomentosa, Uncaria africana and Uncaria qabir.
The flavans can be found in different parts of plants, including but not limited to stems, stem barks, trunks, trunk barks, twigs, tubers, roots, root barks, young shoots, seeds, rhizomes, flowers and other reproductive organs, leaves and other aerial parts. Methods for the isolation and purification of flavans are described in U.S. application Ser. No. 10/104,477, filed Mar. 22, 2002, entitled “Isolation of a Dual COX-2 and 5-Lipoxygenase Inhibitor from Acacia,” which is incorporated herein by reference in its entirety.
In one specific embodiment of the invention, the Free-B-ring flavonoids are isolated from a plant or plants in the Scutellaria genus of plants and flavans are isolated from a plant or plants in the Acacia genus of plants.
The present invention implements a strategy that combines several in vivo cognitive tasks as well as in vitro biochemical, cellular and gene expression screens to identify active plant extracts that specifically inhibit COX and LOX enzymatic activity, decrease pro-inflammatory cytokines via down-regulation of key transcription factors that promote the production of the mRNA of said cytokines, and ROS production, maintain antioxidant properties pertaining to the prevention and treatment of neurodegradation, neuroinflammation, and cumulative cognitive declines, disorders, diseases and conditions resulting from the exposure to reactive oxygen species (ROS), inflammatory proteins, and eicosanoids. The extracts are further evaluated for their impact on mRNA gene expression. Free-B-Ring flavonoids and flavans were tested for their ability in prevent age-related cognitive decline when administered orally as an added component to food.
Example 1 sets forth a general method for the preparation of Lasoperin™, using two standardized extracts isolated from Acacia and Scutellaria, respectively, together with one or more excipient(s). With reference to Table 1, this specific batch of Lasoperin™ contained 86% total active ingredients, including 75.7% Free-B-Ring flavonoids and 10.3% flavans. One or more excipient(s) can optionally be added to the composition of matter. The amount of excipient added can be adjusted based on the actual active content of each ingredient desired.
In order to evaluate the effects of Lasoperin™ on cognitive function two specific behavioral tests, the radial arm water maze (RAWM) and the contextual fear conditioning (CFC) test, which assess hippocampal-dependent working memory were carried out using an animal model. Example 2 illustrates the effect of Lasoperin™ on hippocampal-dependant cognitive function as measured by the radial arm water maze (RAWM) test. The results are set forth in FIGS. 1A-1C , which depict graphically the effect of Lasoperin™ administered daily in a 13-week radial arm water maze (RAWM) test to Fisher 344 aged male rats fed a diet supplemented with 3, 7 or 34 mg/kg Lasoperin™, respectively. Young Fisher 344 male rats, maintained on a normal diet, served as a control for normal age-related changes in behavior. The data are presented as the mean total errors vs. trial number (four trials were performed on each test day). FIG. 1A illustrates the results following pre-testing during weeks 1 and 2 (baseline). FIG. 1B illustrates the results following week 5 (Session II) and FIG. 1C illustrates the results following week 11 (Session III). The data depicted in FIGS. 1A-C demonstrate that Lasoperin™ (7 and 34 mg/kg dose groups) prevents age-related memory impairment.
Because the RAWM contains a motor function component, it is possible that an improvement in this task could be experienced if the administered formulation alleviated joint pain and discomfort. To control for this, the CFC test was also carried out as this test does not require the animal to move and therefore confirms the cognitive aspect of both tasks (nociceptive shock threshold was used to test for analgesic properties of the formulation in evaluating the CFC results). Example 3 illustrates the effect of Lasoperin™ on hippocampal-dependent cognitive function as measured by the contextual fear conditioning (CFC) test. Sixty Fisher 344 male rats were used in this study as described in Example 2. The results are set forth in FIG. 2 , which illustrates the effect of Lasoperin™ administered daily for 12 weeks prior to contextual fear conditioning testing in 344 aged male rats fed a diet supplemented with 3, 7 or 34 mg/kg Lasoperin™. Young Fisher 344 male rats, maintained on a normal diet, served as a control for normal age-related changes in behavior. The data are presented as mean percent freezing vs. dose group. FIG. 2 demonstrates that Lasoperin™ (7 and 34 mg/kg dose groups) ameliorated age-related impairments.
Examples 4 and 5 illustrate the effect of Lasoperin™ administered daily at 300 mg/day over a 4 week period to 40 individuals in a randomized, placebo-controlled, double-blind clinical trial on cognitive function. The results were compared to 46 individuals who were treated with a placebo. Measurement of cognitive performance was obtained using a series of web-based Cognitive Care tests which assess Psychomotor speed, Working Memory Speed (executive decision making, quickness & flexibility) and Immediate Memory (verbal & spatial memory processing). Before the study began, participants were required to practice the tests on two consecutive days to establish baseline performance. The data analysis compares baseline performance to performance post-treatment.
Psychomotor speed or physical reflexes is a simple reaction time test that requires the person to respond by pressing a key as quickly as possible after a figure appears on the computer screen.
Working Memory Speed presents a word and picture simultaneously and requires the person to decide if they are the same or different. A reversal cue is also presented randomly and requires the person to respond opposite of the correct response, so that a response to a correct pair would be no and visa versa. This task requires suppression or “inhibition of a learned response” and then a reversal (“task shifting”) of the response contingency. The speed of switching from one task or one response mode to another is often equated with mental flexibility and higher-order cognitive processing, as well as superior decision-making.
Immediate Memory is similar to the classic Sternberg task in which a string of stimulus “target” items to be remembered are followed by a “probe” item. The subject must determine if the probe item was a member of the previous target list. List length can be varied to provide an estimate of the short-term memory capacity of the individual. Both letters and spatial position are examined in this task.
The results are set forth in FIG. 3 , which depicts graphically the effect of Lasoperin™ on complex choice reaction time and FIG. 4 , which depicts graphically the effect of Lasoperin™ on reaction time standard deviation (RTSD). Reaction time standard deviation represents the intra-trial variance. FIGS. 3 and 4 demonstrate that Lasoperin™ increases the speed of processing in subjects presented with complex choices and information.
Example 6 describes a COX inhibition assay performed using Lasoperin™. The biochemical assay, used to measure inhibition of COX, relies on the protein's peroxidase activity in the presence of heme and arachidonic acid. The dose response and IC50 results for Lasoperin™ are set forth in FIG. 5 . The IC50 for COX-1 was 0.38 μg/mL/unit of enzyme, while the IC50 for COX-2 was 0.84 μg/mL/unit.
Example 7 describes a LOX inhibition assay using the flavan catechin isolated from A. catechu. The inhibition of LOX activity was assessed using a lipoxygenase screening assay in vitro. The results of this assay are set forth in FIG. 6 . The IC50 for 5-LO inhibition by catechin was determined to be 1.38 μg/mL/unit of enzyme.
Example 8 describes cell assays performed that targeted inhibition of compounds in the breakdown of arachidonic acid in the LOX pathway, namely LTB4. The results are set forth in FIG. 7 . With reference to FIG. 7 it can be seen that Lasoperin™ inhibited the generation of 80% of the newly synthesized LTB4 in HT-29 cells. Ibuprofen showed only a 20% reduction in the amount of LTB4 over the same time period.
Example 9 describes the measurement of the effect of Lasoperin™ on LPS-induced levels of TNFα, IL-1β, and IL-6 in Peripheral Blood Monocytes. The results are set forth in FIGS. 8-10 . With reference to FIG. 8 , it can be seen that the extract decreased TNFα secreted into the cell culture supernatant substantially over a wide range of concentrations from 2 to 100 μg/mL. With reference to these figures it can be seen that a concentration of 10 μg/mL of LPS showed the greatest level of TNFα and IL-1β induction following co-incubation with Lasoperin™ for one and four hours respectively. The extract decreased TNFα and IL-1β excreted in the cell culture supernatant substantially over a wide range of concentrations from 2 to 100 μg/mL (see FIGS. 8 and 9 ). Since TNFα, IL-1β, and IL-6 are elevated during inflammation and aging-related disorders, by decreasing these pro-inflammatory cytokines and transcription factors in primed inflammatory cells Lasoperin™ can have significant impact with respect to these disorders.
Example 10 describes an experiment performed to determine the differential inhibition of the cox-2 gene by Lasoperin™ versus other NSAIDS. Gene expression data was obtained for the inhibition of cox-1 and cox-2 mRNA production in a semi-quantitative RT-qPCR assay. The results are set forth in FIGS. 11-13 . With reference to FIG. 11 , it can be seen that Lasoperin™ inhibited cox-2 mRNA production without effecting cox-1 gene expression. In addition, when compared with other cox-2 inhibitor drugs, Lasoperin™ was able to decrease LPS-stimulated increases in cox-1 and cox-2 gene expression Importantly, celecoxib and ibuprofen both increased cox-2 gene expression (FIG. 12 ). Finally, with reference to FIGS. 13A and B it can be seen that treatment with Lasoperin™ resulted in a decrease in the production of both tnfα-1 and il-1 αβ.
Example 11 describes an experiment performed to determine the effect of Lasoperin™ on the LPS-induced level of cox-1, cox-2, il-1β, tnfα, il-6, nfκb and pparγ in peripheral blood monocytes (PBMC) from three subjects following exposure for four hours as described in Example 11. The results are set forth in FIG. 14 . With reference to FIG. 14 , it can be seen that the Lasoperin™ extract decreased gene expression for all mRNA species significantly.
Example 12 describes the down-regulation of promoter elements of inflammatory genes by Lasoperin™. These promoter elements are shown in FIG. 15 .
Example 13 describes a method used to determine the effectiveness of Lasoperin™ as an antioxidant as measured by the Oxygen Radical Absorption Capacity (ORAC) test. The ORAC analysis, which utilizes fluorescein as a fluorescent probe, provides a measure of the capacity of antioxidants to scavenge for peroxyl radicals, which are one of the most common reactive oxygen species found in the body. The results are set forth in Table 2 which illustrates that relative to concentrates of several well-known food-based antioxidants. Lasoperin™ has a high ORAC score. In fact, the ORAC of Lasoperin™ is comparable to the antioxidant Vitamin C and thus should effectively decrease ROS levels in the body.
Examples 14 and 15 describe two methods used to determine the amount of Free-B-Ring flavonoids and flavans in the standardized extract. The results are set forth in FIGS. 16 and 17 .
The following examples are provided for illustrative purposes only and are not intended to limit the scope of the invention.
Lasoperin™ was formulated using two standardized extracts isolated from Acacia and Scutellaria, respectively, together with one or more excipient(s). The Acacia extract used contained >60% total flavans, as catechin and epicatechin, and the Scutellaria extract contained >70% Free-B-Ring flavonoids, which was primarily baicalin. The Scutellaria extract contained other minor amounts of Free-B-Ring flavonoids as set forth in Table 1. One or more excipient(s) were added to the composition of matter. The ratio of flavans and Free-B-Ring flavonoids can be adjusted based on the indications and the specific requirements with respect to inhibition of COX-2 vs. 5-LO and potency requirements of the product. The amount of the excipient(s) can be adjusted based on the actual active content of each ingredient. A blending table for each individual batch of product must be generated based on the product specification and quality control (QC) results. Additional amounts of active ingredients in the range of 2-5% are recommended to meet the product specification.
Table 1 illustrates a blending table generated for one batch of Lasoperin™ (lot # G1702-COX-2). Briefly, Scutellaria baicalensis root extract (38.5 kg) (lot # RM052302-01) having a Free-B-Ring flavonoid content of 82.2% (baicalin); Acacia catechu bark extract (6.9 kg) (lot # RM052902-01) with a total flavan content of 80.4% and the excipient Candex (5.0 kg) were combined to provide a Lasoperin™ formulation (50.4 kg) having a blending ratio of 85:15. Table 1 provides the quantification of the active Free-B-Ring flavonoids and flavans of this specific batch of Lasoperin™ (lot # G1702-COX-2), determined using the methods described in U.S. application Ser. No. 10/427,746, filed Apr. 30, 2003, entitled “Formulation With Dual Cox-2 And 5-Lipoxygenase Inhibitory Activity,” which is incorporated herein by reference in its entirety.
TABLE 1 |
Free-B-Ring Flavonoid and Flavan content of |
a Lasoperin ™ Formulation |
Active Components | % Content | |
Flavonoids | ||
Baicalin | 62.5% | |
Minor flavonoids | ||
wogonin-7-glucuronide | 6.7% | |
oroxylin A 7-glucuronide | 2.0% | |
baicalein | 1.5% | |
wogonin | 1.1% | |
Chrysin-7-glucuronide | 0.8% | |
5-methyl-wogonin-7-glucuronide | 0.5% | |
scutellarin | 0.3% | |
norwogonin | 0.3% | |
Chrysin | <0.2% | |
oroxylin A | <0.2% | |
Total Free-B-ring Flavonoids | 75.7% | |
Flavans | ||
catechin | 9.9% | |
epicatechin | 0.4% | |
Total Flavans | 10.3% | |
Total Active Ingredients | 86% | |
With reference to Table 1, this specific batch of Lasoperin™ is comprised of 86% total active ingredients, including 75.7% Free-B-Ring flavonoids and 10.3% flavans. Two different dosage levels of final product in capsule form were produced from this batch of Lasoperin™ (50.0 kg): 125 mg per dose (60 capsules) and 250 mg per dose (60 capsules). Using the same approach, two additional batches of Lasoperin™ were prepared having a blending ratio of 50:50 and 20:80, respectively.
A Lasoperin™ formulation (80:20) was prepared as described in Example 1. (See also Example 14 of U.S. patent application Ser. No. 10/427,746, filed Apr. 30, 2003, entitled “Formulation With Dual COX-2 And 5-Lipoxygenase Inhibitory Activity,” which is incorporated herein by reference in its entirety) by combining a standardized Free-B-Ring flavonoid extract isolated from Scutellaria baicalensis roots and a standardized flavan extract isolated from Acacia catechu bark with a blending ratio of 80:20. To investigate the effect of Lasoperin™ on hippocampal-dependent cognitive function, the performance of sixty Fisher 344 male rats (ages listed below) was evaluated using a radial arm testing maze (RAWM). This test measures changes in learning and memory over the course of treatment. Baseline measurements were determined prior to starting the experimental diet and the test was performed again at 5 and 11 weeks subsequent to initiation of the experimental diet. The No Delay condition demonstrates the animal's ability to perform the task and acts as a control for differences in the ability to perform the task (e.g., locomotion, vision, motivation, etc.). The Delay condition introduces a 4 hour delay between trials 3 and 4, making the task more difficult. It is under the Delay condition that the age-related memory impairments are demonstrated.
Animals.
Male Fischer 344 rats (National Institute on Aging contract colony; Harlan Sprague Dawley, Indianapolis, Ind.) (6 mo of age, n=12 and 17 mo of age, n=48) were housed in pairs, maintained in environmentally controlled chambers on a 12 hour light/dark cycle at 21±1° C. and provided food and water ad libitum. Young and aged control animals were provided with a NIH-31 (TD 00365; Harlan Teklab, Madison, Wis.) rodent diet. The test groups received a NIH-31 rodent diet supplemented with Lasoperin™ (3, 7 or 34 mg/kg). The control diet and the experimental formulation were prepared by Harlan Teklab and provided in extruded pellet form to the animals. The rats were microchipped to ensure proper identification during all aspects of the study. Due to the large number of animals, the experiment was split into two cohorts of 30 rats, which each group containing 6 animals To obtain a baseline the animals were assessed in the RAWM prior to being placed on the experimental diet. Upon completion of the initial RAWM test, the aged rats were assigned to one of four groups (Aged Control, 3, 7, and 34 mg/kg Lasoperin™) in a counter-balanced manner, such that each group was equivocal in RAWM performance. Animal weight and food intake were monitored weekly to determine general health and the ingestion of food. No differences in these indexes were observed between groups.
Radial Arm Water Maze (RAWM).
The RAWM consisted of 12 arms (15 cm wide×43 cm long) emanating from a circular choice area (60 cm diameter) in a 1.5 m tank of water. An escape platform (10 cm×13 cm) was situated at the end of one of the arms, 2 cm below the surface of the water. Rats were pre-trained in the maze for five days. Pre-training consisted of shaping the animals to find the goal arm by initially blocking entry into the non-goal arms and gradually increasing the number of available arms until all 12 were open. The rats were then trained for two blocks of five days each. The entire training process required three weeks. The start arm for each trial was determined in a pseudo-random manner from the 11 available arms. A given arm was used only once per day so that there were four different start arms each day. To avoid place and position preferences, the start and goal arms were different for each animal within a group on a given day, but equivalent across groups. Four trials were administered per day (180 second (s) maximum) with a 30 s inter-trial interval. If a rat did not find the escape platform within 180 s, it was gently guided to the correct arm. The number of arms entered prior to entering the arm containing the escape platform (Errors) was recorded. A 3 hour delay was introduced between trials three and four for days six through ten. During the delay, the rats were placed back into their home cage. The results are set forth in FIGS. 1A-C . Data are presented as the mean for each trial versus trial number.
With reference to FIGS. 1A-C , in all sessions there was a significant decrease in Total Errors as the trials progressed, indicating that the rats could learn the task. In the No Delay task, there were no age- or drug-related differences in performance. In the Delay task, there was a significant age effect for all three delay sessions (Baseline, Session II, and Session III; see FIGS. 1A , B and C, respectively). The aged animals performed significantly worse in trial 4 than did the young controls. There was no effect due to the drug during the Baseline (FIG. 1A ) and the Session II (FIG. 1B ) Delay tests. There was, however, a significant effect due to the drug in the Session III delay test (FIG. 1C ). The 7 and 34 mg/kg groups had significantly fewer errors than did the Aged Controls. They were not significantly different from the Young Controls, suggesting that Lasoperin™ prevented the age-related memory impairment. The analyses are 2-way ANOVA with repeated measures.
Sixty Fisher 344 male rats were used in this study as described in Example 2.
Contextual fear conditioning (CFC). One week after completing the RAWM testing, the rats were placed in a box (30.5 cm×24.1 cm×21 cm, Med Associates, St. Albans, Vt.) with a grid floor (4.8 mm diameter rods, spaced 1.6 cm apart) connected to a constant current shocker (Med Associates). Prior to placing each rat in the box, the box was cleaned with 3% acetic acid, which functioned as a specific odorant for the original context. Two consecutive training blocks were administered. Each training block was 180 seconds (s) long with a 30 s, 85-dB white noise conditioned stimulus (CS) and a 2 s, 0.5 mA footshock (US). The CS and US co-terminated at the end of the training block. All rats reacted to the footshock by jumping. The rats remained in the training box for 30 s following the second training block. Retention was tested 2 days after training by first placing the animals in the same apparatus, using 3% acetic acid as an odorant, in which training was performed for 5 minutes (min), without the CS or US. Two to three hours later, the rats were placed in a the same chamber except that the grid floor was covered with a piece of black Formica and the cage was cleaned with 3% ammonium hydroxide (Novel Context) for 6 min, during which the CS was administered for the final 3 min Freezing was quantified manually every 10 s by an experimenter blind to the treatment groups of the rats. At 10 s intervals the experimenter assessed whether the rat was freezing or not. Percent freezing was calculated as: number of intervals during which the rat was assessed as freezing/by the total number of intervals×100. The results are set forth in FIG. 2 .
Freezing in the Training Context: In this analysis, there was a statistically significant decrease in freezing in the aged controls compared to the young controls (see FIG. 2 ). The 7 and 34 mg/kg doses of Lasoperin™ ameliorated this age-related impairment. There was a non-statistically significant trend for the 3 mg/kg dose to ameliorate the age-related impairment. None of the Lasoperin™-treated rats were significantly different from the young controls.
Freezing to the noise conditioned stimulus (CS) measures non-hippocampal dependent memory. With respect to this measurement, there were no statistically significant differences in freezing between any of the groups (data not shown).
Freezing to the novel context is a control measure to determine baseline freezing. To obtain this measurement, the amount of freezing that occurs during the training context and the CS are compared to the baseline freezing to determine if learning occurred. There were no statistically significant differences in freezing between any of the groups (data not shown).
Nociceptive Threshold. The apparatus consisted of a test chamber 30.5×25.4×30.5 cm (Coulbourn Instruments, Allenstown, Pa.). The top and two sides of the chamber were made of aluminum. The two other sides were made of transparent plastic. The box was dimly illuminated (xx lux). The floor consisted of stainless steel rods (5 mm dia, 1.68 cm between rods). Shock was delivered with a Precision Regulated Shocker (Model H12-16, Coulbourn Instruments). Rats were placed in a cage with a metal grid floor (grid dimensions). A mirror was placed on the opposite side of the chamber from the experimenter to facilitate observation. All rats were given a 2 min habituation period prior to the start of an experiment. Each rat was placed in the chamber for 2 min before a shock series was begun and after the grid floor had been cleaned with steel wool and water. Each shock pulse was 0.5 s in duration and the shocks were delivered at approximately 10 s intervals. Shock intensities were available from 0.05 to 4.0 mA in 20 steps arranged logarithmically. The full range was not used in determining thresholds. The ranges of intensities within which thresholds were to be found were estimated from preliminary observations. The midpoints of these ranges served as the beginning intensities in the experiments. A flinch was defined as elevation of one paw and jump as rapid movement of three or more paws, both responses required withdrawal from the floor. An adaptation of the “up-and-down” method for small samples was used for determining the order of presentation of shock intensities during each shock series.
The steps in the procedure were as follows: 1) The first series began with a shock intensity as close as possible to the flinch or jump threshold for the treatment being observed; 2) A series of trials was carried out such that the responses (flinch or jump) were followed by a decrease (0.1 log10 unit) in shock intensity and non-responses were followed by an increase (0.1 log10 unit) in shock intensity. Trials were continued in each series until a change in behavior occurred and were terminated four trials thereafter. The estimated median effective intensity (EI50) was calculated by the formula EI50=Xf+kd, where Xf=last intensity administered, k is the value in Table 1 of the Dixon reference (Dixon (1965) J. Am. Stat. Assoc. 60:47-55, and d is the log interval between shock intensities. Two series of shocks were performed to assess the flinch threshold, which were followed by two series of shocks to assess the jump threshold. This test controls for shock intensities given in the contextual fear conditioning behavioral paradigm and does not have separate results associated with it.
To assess the effect of Lasoperin™ on cognitive function a series of tests were performed over a 4 week period in cognitively intact individuals 35-65 years old. The individuals were treated with 300 mg/day of a Lasoperin™ formulation (80:20), which was prepared as described in Example 1. Measurement of cognitive performance was obtained using a series of web-based Cognitive Care tests which assess Psychomotor speed, Working Memory Speed (executive decision making, quickness & flexibility) and Immediate Memory (verbal & spatial memory processing). Before the study began, participants were required to practice the tests on two consecutive days to establish baseline performance. The data analysis compares baseline performance to performance post-treatment. The treated individuals were given weekly exams to determine if treatment with the dietary supplement resulted in a change in cognitive function. An analysis of the data compares baseline performance of treated individuals to those given a placebo over the same time period. Only subjects who completed the tests for the baseline and all dosing weeks were included in the analysis. Outliers who scored more than 2 standard deviations from the test mean, and who were not internally consistent with other test scores, were eliminated to exclude abnormal results that may be due to distractions or web/computer “glitches” that could invalidate the test session. Data was analyzed with a repeated measures analysis of variance (ANOVA) across days of testing, and comparisons between baseline and the final week of testing, with appropriate post hoc tests.
Psychomotor speed or physical reflex is a simple reaction time test that requires the subject to respond by pressing a key as quickly as possible after a figure appears on a computer screen. Overall performance for all ages on the psychomotor task was very stable and did not show any significant difference between groups for the mean, median or standard deviation measures (p>0.05). Thus, the Psychomotor speed test did not indicate any differences between treatment and control groups. There was however a generalized improvement in performance for all groups over the period of testing.
Working Memory Speed, a Complex Choice Reaction Time task, presents a word and a picture simultaneously and requires the person to determine if they are the same or different. A reversal cue is also presented randomly and requires the person to respond opposite to the correct response, so that a response to a correct pair would be no and visa versa. This task requires suppression or “inhibition of a learned response” and then a reversal (“task shifting”) of the response contingency. The speed of switching from one task or one response mode to another is often equated with mental flexibility and higher-order cognitive processing, as well as superior decision-making. The cognitive aspects of this test can assess the executive cognitive function, including processing speed, sustained attention, cognitive fluidity and ability to correctly make rapid decisions in a complex and demanding cognitive task.
Immediate Memory is similar to the classic Sternberg task in which a string of stimulus “target” items to be remembered are followed by a “probe” item. The subject must determine if the probe item was a member of the previous target list. List length can be varied to provide an estimate of the short-term memory capacity of the individual. Both letters and spatial position are examined in this task.
The results are set forth in FIG. 3 which demonstrates that Lasoperin™ can increase cognitive processing (decision making) speed without impairing choice accuracy, thus, improving the rate of responding to cognitively demanding, or complex choice situations.
To assess the effect of Lasoperin™ on cognitive function a series of tests were performed over a 4 week period in cognitively intact individuals 35-65 years old as described in Example 4. Reaction time standard deviation (RTSD) is often used as a measure of attention, and in the cognitive sciences, is typically considered to reflect processing efficiency and neural noise (Jensen). With reference to FIG. 4 it can be seen that there was significant improvement in RTSD over the 4 week testing period. That is there was a decrease in the standard deviation from baseline to week 4 for subjects administered Lasoperin™. Subjects administered the placebo also showed improvement, but not to the same degree. This suggests that the effect was due to improvement in consistency of task performance which was enhanced by treatment Lasoperin™, rather than simply learning to perform the test better. These results suggest that Lasoperin™ may increase sustained attention, improving the consistency of responding to cognitively demanding or complex choice situations.
Measurement of the IC50 of Lasoperin™ was performed using the following method. A cleavable, peroxide chromophore was included in the assay to visualize the peroxidase activity of each enzyme in the presence of arachidonic acid as a cofactor. Typically, the assays were performed in a 96-well format. Each inhibitor, taken from a 10 mg/mL stock in 100% DMSO, was tested in triplicate at room temperature using the following range of concentrations: 0, 0.1, 1, 5, 10, 20, 50, 100, and 500 μg/mL To each well, 150 μL of 100 mM Tris-HCl, pH 7.5 was added together with 10 μL of 22 μM Hematin diluted in tris buffer, 10 μL of inhibitor diluted in DMSO, and 25 units of either COX-1 or COX-2 enzyme. The components were mixed for 10 seconds on a rotating platform, after which 20 μL of 2 mM N,N,N′N′-tetramethyl-p-phenylenediamine dihydrochloride (TMPD) and 20 μL of 1.1 mM AA was added to initiate the reaction. The plate was shaken for 10 seconds and then incubated for 5 minutes before reading the absorbance at 570 nm The inhibitor concentration vs. percentage inhibition was plotted and the IC50 determined by taking the half-maximal point along the isotherm and intersecting the concentration on the x-axis. The IC50 was then normalized to the number of enzyme units in the assay. The dose response and IC50 results for Lasoperin™ are provided in FIG. 5 .
One of the most important pathways involved in the inflammatory response is produced by non-heme, iron-containing lipoxygenases (5-LO, 12-LO, and 15-LO), which catalyze the addition of molecular oxygen onto fatty acids such as arachidonic acid (AA) to produce the hydroperoxides 5-, 12- and 15-HPETE, which are then converted to leukotrienes. There were early indications that the flavan extract from A. catechu may provide some degree of 5-LO inhibition, thereby preventing the formation of 5-HPETE. A Lipoxygenase Inhibitor Screening Assay Kit (Cayman Chemical, Inc., Cat #760700) was used to assess whether the purified flavan catechin from A. catechu directly inhibited 5-LO in vitro. The 15-LO from soybeans normally used in the kit was replaced with potato 5-LO after a buffer change from phosphate to a Tris-based buffer using microfiltration was performed. This assay detects the formation of hydroperoxides through an oxygen sensing chromagen. Briefly, the assay was performed in triplicate by adding 90 μL of 0.17 units/μL potato 5-LO, 20 μL of 1.1 mM AA, 100 μL of oxygen-sensing chromagen, and 1 μL of purified flavan inhibitor to final concentrations ranging from 0 to 500 μg/mL. The results are set forth in FIG. 6 . The IC50 for 5-LO inhibition from catechin was determined to be 1.38 μg/mL/unit of enzyme.
A Lasoperin™ formulation was prepared as outlined in Example 1, using a standardized Free-B-Ring flavonoid extract from S. baicalensis roots and a standardized flavan extract from A. catechu bark with a blending ratio of 80:20 Lasoperin™. The Lasoperin™ and ibuprofen, another known 5-LO inhibitor, were added to HT-29 cells, monocyte cell lines that express COX-1, COX-2 and 5-LO, at 3 μg/mL and incubated for 48 hours at 37° C. with 5% CO2 in a humidified environment. Each treated cell line was then harvested by centrifugation and disrupted by gentle dounce homogenization in physiological lysis buffer. A competitive ELISA for LTB4 (LTB4; Neogen, Inc., Cat #406110) was used to assess the effect of Lasoperin™ on newly synthesized levels of LTB4 present in each cell line as a measure of Lasoperin's™ inhibitory effect on the 5-LO pathway. The assay was performed in duplicate by adding 160,000 to 180,000 cells per well in 6-well plates. The results are set forth in FIG. 7 . As shown in FIG. 7 , Lasoperin™ inhibited generation of 80% of the newly synthesized LTB4 in HT-29 cells. Ibuprofen only showed a 20% reduction in the amount of LTB4 over the same time period.
Peripheral blood monocytes (PBMCs) from human blood donors were isolated using a Histopaque gradient (Sigma). The cells were then cultured in RPMI 1640 supplemented with 1% bovine serum albumin for approximately 12 hours before being treated with lipopolysaccharide (LPS) at increasing concentrations to induce inflammation in the presence of various concentrations of Lasoperin™ (80:20). The results are set forth in FIGS. 8-10 .
To evaluate whether Lasoperin™ is operating on the genomic level, isolated human, peripheral blood monocytes (PBMCs) were stimulated with lipopolysaccharide (LPS), treated with Lasoperin™, celecoxib, ibuprofen or acetaminophen and the total RNA produced was then harvested and evaluated by semi-quantitative RT-qPCR. Specifically, the assay was constructed by adding 130,000 cells per well in 6-well plates. The cells were then stimulated with 10 ng/mL LPS and co-incubated with Lasoperin™ at 1, 3, 10, 30 and 100 μg/mL and celecoxib, ibuprofen and acetaminophen at 3 μg/mL for 18 hours at 37° C. with 5% CO2 in a humidified environment. Each cell-treatment condition was then harvested by centrifugation and total RNA produced was isolated using TRIzol® reagent (Invitrogen™ Life Technologies, Cat #15596-026) and the recommended TRIzol® reagent manufacturer protocol. Total RNA was reverse transcribed using Moloney Murine Leukemia Virus reverse transcriptase (M-MLV RT; Promega Corp., Cat # M1701) using random hexamers (Promega Corp., Cat#C1181). qPCR experiments were performed on an ABI Prism®7700 Sequence Detection System using pre-developed validated Assays-on-Demand products (AOD from Applied Biosystems, Inc., Cat #4331182) for 18S rRNA internal standard and gene specific assays. Gene specific expression values were standardized to their respective 18S rRNA gene expression values (internal control) and then the no-LPS no-drug treatment condition normalized to 100. Treatment conditions are relative to this null condition. Lasoperin™ decreased normalized gene expression of cox-2 by over 100-fold while cox-1 normalized gene expression showed little variation. Under the same treatment conditions, normalized TNFα gene expression was decreased 6-fold and normalized IL-1β gene expression was decreased by over 100-fold. When PBMCs were treated with 3 μg/mL Lasoperin™, celecoxib, ibuprofen or acetaminophen, only Lasoperin™ did not increase gene expression of cox-2. This work has been coupled with ELISA-based assays to evaluate changes in protein levels as well as enzyme function assays to evaluate alterations in protein function. As a result of these studies, both genomic and proteomic coupled effects following treatment with Lasoperin™ have been demonstrated. Other studies cited in the literature have used protein specific methods to infer gene expression rather than show it directly. The results are set forth in FIGS. 11-13 .
PBMCs from human blood donors (obtained from a local blood bank) were isolated using a Histopaque gradient (Sigma). The cells were then cultured in RPMI 1640 supplemented with 1% bovine serum albumin for approximately 24 hours before being treated with LPS (10 μg/mL) and increasing concentrations Lasoperin™ (80:20). Specifically, the assay was constructed by adding 130,000 cells per well in 6-well plates. The cells were then stimulated with 10 μg/mL LPS and co-incubated with Lasoperin™ at 100 μg/mL for 18 hours at 37° C. with 5% CO2 in a humidified environment. Each cell-treatment condition was then harvested by centrifugation and total RNA produced was isolated using TRIzol® reagent (Invitrogen™ Life Technologies, Cat #15596-026) and the recommended TRIzol® reagent manufacturer protocol. Total RNA was reverse transcribed using Moloney Murine Leukemia Virus reverse transcriptase (M-MLV RT; Promega Corp., Cat # M1701) using random hexamers (Promega Corp., Cat#C1181). qPCR experiments were performed on an ABI Prism®7700 Sequence Detection System using pre-developed validated Assays-on-Demand products (AOD from Applied Biosystems, Inc., Cat #4331182) for 18S rRNA internal standard and gene specific assays. Gene specific expression values were standardized to their respective cyclophylin A mRNA gene expression values (internal control) and then the no-LPS no-drug treatment condition normalized to 100. Treatment conditions are relative to this null condition. The results are set forth in FIG. 14 .
With reference to FIG. 14 it can be seen that Lasoperin™ decreased normalized gene expression of cox-2 by an average of 3-fold while cox-1 normalized gene expression showed little variation. Under the same treatment conditions, normalized tnfα gene expression was decreased by an average of 3-fold, normalized il-1β gene expression was decreased by an average of 45-fold, and normalized il-6 gene expression was decreased by an average of 37-fold. Other studies cited in the literature have used protein specific methods to infer gene expression rather than show it directly as put forth in FIG. 14 .
The promoter regions for the inflammatory genes tnfα, il-1β, il-6 and cox-2 all contain NFκB binding sites which may account for down-regulation of gene expression when cells are treated with Lasoperin™. The cox-2 promoter region also contains a PPARγ responsive element (PPRE) which interacts with the retinoid X receptor transcription protein. Lasoperin™ down-regulates pparγ gene expression which presumably decreases PPARγ protein such that it cannot interact to stimulate cox-2 gene expression. Additionally, Lasoperin™ also down-regulates nfκb gene expression. Therefore, the compound hits two transcription factors that affect cox-2 gene expression and presumably COX-2 protein production. These promoter elements are shown in FIG. 15 .
Lasoperin™ was tested for its Oxygen Radical Absorption Capacity (ORAC) relative to several well known food based antioxidants using the experimental procedures described in Cao et al. (1994) Free Radic. Biol. Med. 16:135-137 and Prior and Cao (1999) Proc. Soc. Exp. Biol. Med. 220:255-261. The ORAC analysis, which utilizes fluorescein as a fluorescent probe, provides a measure the capacity of antioxidants to scavenge for the peroxyl radical, which is one of the most common reactive oxygen species found in the body. ORAChydro reflects the water-soluble antioxidant capacity and the ORAClipo is the lipid soluble antioxidant capacity. Trolox, a water-soluble Vitamin E analog, is used as the calibration standard and the results are expressed as micromole Trolox equivalent (TE) per gram. Lasoperin™ has an ORAChydro of 5,517 μmole TE/g and an ORAClipo of 87 μmole TE/g for an ORACtotal of 5,604 μmole TE/g. The results are set forth in the Table 2, which illustrates that Lasoperin™ has an ORAC comparable to Vitamin C and thus should decrease ROS levels in the body.
TABLE 2 |
ORAC of Lasoperin ™ Relative to Common Antioxidants. |
Sample ID | ORAC (μmole TE/g) | |
Vitamin C (aqueous Sol) | 5,000 | |
Vitamin E (lipid soluble) | 1,100 | |
Lasoperin Powder | 5,517 | |
Grape Concentrate | 133 | |
Cherry Concentrate | 79 | |
|
90 | |
|
125 | |
The mixture of Free-B-Ring flavonoids and flavans (20 μL of a 1.13 mg/mL standardized extract) in 80%:20% methanol: tetrahydrofuran was loaded onto a Phenomenex Luna C-18 column (250×4.6 mm, 5 μm bead size) and eluted with a 1.0 mL/min, linear 80% A to 20% A gradient for 19 minutes (A=0.1% (v/v) phosphoric acid; B=acetonitrile) at 35° C. As can be seen in FIG. 16 , under these conditions the Free-B-Ring flavonoids (bacalein and bacalin) eluted as the major peak between 11 to 14 minutes and the flavans (catechins and epicatechins) eluted as the minor peak at approximately 3 to 5 minutes. The amount of Free-B-Ring flavonoids and flavans were determined by measuring the area under each curve and comparison with known standards.
The mixture of Free-B-Ring flavonoids and flavans (20 mL of a 3.55 mg/mL standardized extract) in 80%:20% methanol:water was loaded onto a Phenomenex Luna C-18 column (250×4.6 mm, 5 mm bead size) and eluted isocratically with 80% A (A=0.1% (v/v) phosphoric acid; B=acetonitrile) at 35° C. As can be seen in FIG. 17 , under these conditions the two flavans (catechins and epicatechins) eluted between 4.5 to 5.5 minutes and the Free-B-Ring flavonoids (bacalein and bacalin) eluted between 12 and 13.5 minutes in the washout. Quantification of the flavan peaks was performed as described in Example 14.
Claims (15)
1. A method for treating a subject having one or more neuroinflammatory conditions associated with a neurodegenerative disorder, the method comprising administering to the subject a therapeutically effective amount of a composition comprising baicalin extracted from a Scutellaria plant species and catechin, epicatechin or combinations thereof extracted from an Acacia plant species, an Uncaria plant species or combinations thereof, wherein the subject has a neurodegenerative disorder that results in the subject having one or more neuroinflammatory conditions.
2. The method of claim 1 , wherein the baicalin and the catechin, epicatechin or combinations thereof are present in the composition in a ratio ranging from about 90:10 to about 10:90, respectively.
3. The method of claim 1 , wherein the baicalin and the catechin, epicatechin or combinations thereof are present in the composition in a ratio ranging from about 90:10 to about 70:30, respectively.
4. The method of claim 1 , wherein the baicalin and the catechin, epicatechin or combinations thereof are present in the composition in a ratio ranging from about 80:20, respectively.
5. The method of claim 1 , wherein the baicalin, the catechin or the epicatechin is extracted from a plant part, wherein the plant part is a stem, stem bark, trunk, trunk bark, twig, tuber, root, root bark, young shoot, seed, rhizome, flower, leaf or combinations thereof.
6. The method of claim 1 , wherein the Acacia plant species or the Uncaria plant species is Acacia catechu, Acacia concinna, Acacia farnesiana, Acacia Senegal, Acacia speciosa, Acacia Arabica, Acacia caesia, Acacia pennata, Acacia sinuata, Acacia mearnsii, Acacia picnantha, Acacia dealbata, Acacia auriculiformis, Acacia holoserecia, Acacia mangium, Uncaria gambir, Uncaria tomentosa, Uncaria Africana, Uncaria qabir or combinations thereof.
7. The method of claim 1 , wherein the composition is administered in a dosage ranging from 0.001 to 200 mg/kg of body weight of the subject.
8. The method of claim 1 , wherein the composition comprises a pharmaceutically acceptable carrier.
9. The method of claim 1 , wherein the composition is formulated for oral, parenteral or topical administration.
10. The method of claim 1 , wherein the composition comprises an adjuvant or carrier.
11. The method of claim 1 , wherein the composition is formulated for controlled release.
12. The method of claim 1 , wherein the baicalin, the catechin or the epicatechin is extracted with an organic solvent.
13. The method of claim 1 , wherein the baicalin, the catechin or the epicatechin is extracted with an aqueous solvent.
14. The method of claim 1 , wherein the baicalin, the catechin or the epicatechin is extracted with an organic solvent and an aqueous solvent.
15. The method of claim 1 , wherein the baicalin, the catechin or the epicatechin is at least partially purified by evaporation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/218,164 US8652535B2 (en) | 2002-04-30 | 2011-08-25 | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37716802P | 2002-04-30 | 2002-04-30 | |
US10/427,746 US7514469B2 (en) | 2002-04-30 | 2003-04-30 | Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent |
US49974203P | 2003-09-02 | 2003-09-02 | |
US10/932,571 US20050096281A1 (en) | 2002-03-01 | 2004-09-01 | Formulation of a mixture of Free-B-Ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
US11/927,061 US8034387B2 (en) | 2002-04-30 | 2007-10-29 | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
US13/218,164 US8652535B2 (en) | 2002-04-30 | 2011-08-25 | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/927,061 Continuation US8034387B2 (en) | 2002-04-30 | 2007-10-29 | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
Publications (2)
Publication Number | Publication Date |
---|---|
US20120053138A1 US20120053138A1 (en) | 2012-03-01 |
US8652535B2 true US8652535B2 (en) | 2014-02-18 |
Family
ID=46329593
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/927,061 Expired - Fee Related US8034387B2 (en) | 2002-04-30 | 2007-10-29 | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
US11/962,363 Expired - Fee Related US7695743B2 (en) | 2002-04-30 | 2007-12-21 | Formulation of a mixture of Free-B-Ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
US13/218,164 Expired - Lifetime US8652535B2 (en) | 2002-04-30 | 2011-08-25 | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/927,061 Expired - Fee Related US8034387B2 (en) | 2002-04-30 | 2007-10-29 | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
US11/962,363 Expired - Fee Related US7695743B2 (en) | 2002-04-30 | 2007-12-21 | Formulation of a mixture of Free-B-Ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
Country Status (1)
Country | Link |
---|---|
US (3) | US8034387B2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9168242B2 (en) | 2002-03-22 | 2015-10-27 | Unigen, Inc. | Isolation of a dual COX-2 and 5-lipdxygenase inhibitor from Acacia |
US9370544B2 (en) | 2002-04-30 | 2016-06-21 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
US9622964B2 (en) | 2003-04-04 | 2017-04-18 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
WO2022026740A1 (en) | 2020-07-30 | 2022-02-03 | Unigen, Inc. | A standardized bioflavonoid composition for regulation of homeostasis of host defense mechanism |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7972632B2 (en) | 2003-02-28 | 2011-07-05 | Unigen Pharmaceuticals, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
US8945518B2 (en) * | 2002-04-30 | 2015-02-03 | Unigen, Inc. | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
US8034387B2 (en) | 2002-04-30 | 2011-10-11 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
WO2006099217A2 (en) * | 2005-03-10 | 2006-09-21 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
KR100761248B1 (en) | 2006-10-12 | 2007-10-04 | 주식회사 유니젠 | Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria |
CA3015127C (en) | 2015-02-27 | 2023-10-10 | Cognitive Clarity Inc. | Compositions and methods for the treatment of "plaques and tangles" in humans and animals |
JP6564134B2 (en) * | 2015-05-26 | 2019-08-21 | ニュートゥリー カンパニー リミテッド | A composition for preventing and treating muscular diseases or improving muscle function, comprising morsin, kwanonji or mulberry white skin |
KR20190134809A (en) * | 2017-06-15 | 2019-12-04 | 새미 랩스 리미티드 | Compositions and Methods for Inhibiting Beta Secretase |
US11491201B2 (en) | 2018-12-12 | 2022-11-08 | Cognitive Clarity Inc. | Compositions and methods for the treatment of “plaques and tangles” in humans and animals |
Citations (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3686872A (en) | 1970-06-30 | 1972-08-29 | Anthony James Whitworth | Soil grouting process |
US3706581A (en) | 1970-10-05 | 1972-12-19 | Borden Co | Soil grouting process and composition |
US4035510A (en) | 1976-09-15 | 1977-07-12 | Scott Eugene J Van | Treatment of acne utilizing N-methyldiethanolamine |
GB2024817A (en) | 1978-03-15 | 1980-01-16 | Wellcome Found | Flavan derivatives |
US4268517A (en) | 1979-08-30 | 1981-05-19 | Continental Pharma | Pharmaceutical composition and therapeutical method for treating degenerative affections of the articular cartilage |
US4374824A (en) | 1981-01-27 | 1983-02-22 | Krishan Dyal Mathur | Dentifrice |
US4515804A (en) | 1982-02-24 | 1985-05-07 | Zyma Sa | Crystal modifications of (+)-catechin and pharmaceutical preparations containing them |
US4627977A (en) | 1985-09-13 | 1986-12-09 | Colgate-Palmolive Company | Anticalculus oral composition |
EP0296625A2 (en) | 1987-06-26 | 1988-12-28 | Kabushiki Kaisha Vitamin Kenkyusyo | Agent for inhibiting binding of 5 alpha -dihydrotestosterone with androgen receptor as well as process for obtaining same |
US4946684A (en) | 1989-06-20 | 1990-08-07 | American Home Products Corporation | Fast dissolving dosage forms |
US4965067A (en) | 1988-08-10 | 1990-10-23 | The Proctor & Gamble Company | Oral compositions |
FR2651132A1 (en) | 1989-08-30 | 1991-03-01 | Pacific Chem Co Ltd | Agents for protecting cells against chemical species containing active oxygen and their preparation |
US5037635A (en) | 1987-01-30 | 1991-08-06 | Colate-Palmolive Company | Antibacterial antiplaque oral composition |
CN1057196A (en) | 1990-06-13 | 1991-12-25 | 成都中医学院 | A kind of preparation method of Chinese medicine fresh Succus Bambusae |
US5096701A (en) | 1990-12-18 | 1992-03-17 | The Procter & Gamble Company | Oral compositions |
US5098709A (en) | 1987-07-21 | 1992-03-24 | Kang Kwon J | Method of administrating a fused salt from natural substances, namely ginkgo, persimmon, pine, and bamboo in the treatment of inflammations |
US5156835A (en) | 1987-01-30 | 1992-10-20 | Colgate-Palmolive Company | Antibacterial antiplaque oral composition |
CN1093914A (en) | 1993-07-04 | 1994-10-26 | 钟定铨 | Ten thousand answer acute throat trouble to loose and manufacture method |
CN1096680A (en) | 1993-06-19 | 1994-12-28 | 金赞星 | The medicine of treatment cerebrovascular |
CA2126513A1 (en) | 1993-07-09 | 1995-01-10 | Koju Watanabe | Chondroprotective agents |
CN1101856A (en) | 1993-10-20 | 1995-04-26 | 宋海 | Chinese medicine spray for curing burn and scald |
FR2687572B1 (en) | 1992-02-26 | 1995-06-09 | Oreal | USE OF CERTAIN FLAVONOUIDS IN COSMETIC COMPOSITIONS, AND METHOD FOR PROTECTING THE SKIN, ITS PHANERES AND COSMETIC COMPOSITIONS. |
US5437856A (en) | 1992-12-30 | 1995-08-01 | The Procter & Gamble Company | Oral compositions |
US5443983A (en) | 1986-08-08 | 1995-08-22 | Regents Of The University Of Minnesota | Method of culturing lymphocytes and method of treatment using such lymphocytes |
US5470589A (en) | 1990-04-25 | 1995-11-28 | Traditional Chinese Medicine Research Laboratory, Inc. | Hardening agent for affected tissues of the digestive system |
JPH08104628A (en) | 1994-10-04 | 1996-04-23 | Sumitomo Pharmaceut Co Ltd | Inhibitor of matrix metalloprotease |
US5545411A (en) | 1994-12-16 | 1996-08-13 | Bristol-Myers Squibb Company | Method for lowering viscosity by use of gum acacia |
EP0742012A2 (en) | 1995-05-10 | 1996-11-13 | Kureha Chemical Industry Co., Ltd. | Pharmaceutical composition containing substance inhibiting HSP47 production |
US5585371A (en) | 1990-08-29 | 1996-12-17 | Humanetics Corporation | Treatment of immune system with Δ5-androstenes |
US5589160A (en) | 1995-05-02 | 1996-12-31 | The Procter & Gamble Company | Dentifrice compositions |
US5605929A (en) | 1992-05-27 | 1997-02-25 | Arch Development Corp. | Methods and compositions for inhibiting 5α-reductase activity |
GB2306321A (en) | 1995-10-24 | 1997-05-07 | Anne Child | The use of (+)-catechin in the treatment or prophylaxis of connective tissue disorders |
US5643598A (en) | 1988-03-09 | 1997-07-01 | Lvmh Recherche | Method of skin care utilizing liposomes containing Scutellaria extracts |
US5650432A (en) | 1995-03-24 | 1997-07-22 | Jlb, Inc. | Method of treating or preventing non-viral microbial infection |
US5651987A (en) | 1991-12-17 | 1997-07-29 | Fuisz Technologies Ltd. | Ulcer prevention and treatment composition |
WO1997036497A2 (en) | 1996-04-02 | 1997-10-09 | Mars, Incorporated | Cocoa extract compounds and methods for making and using the same |
CN1177492A (en) | 1997-10-21 | 1998-04-01 | 陈新学 | Medicine for preventing and treating eye diseases |
WO1998019651A1 (en) | 1996-11-01 | 1998-05-14 | E-L Management Corporation | Non-chemical sunscreen composition |
US5756538A (en) | 1993-08-17 | 1998-05-26 | University Of Strathclyde | Flavonoid and biflavonoid derivatives, their pharmaceutical compositions, their anxiolytic activity |
US5766614A (en) | 1997-03-20 | 1998-06-16 | Yong; Liu | Burn treatment compositions containing herbal mix |
US5773014A (en) | 1996-10-07 | 1998-06-30 | Bioetica, Inc. | Compositions and methods for inhibiting the formation of unwanted skin pigmentation |
CN1189365A (en) | 1997-01-31 | 1998-08-05 | 雷学军 | Medicine for preventing Aids virus, treponema pallidum, neisseria gonorrhoeae and trichomonad |
US5795911A (en) | 1996-11-18 | 1998-08-18 | Cancer Institute (Hospital), Chinese Academy Of Medical Sciences | Composition for treating Condyloma acuminata |
US5804168A (en) | 1997-01-29 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for protecting and treating sun damaged skin |
WO1998040086A2 (en) | 1997-03-10 | 1998-09-17 | The Riley Fletcher Foundation | Essential oil composition |
WO1998042363A1 (en) | 1997-03-21 | 1998-10-01 | Shiseido Company, Ltd. | Immunopotentiators |
WO1998049256A1 (en) | 1997-04-29 | 1998-11-05 | Lamer-Zarawska, Eliza | Natural antioxidant |
US5852057A (en) | 1996-12-12 | 1998-12-22 | Yasutoshi Muto | Anticarcinogenic drug composition |
US5858371A (en) | 1997-02-05 | 1999-01-12 | Panacea Biotech Limited | Pharmaceutical composition for the control and treatment of anorectal and colonic diseases |
US5886029A (en) | 1997-09-05 | 1999-03-23 | Dhaliwal; Kirpal S. | Method and composition for treatment of diabetes |
US5886155A (en) | 1997-06-18 | 1999-03-23 | Bioresources International Inc. | Purification of miraculin glycoprotein using tandem hydrophobic interaction chromatography |
CN1043406C (en) | 1993-12-27 | 1999-05-19 | 尚庆英 | Method for preparation of compound Qingdaisan powder |
US5908628A (en) | 1998-05-01 | 1999-06-01 | Hou; Liping | Compositions with analgesic, antipyretic and antiinflammatory properties |
US5922756A (en) | 1998-02-14 | 1999-07-13 | Chan; Marion Man-Ying | Method of inhibiting nitric oxide synthase |
CN1228968A (en) | 1998-03-17 | 1999-09-22 | 浙江农业大学 | Production method for extracting flavonoid compound extract or powder from bamboo leaf |
US5962517A (en) | 1997-01-31 | 1999-10-05 | Murad; Howard | Pharmaceutical compositions and methods for treating acne |
US5968973A (en) | 1996-11-18 | 1999-10-19 | Cancer Institute (Hospital), Chinese Academy Of Medical Sciences | Method for treating hyperplasia |
EP0956867A1 (en) | 1998-05-12 | 1999-11-17 | Franz-Peter Dr. Liebel | Use of flavonoid glycosides, tanning agents and microorganisms for the therapy and prophylaxis of diabetes mellitus |
JP2000044481A (en) | 1998-07-30 | 2000-02-15 | Sunstar Inc | Preparation for external use for skin |
US6080401A (en) | 1998-11-19 | 2000-06-27 | Reddy; Malireddy S. | Herbal and pharmaceutical drugs enhanced with probiotics |
US6083921A (en) | 1998-01-12 | 2000-07-04 | Xu; Kai Jian | Pharmaceutical compositions and method of using same |
US6093403A (en) | 1997-08-01 | 2000-07-25 | Phytocell Research, Inc. | Sugar imbalance and diabetes treating herbal formulation |
JP2000226329A (en) | 1998-12-04 | 2000-08-15 | Meiji Milk Prod Co Ltd | Mmp inhibitor |
US6113909A (en) | 1997-08-07 | 2000-09-05 | Young Hee Kim | Pharmaceutical composition containing a mixed extract of Phellodendron amurense RUPRECHT cortex and Patrinia scabiosaefolia FISCH. for treatment of hepatitis C |
CN1265895A (en) | 2000-01-24 | 2000-09-13 | 张俊锋 | Specific medicine for treating common cold |
US6126950A (en) | 1997-06-24 | 2000-10-03 | Council Of Scientific And Industrial Research | Composition useful for healing and protecting skin |
US6126940A (en) | 1994-06-30 | 2000-10-03 | Kyowa Hakko Kogyo Co., Ltd. | Hair-growing agent comprised of proanthocyanidins |
WO2000059523A1 (en) | 1999-04-08 | 2000-10-12 | Metagenics, Inc. | Composition and method for treatment of inflammation and pain in mammals |
WO2000067749A1 (en) | 1999-05-05 | 2000-11-16 | Unilever N.V. | Food product |
WO2000074662A2 (en) | 1999-06-07 | 2000-12-14 | University Of Sheffield | Arthritis treatment |
US6194469B1 (en) | 1998-12-11 | 2001-02-27 | Board Of Trustees Operating Michigan State Univeristy | Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids |
US6193977B1 (en) | 1999-03-18 | 2001-02-27 | Medvill Co., Ltd. | Pharmaceutical composition comprising an aqueous extract of a mixture of anemarrhena rhizoma and phellodedron bark for analgesic and anti-inflammation |
CN1285202A (en) | 2000-08-26 | 2001-02-28 | 田积天 | Huoqingzhengyang medicine |
US6197808B1 (en) | 1996-11-18 | 2001-03-06 | Cancer Instititute (Hospital), Chinese Academy Of Medical Sciences | Methods for treating hyperplasia |
US6217875B1 (en) | 1997-04-23 | 2001-04-17 | Oryza Oil & Fat Chemical Co., Ltd. | Inhibitors of lipoxygenase |
US6221341B1 (en) | 1997-11-19 | 2001-04-24 | Oraceutical Llc | Tooth whitening compositions |
WO2001030341A1 (en) | 1999-10-25 | 2001-05-03 | Japan As Represented By Director General Of Agency Of National Cancer Center | Cyclooxygenase-2 expression inhibitors |
US6235294B1 (en) | 1998-05-15 | 2001-05-22 | Coletica | Flavonoide esters and their use notably in cosmetics |
US6241972B1 (en) | 1999-02-19 | 2001-06-05 | Block Drug Company, Inc. | Oral care formulation for the treatment of sensitivity teeth |
US6248341B1 (en) | 2000-01-14 | 2001-06-19 | Color Access, Inc. | Method of treating topical angiogenesis-related disorders |
KR20010069130A (en) | 2000-01-12 | 2001-07-23 | 김미정 | Manufacturing Method for Extracts of Bamboo Leaves and Use Thereof |
US6264926B1 (en) | 1999-02-12 | 2001-07-24 | Council Of Scientific And Industrial Research | Formulation useful as a natural herbal tooth powder |
US6264995B1 (en) | 1999-10-19 | 2001-07-24 | Thomas Newmark | Herbal composition for reducing inflammation and methods of using same |
JP2001220353A (en) | 2000-02-07 | 2001-08-14 | Noevir Co Ltd | Phospholipase a2 inhibitor |
US6290995B1 (en) | 2000-02-08 | 2001-09-18 | Zhao Xinxian | Plant drug for preventing cancer II |
US20010026813A1 (en) | 2000-02-10 | 2001-10-04 | Kim Ho-Cheol | Extract from scutellariae radix having neuroprotective effects and pharmaceutical preparations containing the same |
EP1147764A2 (en) | 2000-04-19 | 2001-10-24 | Nof Corporation | Cosmetic composition |
US6319523B1 (en) | 2000-06-29 | 2001-11-20 | James H. Zhou | Composition and method for inhibiting oral bacteria |
US20010046963A1 (en) | 2000-02-25 | 2001-11-29 | Uwe Wenzel | Novel use of flavones |
US6333304B1 (en) | 1999-04-20 | 2001-12-25 | Teresa K. Bath | Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue |
WO2002007745A1 (en) | 2000-07-26 | 2002-01-31 | Yuuzou Tsuchida | Antipruritic compositions and compositions promoting wound healing |
WO2002009699A2 (en) | 2000-07-28 | 2002-02-07 | Immupharm Aps | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
JP2002053484A (en) | 2000-08-07 | 2002-02-19 | Asahi Breweries Ltd | Lipase inhibitor, and food and drink containing the same |
KR20020013675A (en) | 2000-08-14 | 2002-02-21 | 김윤사 | Antibiotic and cosmetic compositions containing herb medicines |
KR20020031608A (en) | 2000-10-19 | 2002-05-03 | 이응세 | Scutellariae Radix extracts showing a good anti-microbial effect, preparing methods thereof and pharmaceutical compositions containing the same |
US6387416B1 (en) | 2001-04-05 | 2002-05-14 | Thomas Newmark | Anti-Inflammatory herbal composition and method of use |
US6391346B1 (en) | 2001-04-05 | 2002-05-21 | Thomas Newmark | Anti-inflammatory, sleep-promoting herbal composition and method of use |
US6391872B1 (en) | 1997-11-04 | 2002-05-21 | Pfizer Inc | Indazole bioisostere replacement of catechol in therapeutically active compounds |
WO2002039973A2 (en) | 2000-11-20 | 2002-05-23 | Laboratoires Robert Schwartz | Product preparing and protecting the skin against uv radiation, countering cellular ageing and exerting an immunostimulant action |
WO2002042429A2 (en) | 2000-11-03 | 2002-05-30 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
WO2002047615A2 (en) | 2000-12-13 | 2002-06-20 | University Of Rochester | Oral compositions and use thereof |
US20020086070A1 (en) | 2000-03-11 | 2002-07-04 | Kuhrts Eric Hauser | Anti-inflammatory and connective tissue repair formulations |
US20020122836A1 (en) | 2000-12-15 | 2002-09-05 | Pharmacia Corporation | Selective COX-2 inhibition from non-edible plant extracts |
US20020136784A1 (en) | 2000-12-15 | 2002-09-26 | Pharmacia Corporation | Selective COX-2 inhibition from plant extracts |
US20020146467A1 (en) | 2001-02-08 | 2002-10-10 | Jung Kyu Yong | Herbal composition for the prevention and treatment of dementia |
US6475530B1 (en) | 2000-05-31 | 2002-11-05 | Eric H. Kuhrts | Methods and compositions for producing weight loss |
JP2003002820A (en) | 2001-06-22 | 2003-01-08 | Naris Cosmetics Co Ltd | Skin care composition |
WO2003002134A1 (en) | 2001-06-27 | 2003-01-09 | Unigen Pharmaceuticals, Inc. | Method for generating, screening and dereplicating natural product libraries for the discovery of therapeutic agents |
WO2003009825A2 (en) | 2001-07-07 | 2003-02-06 | Beiersdorf Ag | Cosmetic and dermatological preparations containing catechins or green tea extracts |
WO2003015766A1 (en) | 2001-08-14 | 2003-02-27 | Beiersdorf Ag | Use of wogonin for the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions and/or for skin protection of determinate sensitive and dry skin |
US20030045562A1 (en) | 2001-08-30 | 2003-03-06 | El-Naggar Mawaheb M. | Treatment of inflammatory, cancer, and thrombosis disorders |
KR20030021640A (en) | 2001-09-07 | 2003-03-15 | 학교법인고려중앙학원 | Extracts of Phyllostachys edulis leaf having antioxidant activity and the process for preparation thereof |
JP2003081746A (en) | 2001-09-12 | 2003-03-19 | Pola Chem Ind Inc | Extension inhibitor of dendrite of melanocyte and cosmetic containing the same |
WO2003024470A1 (en) | 2001-09-17 | 2003-03-27 | Philip Wolfson | Standardized extracts of scutellaria lateriflora |
US6555573B2 (en) | 2000-12-21 | 2003-04-29 | The Quigley Corporation | Method and composition for the topical treatment of diabetic neuropathy |
US20030105030A1 (en) | 1997-10-31 | 2003-06-05 | Shutsung Liao | Method and compositions for regulation of 5-alpha reductase activity |
US6576660B1 (en) | 1997-10-31 | 2003-06-10 | Arch Development Corporation | Methods and compositions for regulation of 5-α-reductase activity |
US20030125264A1 (en) | 2001-12-29 | 2003-07-03 | Kimberly-Clark Worldwide, Inc. | Methods For Treating Wounds |
JP2003212771A (en) | 2002-01-23 | 2003-07-30 | Taiyo Kagaku Co Ltd | Anti-neissria bacterium composition |
JP2003212786A (en) | 2002-01-16 | 2003-07-30 | Univ Nihon | Skin care medicament with bamboo extract component as active ingredient |
US20030166583A1 (en) | 2002-02-22 | 2003-09-04 | Oliver Yoa-Pu Hu | Dermal cytochrome P450 1A inhibitors and enhancers |
US20030180402A1 (en) | 2002-03-22 | 2003-09-25 | Unigen Pharmaceuticals, Inc. | Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from Acacia |
US20030203857A1 (en) | 2000-04-11 | 2003-10-30 | Hiromu Ohnogi | Remedies |
CA2484192A1 (en) | 2002-04-30 | 2003-11-13 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
US6685971B2 (en) | 2001-06-28 | 2004-02-03 | Rongxiang Xu | Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract |
US20040028639A1 (en) | 1999-02-08 | 2004-02-12 | Maes Daniel H. | Cholesterol sulfate compositions for enhancement of stratum corneum function |
US20040057908A1 (en) | 2001-12-13 | 2004-03-25 | Bowen William H. | Oral compositions and use thereof |
WO2004058279A1 (en) | 2002-12-27 | 2004-07-15 | Zhang, Xiaoli | Composition comprising scutellaria baicalensis and their uses thereof |
JP2004244385A (en) | 2003-02-14 | 2004-09-02 | Pigeon Corp | Mouth wash for infant having anticarious activity |
US20040185124A1 (en) | 2002-10-24 | 2004-09-23 | Hiromichi Hayashi | Health food and antitumor agent |
WO2004089392A1 (en) | 2003-04-04 | 2004-10-21 | Unigen Pharmaceuticals, Inc. | Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care |
US20050049206A1 (en) | 2003-09-01 | 2005-03-03 | Gong Bang Qiang | Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases |
WO2005020932A2 (en) | 2003-09-02 | 2005-03-10 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of free-b-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
KR100522579B1 (en) | 2004-04-30 | 2005-10-19 | (주) 한약마을 | Pharmaceutical composition comprising the extracts of scutellaria root and schizandra fruit mixture thereof having an effect of restraint stress |
CN1686187A (en) | 2005-03-23 | 2005-10-26 | 贵阳高新瑞得科技开发有限公司 | Infantile lung clearing phlegm transforming effervescent granules and its making method |
US20060008749A1 (en) | 2004-07-08 | 2006-01-12 | Frank Sobel | Method for manufacturing of a mask blank for EUV photolithography and mask blank |
US20060079467A1 (en) | 2002-04-30 | 2006-04-13 | Unigen Pharmaceuticals, Inc. | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
US20060140881A1 (en) | 2004-12-22 | 2006-06-29 | Guofeng Xu | Oral care compositions containing flavonoids and flavans |
US20060141073A1 (en) | 2004-12-23 | 2006-06-29 | Colgate-Palmolive Company | Oral care composition containing extract of unoxidized Camellia |
US20060204596A1 (en) | 2005-03-10 | 2006-09-14 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of Free-B-Ring flavonoids and flavans as a therapeutic agent |
US7192611B2 (en) | 2002-03-01 | 2007-03-20 | Unigen Pharmaceuticals, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
US20070065524A1 (en) | 2003-11-07 | 2007-03-22 | Oaky Natural Co., Ltd. | Pharmaceutical composition containing guaiacol derivatives and syringol derivatives extracted from natural plant vinegar |
US20070135359A1 (en) | 2003-02-28 | 2007-06-14 | Unigen Pharmaceuticals, Inc. | Identification of Free-B-Ring Flavonoids as Potent COX-2 Inhibitors |
US20070264361A1 (en) | 2004-09-01 | 2007-11-15 | Unigen, Inc. | Composition for Suppressing Cyclooxygenase and/or 5-Lypoxygenase |
US20080096827A1 (en) | 2002-04-30 | 2008-04-24 | Unigen Pharmaceuticals, Inc. | Formulation Of A Mixture Of Free-B-Ring Flavonoids And Flavans For Use In The Prevention And Treatment Of Cognitive Decline And Age-Related Memory Impairments |
US20080107759A1 (en) | 2003-03-27 | 2008-05-08 | Unigen, Inc. | Composition Comprising Bamboo Extract and the Compounds Isolated Therefrom Showing Treating and Preventing Activity for Inflammatory and Blood Circulation Disease |
US20080176811A1 (en) | 2000-04-18 | 2008-07-24 | Bernadette Geers | Novel flavone glycoside derivatives for use in cosmetics, pharmaceuticals and nutrition |
US20080214658A1 (en) | 2005-03-18 | 2008-09-04 | Unigen, Inc. | Composition Comprising Isoorientin for Suppressing Histamine |
US20080279969A1 (en) | 2004-06-11 | 2008-11-13 | Unigen Inc. | Composition Comprising Bamboo Extract for Androgen Agonist |
US7531521B2 (en) | 2003-02-26 | 2009-05-12 | Unigen Pharmaceuticals, Inc. | Formulation for use in the prevention and treatment of carbohydrate induced diseases and conditions |
US7615239B2 (en) | 2002-04-15 | 2009-11-10 | Tetsuo Santo | Tea for treating dermatitis comprising herbal extracts |
US8247007B2 (en) | 2006-10-12 | 2012-08-21 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of bamboo and Scutellaria |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3121146A1 (en) * | 1981-05-27 | 1983-01-05 | Siemens AG, 1000 Berlin und 8000 München | DIGITAL RADIO SYSTEM |
JPS61238719A (en) * | 1985-04-17 | 1986-10-24 | Shiseido Co Ltd | Hair cosmetic |
JPH03240725A (en) | 1990-02-15 | 1991-10-28 | Senjiyu Seiyaku Kk | Maillard reaction inhibitor |
JPH0710768A (en) | 1993-05-24 | 1995-01-13 | Suntory Ltd | Hyaluronidase inhibitor containing extract of plant belonging to family leguminosae as active ingredient |
JP3529811B2 (en) * | 1993-06-30 | 2004-05-24 | 三省製薬株式会社 | External preparation for skin |
JPH07223941A (en) | 1994-02-14 | 1995-08-22 | Nippon Ham Kk | Anticomplementary substance |
JPH09227374A (en) | 1996-02-28 | 1997-09-02 | Taiyo Kagaku Co Ltd | Composition for inhibiting production of stress protein |
FR2781693B1 (en) * | 1998-07-31 | 2000-09-08 | Inst Francais Du Petrole | PROCESS AND PLANT FOR THE TREATMENT OF A NATURAL GAS WITH HIGH CO2 AND N2 CONTENTS WITH RECYCLING |
US6162950A (en) * | 1999-12-03 | 2000-12-19 | Albemarle Corporation | Preparation of alkali metal tetrakis(F aryl)borates |
-
2007
- 2007-10-29 US US11/927,061 patent/US8034387B2/en not_active Expired - Fee Related
- 2007-12-21 US US11/962,363 patent/US7695743B2/en not_active Expired - Fee Related
-
2011
- 2011-08-25 US US13/218,164 patent/US8652535B2/en not_active Expired - Lifetime
Patent Citations (182)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3686872A (en) | 1970-06-30 | 1972-08-29 | Anthony James Whitworth | Soil grouting process |
US3706581A (en) | 1970-10-05 | 1972-12-19 | Borden Co | Soil grouting process and composition |
US4035510A (en) | 1976-09-15 | 1977-07-12 | Scott Eugene J Van | Treatment of acne utilizing N-methyldiethanolamine |
GB2024817A (en) | 1978-03-15 | 1980-01-16 | Wellcome Found | Flavan derivatives |
US4268517A (en) | 1979-08-30 | 1981-05-19 | Continental Pharma | Pharmaceutical composition and therapeutical method for treating degenerative affections of the articular cartilage |
US4374824A (en) | 1981-01-27 | 1983-02-22 | Krishan Dyal Mathur | Dentifrice |
US4515804A (en) | 1982-02-24 | 1985-05-07 | Zyma Sa | Crystal modifications of (+)-catechin and pharmaceutical preparations containing them |
US4627977A (en) | 1985-09-13 | 1986-12-09 | Colgate-Palmolive Company | Anticalculus oral composition |
US5443983A (en) | 1986-08-08 | 1995-08-22 | Regents Of The University Of Minnesota | Method of culturing lymphocytes and method of treatment using such lymphocytes |
US5037635A (en) | 1987-01-30 | 1991-08-06 | Colate-Palmolive Company | Antibacterial antiplaque oral composition |
US5156835A (en) | 1987-01-30 | 1992-10-20 | Colgate-Palmolive Company | Antibacterial antiplaque oral composition |
EP0296625A2 (en) | 1987-06-26 | 1988-12-28 | Kabushiki Kaisha Vitamin Kenkyusyo | Agent for inhibiting binding of 5 alpha -dihydrotestosterone with androgen receptor as well as process for obtaining same |
US5098709A (en) | 1987-07-21 | 1992-03-24 | Kang Kwon J | Method of administrating a fused salt from natural substances, namely ginkgo, persimmon, pine, and bamboo in the treatment of inflammations |
US5643598A (en) | 1988-03-09 | 1997-07-01 | Lvmh Recherche | Method of skin care utilizing liposomes containing Scutellaria extracts |
US4965067A (en) | 1988-08-10 | 1990-10-23 | The Proctor & Gamble Company | Oral compositions |
US4946684A (en) | 1989-06-20 | 1990-08-07 | American Home Products Corporation | Fast dissolving dosage forms |
FR2651132A1 (en) | 1989-08-30 | 1991-03-01 | Pacific Chem Co Ltd | Agents for protecting cells against chemical species containing active oxygen and their preparation |
US5470589A (en) | 1990-04-25 | 1995-11-28 | Traditional Chinese Medicine Research Laboratory, Inc. | Hardening agent for affected tissues of the digestive system |
CN1057196A (en) | 1990-06-13 | 1991-12-25 | 成都中医学院 | A kind of preparation method of Chinese medicine fresh Succus Bambusae |
US5585371A (en) | 1990-08-29 | 1996-12-17 | Humanetics Corporation | Treatment of immune system with Δ5-androstenes |
US5096701A (en) | 1990-12-18 | 1992-03-17 | The Procter & Gamble Company | Oral compositions |
US5651987A (en) | 1991-12-17 | 1997-07-29 | Fuisz Technologies Ltd. | Ulcer prevention and treatment composition |
FR2687572B1 (en) | 1992-02-26 | 1995-06-09 | Oreal | USE OF CERTAIN FLAVONOUIDS IN COSMETIC COMPOSITIONS, AND METHOD FOR PROTECTING THE SKIN, ITS PHANERES AND COSMETIC COMPOSITIONS. |
US5605929A (en) | 1992-05-27 | 1997-02-25 | Arch Development Corp. | Methods and compositions for inhibiting 5α-reductase activity |
US5437856A (en) | 1992-12-30 | 1995-08-01 | The Procter & Gamble Company | Oral compositions |
CN1096680A (en) | 1993-06-19 | 1994-12-28 | 金赞星 | The medicine of treatment cerebrovascular |
CN1093914A (en) | 1993-07-04 | 1994-10-26 | 钟定铨 | Ten thousand answer acute throat trouble to loose and manufacture method |
CA2126513A1 (en) | 1993-07-09 | 1995-01-10 | Koju Watanabe | Chondroprotective agents |
US5650433A (en) | 1993-07-09 | 1997-07-22 | Kureha Chemical Industry Co., Ltd. | Chondroprotective agents |
EP0633022B1 (en) | 1993-07-09 | 1997-02-19 | Kureha Chemical Industry Co., Ltd. | Chondroprotective flavones |
US5756538A (en) | 1993-08-17 | 1998-05-26 | University Of Strathclyde | Flavonoid and biflavonoid derivatives, their pharmaceutical compositions, their anxiolytic activity |
CN1101856A (en) | 1993-10-20 | 1995-04-26 | 宋海 | Chinese medicine spray for curing burn and scald |
CN1043406C (en) | 1993-12-27 | 1999-05-19 | 尚庆英 | Method for preparation of compound Qingdaisan powder |
US6126940A (en) | 1994-06-30 | 2000-10-03 | Kyowa Hakko Kogyo Co., Ltd. | Hair-growing agent comprised of proanthocyanidins |
JPH08104628A (en) | 1994-10-04 | 1996-04-23 | Sumitomo Pharmaceut Co Ltd | Inhibitor of matrix metalloprotease |
US5545411A (en) | 1994-12-16 | 1996-08-13 | Bristol-Myers Squibb Company | Method for lowering viscosity by use of gum acacia |
US5650432A (en) | 1995-03-24 | 1997-07-22 | Jlb, Inc. | Method of treating or preventing non-viral microbial infection |
US5589160A (en) | 1995-05-02 | 1996-12-31 | The Procter & Gamble Company | Dentifrice compositions |
EP0742012A2 (en) | 1995-05-10 | 1996-11-13 | Kureha Chemical Industry Co., Ltd. | Pharmaceutical composition containing substance inhibiting HSP47 production |
GB2306321A (en) | 1995-10-24 | 1997-05-07 | Anne Child | The use of (+)-catechin in the treatment or prophylaxis of connective tissue disorders |
WO1997036497A2 (en) | 1996-04-02 | 1997-10-09 | Mars, Incorporated | Cocoa extract compounds and methods for making and using the same |
JP2000506901A (en) | 1996-04-02 | 2000-06-06 | マーズ・インコーポレイテツド | Cocoa extract compounds and methods for making and using same |
US5773014A (en) | 1996-10-07 | 1998-06-30 | Bioetica, Inc. | Compositions and methods for inhibiting the formation of unwanted skin pigmentation |
WO1998019651A1 (en) | 1996-11-01 | 1998-05-14 | E-L Management Corporation | Non-chemical sunscreen composition |
US5795911A (en) | 1996-11-18 | 1998-08-18 | Cancer Institute (Hospital), Chinese Academy Of Medical Sciences | Composition for treating Condyloma acuminata |
US6197808B1 (en) | 1996-11-18 | 2001-03-06 | Cancer Instititute (Hospital), Chinese Academy Of Medical Sciences | Methods for treating hyperplasia |
US5968973A (en) | 1996-11-18 | 1999-10-19 | Cancer Institute (Hospital), Chinese Academy Of Medical Sciences | Method for treating hyperplasia |
US5852057A (en) | 1996-12-12 | 1998-12-22 | Yasutoshi Muto | Anticarcinogenic drug composition |
US5804168A (en) | 1997-01-29 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for protecting and treating sun damaged skin |
CN1189365A (en) | 1997-01-31 | 1998-08-05 | 雷学军 | Medicine for preventing Aids virus, treponema pallidum, neisseria gonorrhoeae and trichomonad |
US5962517A (en) | 1997-01-31 | 1999-10-05 | Murad; Howard | Pharmaceutical compositions and methods for treating acne |
US5858371A (en) | 1997-02-05 | 1999-01-12 | Panacea Biotech Limited | Pharmaceutical composition for the control and treatment of anorectal and colonic diseases |
WO1998040086A2 (en) | 1997-03-10 | 1998-09-17 | The Riley Fletcher Foundation | Essential oil composition |
US6280751B1 (en) | 1997-03-10 | 2001-08-28 | Jane Clarissa Fletcher | Essential oil composition |
US5766614A (en) | 1997-03-20 | 1998-06-16 | Yong; Liu | Burn treatment compositions containing herbal mix |
WO1998042363A1 (en) | 1997-03-21 | 1998-10-01 | Shiseido Company, Ltd. | Immunopotentiators |
US6217875B1 (en) | 1997-04-23 | 2001-04-17 | Oryza Oil & Fat Chemical Co., Ltd. | Inhibitors of lipoxygenase |
WO1998049256A1 (en) | 1997-04-29 | 1998-11-05 | Lamer-Zarawska, Eliza | Natural antioxidant |
US5886155A (en) | 1997-06-18 | 1999-03-23 | Bioresources International Inc. | Purification of miraculin glycoprotein using tandem hydrophobic interaction chromatography |
US6126950A (en) | 1997-06-24 | 2000-10-03 | Council Of Scientific And Industrial Research | Composition useful for healing and protecting skin |
US6093403A (en) | 1997-08-01 | 2000-07-25 | Phytocell Research, Inc. | Sugar imbalance and diabetes treating herbal formulation |
US6113909A (en) | 1997-08-07 | 2000-09-05 | Young Hee Kim | Pharmaceutical composition containing a mixed extract of Phellodendron amurense RUPRECHT cortex and Patrinia scabiosaefolia FISCH. for treatment of hepatitis C |
US5886029A (en) | 1997-09-05 | 1999-03-23 | Dhaliwal; Kirpal S. | Method and composition for treatment of diabetes |
CN1177492A (en) | 1997-10-21 | 1998-04-01 | 陈新学 | Medicine for preventing and treating eye diseases |
US6576660B1 (en) | 1997-10-31 | 2003-06-10 | Arch Development Corporation | Methods and compositions for regulation of 5-α-reductase activity |
US20030105030A1 (en) | 1997-10-31 | 2003-06-05 | Shutsung Liao | Method and compositions for regulation of 5-alpha reductase activity |
US6391872B1 (en) | 1997-11-04 | 2002-05-21 | Pfizer Inc | Indazole bioisostere replacement of catechol in therapeutically active compounds |
US7189385B2 (en) | 1997-11-19 | 2007-03-13 | Discus Dental Impressions, Inc. | Tooth whitening compositions |
US6221341B1 (en) | 1997-11-19 | 2001-04-24 | Oraceutical Llc | Tooth whitening compositions |
US6083921A (en) | 1998-01-12 | 2000-07-04 | Xu; Kai Jian | Pharmaceutical compositions and method of using same |
US5922756A (en) | 1998-02-14 | 1999-07-13 | Chan; Marion Man-Ying | Method of inhibiting nitric oxide synthase |
CN1228968A (en) | 1998-03-17 | 1999-09-22 | 浙江农业大学 | Production method for extracting flavonoid compound extract or powder from bamboo leaf |
US5908628A (en) | 1998-05-01 | 1999-06-01 | Hou; Liping | Compositions with analgesic, antipyretic and antiinflammatory properties |
EP0956867A1 (en) | 1998-05-12 | 1999-11-17 | Franz-Peter Dr. Liebel | Use of flavonoid glycosides, tanning agents and microorganisms for the therapy and prophylaxis of diabetes mellitus |
US6235294B1 (en) | 1998-05-15 | 2001-05-22 | Coletica | Flavonoide esters and their use notably in cosmetics |
JP2000044481A (en) | 1998-07-30 | 2000-02-15 | Sunstar Inc | Preparation for external use for skin |
US6080401A (en) | 1998-11-19 | 2000-06-27 | Reddy; Malireddy S. | Herbal and pharmaceutical drugs enhanced with probiotics |
JP2000226329A (en) | 1998-12-04 | 2000-08-15 | Meiji Milk Prod Co Ltd | Mmp inhibitor |
US6194469B1 (en) | 1998-12-11 | 2001-02-27 | Board Of Trustees Operating Michigan State Univeristy | Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids |
US20010002407A1 (en) | 1998-12-11 | 2001-05-31 | Board Of Trustees Operating Michigan State University | Method for inhibiting cyclooxygenase and inflammation using cyanidin |
US20040028639A1 (en) | 1999-02-08 | 2004-02-12 | Maes Daniel H. | Cholesterol sulfate compositions for enhancement of stratum corneum function |
US6264926B1 (en) | 1999-02-12 | 2001-07-24 | Council Of Scientific And Industrial Research | Formulation useful as a natural herbal tooth powder |
US6241972B1 (en) | 1999-02-19 | 2001-06-05 | Block Drug Company, Inc. | Oral care formulation for the treatment of sensitivity teeth |
US6193977B1 (en) | 1999-03-18 | 2001-02-27 | Medvill Co., Ltd. | Pharmaceutical composition comprising an aqueous extract of a mixture of anemarrhena rhizoma and phellodedron bark for analgesic and anti-inflammation |
WO2000059523A1 (en) | 1999-04-08 | 2000-10-12 | Metagenics, Inc. | Composition and method for treatment of inflammation and pain in mammals |
US6333304B1 (en) | 1999-04-20 | 2001-12-25 | Teresa K. Bath | Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue |
WO2000067749A1 (en) | 1999-05-05 | 2000-11-16 | Unilever N.V. | Food product |
WO2000074662A2 (en) | 1999-06-07 | 2000-12-14 | University Of Sheffield | Arthritis treatment |
US6264995B1 (en) | 1999-10-19 | 2001-07-24 | Thomas Newmark | Herbal composition for reducing inflammation and methods of using same |
WO2001030341A1 (en) | 1999-10-25 | 2001-05-03 | Japan As Represented By Director General Of Agency Of National Cancer Center | Cyclooxygenase-2 expression inhibitors |
KR20010069130A (en) | 2000-01-12 | 2001-07-23 | 김미정 | Manufacturing Method for Extracts of Bamboo Leaves and Use Thereof |
US6248341B1 (en) | 2000-01-14 | 2001-06-19 | Color Access, Inc. | Method of treating topical angiogenesis-related disorders |
CN1265895A (en) | 2000-01-24 | 2000-09-13 | 张俊锋 | Specific medicine for treating common cold |
JP2001220353A (en) | 2000-02-07 | 2001-08-14 | Noevir Co Ltd | Phospholipase a2 inhibitor |
US6290995B1 (en) | 2000-02-08 | 2001-09-18 | Zhao Xinxian | Plant drug for preventing cancer II |
US20010026813A1 (en) | 2000-02-10 | 2001-10-04 | Kim Ho-Cheol | Extract from scutellariae radix having neuroprotective effects and pharmaceutical preparations containing the same |
US20010046963A1 (en) | 2000-02-25 | 2001-11-29 | Uwe Wenzel | Novel use of flavones |
US20020086070A1 (en) | 2000-03-11 | 2002-07-04 | Kuhrts Eric Hauser | Anti-inflammatory and connective tissue repair formulations |
US20030203857A1 (en) | 2000-04-11 | 2003-10-30 | Hiromu Ohnogi | Remedies |
US20080176811A1 (en) | 2000-04-18 | 2008-07-24 | Bernadette Geers | Novel flavone glycoside derivatives for use in cosmetics, pharmaceuticals and nutrition |
EP1147764A2 (en) | 2000-04-19 | 2001-10-24 | Nof Corporation | Cosmetic composition |
US6475530B1 (en) | 2000-05-31 | 2002-11-05 | Eric H. Kuhrts | Methods and compositions for producing weight loss |
US6319523B1 (en) | 2000-06-29 | 2001-11-20 | James H. Zhou | Composition and method for inhibiting oral bacteria |
WO2002007745A1 (en) | 2000-07-26 | 2002-01-31 | Yuuzou Tsuchida | Antipruritic compositions and compositions promoting wound healing |
WO2002009699A2 (en) | 2000-07-28 | 2002-02-07 | Immupharm Aps | Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
JP2002053484A (en) | 2000-08-07 | 2002-02-19 | Asahi Breweries Ltd | Lipase inhibitor, and food and drink containing the same |
KR20020013675A (en) | 2000-08-14 | 2002-02-21 | 김윤사 | Antibiotic and cosmetic compositions containing herb medicines |
CN1285202A (en) | 2000-08-26 | 2001-02-28 | 田积天 | Huoqingzhengyang medicine |
KR20020031608A (en) | 2000-10-19 | 2002-05-03 | 이응세 | Scutellariae Radix extracts showing a good anti-microbial effect, preparing methods thereof and pharmaceutical compositions containing the same |
WO2002042429A2 (en) | 2000-11-03 | 2002-05-30 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
WO2002039973A2 (en) | 2000-11-20 | 2002-05-23 | Laboratoires Robert Schwartz | Product preparing and protecting the skin against uv radiation, countering cellular ageing and exerting an immunostimulant action |
WO2002047615A2 (en) | 2000-12-13 | 2002-06-20 | University Of Rochester | Oral compositions and use thereof |
US20020122836A1 (en) | 2000-12-15 | 2002-09-05 | Pharmacia Corporation | Selective COX-2 inhibition from non-edible plant extracts |
US20020136784A1 (en) | 2000-12-15 | 2002-09-26 | Pharmacia Corporation | Selective COX-2 inhibition from plant extracts |
US6555573B2 (en) | 2000-12-21 | 2003-04-29 | The Quigley Corporation | Method and composition for the topical treatment of diabetic neuropathy |
US20020146467A1 (en) | 2001-02-08 | 2002-10-10 | Jung Kyu Yong | Herbal composition for the prevention and treatment of dementia |
US6387416B1 (en) | 2001-04-05 | 2002-05-14 | Thomas Newmark | Anti-Inflammatory herbal composition and method of use |
US6391346B1 (en) | 2001-04-05 | 2002-05-21 | Thomas Newmark | Anti-inflammatory, sleep-promoting herbal composition and method of use |
JP2003002820A (en) | 2001-06-22 | 2003-01-08 | Naris Cosmetics Co Ltd | Skin care composition |
CA2451844A1 (en) | 2001-06-27 | 2003-01-09 | Unigen Pharmaceuticals, Inc. | Method for generating, screening and dereplicating natural product libraries for the discovery of therapeutic agents |
WO2003002134A1 (en) | 2001-06-27 | 2003-01-09 | Unigen Pharmaceuticals, Inc. | Method for generating, screening and dereplicating natural product libraries for the discovery of therapeutic agents |
US20030113797A1 (en) | 2001-06-27 | 2003-06-19 | Unigen Pharmaceuticals, Inc. | Method for generating, screening and dereplicating natural product libraries for the discovery of therapeutic agents |
US6685971B2 (en) | 2001-06-28 | 2004-02-03 | Rongxiang Xu | Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract |
US7074438B2 (en) | 2001-06-28 | 2006-07-11 | Rongxiang Xu | Compositions for oral delivery of nutrients and pharmaceuticals |
WO2003009825A2 (en) | 2001-07-07 | 2003-02-06 | Beiersdorf Ag | Cosmetic and dermatological preparations containing catechins or green tea extracts |
WO2003015766A1 (en) | 2001-08-14 | 2003-02-27 | Beiersdorf Ag | Use of wogonin for the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions and/or for skin protection of determinate sensitive and dry skin |
US20030045562A1 (en) | 2001-08-30 | 2003-03-06 | El-Naggar Mawaheb M. | Treatment of inflammatory, cancer, and thrombosis disorders |
US8148416B2 (en) | 2001-08-30 | 2012-04-03 | El-Naggar Mawaheb M | Treatment of inflammatory, cancer, and thrombosis disorders |
KR20030021640A (en) | 2001-09-07 | 2003-03-15 | 학교법인고려중앙학원 | Extracts of Phyllostachys edulis leaf having antioxidant activity and the process for preparation thereof |
JP2003081746A (en) | 2001-09-12 | 2003-03-19 | Pola Chem Ind Inc | Extension inhibitor of dendrite of melanocyte and cosmetic containing the same |
US7045158B2 (en) | 2001-09-17 | 2006-05-16 | Wolfson Philip E | Standardized extracts of Scutellaria lateriflora |
WO2003024470A1 (en) | 2001-09-17 | 2003-03-27 | Philip Wolfson | Standardized extracts of scutellaria lateriflora |
US20040057908A1 (en) | 2001-12-13 | 2004-03-25 | Bowen William H. | Oral compositions and use thereof |
US20030125264A1 (en) | 2001-12-29 | 2003-07-03 | Kimberly-Clark Worldwide, Inc. | Methods For Treating Wounds |
JP2003212786A (en) | 2002-01-16 | 2003-07-30 | Univ Nihon | Skin care medicament with bamboo extract component as active ingredient |
JP2003212771A (en) | 2002-01-23 | 2003-07-30 | Taiyo Kagaku Co Ltd | Anti-neissria bacterium composition |
US20030166583A1 (en) | 2002-02-22 | 2003-09-04 | Oliver Yoa-Pu Hu | Dermal cytochrome P450 1A inhibitors and enhancers |
US7192611B2 (en) | 2002-03-01 | 2007-03-20 | Unigen Pharmaceuticals, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
US20050096281A1 (en) | 2002-03-01 | 2005-05-05 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of Free-B-Ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
US20130012463A1 (en) | 2002-03-01 | 2013-01-10 | Unigen, Inc. | Identification of free-b-ring flavonoids as potent cox-2 inhibitors |
US20110245333A1 (en) | 2002-03-01 | 2011-10-06 | Unigen, Inc. | Identification of free-b-ring flavonoids as potent cox-2 inhibitors |
US20030180402A1 (en) | 2002-03-22 | 2003-09-25 | Unigen Pharmaceuticals, Inc. | Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from Acacia |
US20060269627A1 (en) | 2002-03-22 | 2006-11-30 | Unigen Pharmaceuticals, Inc. | Isolation of a Dual Cox-2 and 5-Lipoxygenase Inhibitor from Acacia |
US20120329863A1 (en) | 2002-03-22 | 2012-12-27 | Unigen, Inc. | Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia |
US7108868B2 (en) | 2002-03-22 | 2006-09-19 | Unigen Pharmaceuticals, Inc. | Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia |
WO2003082312A1 (en) | 2002-03-22 | 2003-10-09 | Unigen Pharmaceuticals, Inc. | Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia |
US8124134B2 (en) | 2002-03-22 | 2012-02-28 | Unigen, Inc. | Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from Acacia |
US7615239B2 (en) | 2002-04-15 | 2009-11-10 | Tetsuo Santo | Tea for treating dermatitis comprising herbal extracts |
US7695743B2 (en) | 2002-04-30 | 2010-04-13 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of Free-B-Ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
US20080096827A1 (en) | 2002-04-30 | 2008-04-24 | Unigen Pharmaceuticals, Inc. | Formulation Of A Mixture Of Free-B-Ring Flavonoids And Flavans For Use In The Prevention And Treatment Of Cognitive Decline And Age-Related Memory Impairments |
US20060177528A1 (en) | 2002-04-30 | 2006-08-10 | Unigen Pharmaceuticals, Inc. | Formulation Of A Mixture Of Free-B-Ring Flavonoids And Flavans As A Therapeutic Agent |
US7674830B2 (en) | 2002-04-30 | 2010-03-09 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
US20060079467A1 (en) | 2002-04-30 | 2006-04-13 | Unigen Pharmaceuticals, Inc. | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
US8034387B2 (en) | 2002-04-30 | 2011-10-11 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
US7514469B2 (en) | 2002-04-30 | 2009-04-07 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent |
CA2484192A1 (en) | 2002-04-30 | 2003-11-13 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
US20040185124A1 (en) | 2002-10-24 | 2004-09-23 | Hiromichi Hayashi | Health food and antitumor agent |
WO2004058279A1 (en) | 2002-12-27 | 2004-07-15 | Zhang, Xiaoli | Composition comprising scutellaria baicalensis and their uses thereof |
JP2004244385A (en) | 2003-02-14 | 2004-09-02 | Pigeon Corp | Mouth wash for infant having anticarious activity |
US7531521B2 (en) | 2003-02-26 | 2009-05-12 | Unigen Pharmaceuticals, Inc. | Formulation for use in the prevention and treatment of carbohydrate induced diseases and conditions |
US7972632B2 (en) | 2003-02-28 | 2011-07-05 | Unigen Pharmaceuticals, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
US20070135359A1 (en) | 2003-02-28 | 2007-06-14 | Unigen Pharmaceuticals, Inc. | Identification of Free-B-Ring Flavonoids as Potent COX-2 Inhibitors |
US20080107759A1 (en) | 2003-03-27 | 2008-05-08 | Unigen, Inc. | Composition Comprising Bamboo Extract and the Compounds Isolated Therefrom Showing Treating and Preventing Activity for Inflammatory and Blood Circulation Disease |
US20110117224A1 (en) | 2003-03-27 | 2011-05-19 | Unigen, Inc. | Composition Comprising Bamboo Extract and the Compounds Isolated Therefrom Showing Treating and Preventing Activity for Inflammatory and Blood Circulation Disease |
US7897182B2 (en) | 2003-03-27 | 2011-03-01 | Unigen, Inc. | Composition comprising bamboo extract and the compounds isolated therefrom showing treating and preventing activity for inflammatory and blood circulation disease |
WO2004089392A1 (en) | 2003-04-04 | 2004-10-21 | Unigen Pharmaceuticals, Inc. | Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care |
US20110207806A1 (en) | 2003-04-04 | 2011-08-25 | Unigen, Inc. | Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care |
US20050049206A1 (en) | 2003-09-01 | 2005-03-03 | Gong Bang Qiang | Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases |
WO2005020932A2 (en) | 2003-09-02 | 2005-03-10 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of free-b-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
US20070065524A1 (en) | 2003-11-07 | 2007-03-22 | Oaky Natural Co., Ltd. | Pharmaceutical composition containing guaiacol derivatives and syringol derivatives extracted from natural plant vinegar |
KR100522579B1 (en) | 2004-04-30 | 2005-10-19 | (주) 한약마을 | Pharmaceutical composition comprising the extracts of scutellaria root and schizandra fruit mixture thereof having an effect of restraint stress |
US20090304830A1 (en) | 2004-06-11 | 2009-12-10 | Unigen, Inc. | Composition Comprising Bamboo Extract for Androgen Agonist |
US20080279969A1 (en) | 2004-06-11 | 2008-11-13 | Unigen Inc. | Composition Comprising Bamboo Extract for Androgen Agonist |
US20060008749A1 (en) | 2004-07-08 | 2006-01-12 | Frank Sobel | Method for manufacturing of a mask blank for EUV photolithography and mask blank |
US20070264361A1 (en) | 2004-09-01 | 2007-11-15 | Unigen, Inc. | Composition for Suppressing Cyclooxygenase and/or 5-Lypoxygenase |
US20060140881A1 (en) | 2004-12-22 | 2006-06-29 | Guofeng Xu | Oral care compositions containing flavonoids and flavans |
US20060141073A1 (en) | 2004-12-23 | 2006-06-29 | Colgate-Palmolive Company | Oral care composition containing extract of unoxidized Camellia |
US20060204596A1 (en) | 2005-03-10 | 2006-09-14 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of Free-B-Ring flavonoids and flavans as a therapeutic agent |
US20080214658A1 (en) | 2005-03-18 | 2008-09-04 | Unigen, Inc. | Composition Comprising Isoorientin for Suppressing Histamine |
CN1686187A (en) | 2005-03-23 | 2005-10-26 | 贵阳高新瑞得科技开发有限公司 | Infantile lung clearing phlegm transforming effervescent granules and its making method |
US8247007B2 (en) | 2006-10-12 | 2012-08-21 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of bamboo and Scutellaria |
US20130064910A1 (en) | 2006-10-12 | 2013-03-14 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria |
Non-Patent Citations (250)
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9168242B2 (en) | 2002-03-22 | 2015-10-27 | Unigen, Inc. | Isolation of a dual COX-2 and 5-lipdxygenase inhibitor from Acacia |
US9370544B2 (en) | 2002-04-30 | 2016-06-21 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
US9849152B2 (en) | 2002-04-30 | 2017-12-26 | Unigen, Inc. | Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent |
US9622964B2 (en) | 2003-04-04 | 2017-04-18 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
WO2022026740A1 (en) | 2020-07-30 | 2022-02-03 | Unigen, Inc. | A standardized bioflavonoid composition for regulation of homeostasis of host defense mechanism |
Also Published As
Publication number | Publication date |
---|---|
US8034387B2 (en) | 2011-10-11 |
US20080096826A1 (en) | 2008-04-24 |
US20120053138A1 (en) | 2012-03-01 |
US7695743B2 (en) | 2010-04-13 |
US20080096827A1 (en) | 2008-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8652535B2 (en) | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments | |
AU2004268679B2 (en) | Formulation of a mixture of Free-B-Ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments | |
US9849152B2 (en) | Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent | |
US9622964B2 (en) | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |